<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Amiodarone: Drug information</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Amiodarone: Drug information</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="drugTitle">Amiodarone: Drug information</div><div class="clear"></div><div id="topicText">(For additional information <a class="drug drug_patient" data-topicid="10822" href="/d/html/10822.html" rel="external">see "Amiodarone: Patient drug information"</a> and <a class="drug drug_pediatric" data-topicid="12587" href="/d/html/12587.html" rel="external">see "Amiodarone: Pediatric drug information"</a>)<br/><br/>For abbreviations, symbols, and age group definitions used in Lexicomp (<a class="graphic graphic_table" href="/d/html/57469.html" rel="external">show table</a>)<div class="block black-box-warn drugH1Div" id="F5708616"><span class="drugH1">ALERT: US Boxed Warning</span>
<div class="collapsible">
<span class="collapsible-title">Life-threatening arrhythmias (tablet):</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">Amiodarone is intended for use only in patients with indicated life-threatening arrhythmias because its use is accompanied by substantial toxicity.</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">Pulmonary toxicity (tablet):</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">Amiodarone can cause pulmonary toxicity (hypersensitivity pneumonitis or interstitial/alveolar pneumonitis) that has resulted in clinically manifest disease at rates as high as 17% in some series of patients. Pulmonary toxicity has been fatal about 10% of the time. Obtain a baseline chest X-ray and pulmonary function tests, including diffusion capacity, when amiodarone therapy is initiated. Repeat history, physical exam, and chest X-ray every 3 to 6 months.</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">Hepatotoxicity:</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">Amiodarone can cause hepatotoxicity, which can be fatal. Obtain baseline and periodic liver transaminases and discontinue or reduce dose if the increase exceeds 3 times normal or doubles in a patient with an elevated baseline. Discontinue amiodarone if the patient experiences signs or symptoms of clinical liver injury.</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">Worsened arrhythmia (tablet):</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">Amiodarone can exacerbate arrhythmias. Initiate amiodarone in a clinical setting where continuous ECGs and cardiac resuscitation are available.</p></div>
</div>
</div>
<div class="visuallyHidden drugH1Div" id="formulinkBodyPlaceholder"><span class="drugH1"></span></div>
<div class="list ubnlist drugH1Div drugBrandNames" id="F133629"><span class="drugH1">Brand Names: US</span>
<ul>
<li>Nexterone;</li>
<li>Pacerone</li></ul></div>
<div class="list canbnlist drugH1Div drugBrandNames" id="F52865890"><span class="drugH1">Brand Names: Canada</span>
<ul>
<li>APO-Amiodarone;</li>
<li>JAMP-Amiodarone;</li>
<li>PMS-Amiodarone;</li>
<li>PRO-Amiodarone-200;</li>
<li>RIVA-Amiodarone;</li>
<li>SANDOZ Amiodarone;</li>
<li>TEVA-Amiodarone</li></ul></div>
<div class="ex_sect_xr thclist drugH1Div drugBrandNames" id="F133682"><span class="drugH1">Pharmacologic Category</span>
<ul>
<li>
                        Antiarrhythmic Agent, Class III</li></ul></div>
<div class="block doa drugH1Div" id="F133634"><span class="drugH1">Dosing: Adult</span>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="d4e067f9-f76d-40a8-b67c-fc8d2fcb39ad">Supraventricular arrhythmias</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Supraventricular arrhythmias:</b></p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Note:</b> Amiodarone is a preferred antiarrhythmic for patients with structural heart disease.</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>
<b>Atrial fibrillation:</b></i></p>
<p style="text-indent:-2em;margin-left:6em;">
<b>Pharmacologic cardioversion (off-label use) (alternative agent):</b></p>
<p style="text-indent:-2em;margin-left:8em;">
<b>Note:</b> Although amiodarone may slow ventricular response, the use of amiodarone (both IV and oral) is not particularly effective for cardioversion of atrial fibrillation to normal sinus rhythm as compared to other antiarrhythmics (eg, flecainide). Various IV and oral regimens have been described and may be used clinically. The more common regimens utilized include:</p>
<p style="text-indent:-2em;margin-left:10em;">
<b>IV: </b>150 mg over 10 minutes, then 1 mg/minute for 6 hours, then 0.5 mg/minute for 18 hours. Continue for a total loading dose of up to 10 g; may finish load with oral dosing. Change to oral maintenance dose when clinically indicated (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-24682347']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-24682347'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:10em;">
<b>Oral:</b> 400 mg every 8 to 24 hours for a total loading dose of ~6 to 10 g (total of IV plus oral doses), then change to a maintenance dose (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-24682347','lexi-content-ref-Giardina.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-24682347','lexi-content-ref-Giardina.1'])">Ref</a></span>). <b>Note:</b> May initiate loading regimen 2 to 6 weeks prior to direct current cardioversion to reduce the risk of atrial fibrillation recurrence (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Giardina.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Giardina.1'])">Ref</a></span>). Also see "Switching to Oral Amiodarone After IV Administration."</p>
<p style="text-indent:-2em;margin-left:6em;">
<b>Maintenance of sinus rhythm (off-label use):</b>
<b>Oral:</b> 100 to 200 mg once daily (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-24682347','lexi-content-ref-Giardina.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-24682347','lexi-content-ref-Giardina.1'])">Ref</a></span>). Use the lower maintenance dose for elderly patients or patients with low body mass (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-17329700']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-17329700'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">
<b>Prevention of postoperative atrial fibrillation and atrial flutter associated with cardiothoracic surgery (off-label use) (alternative agent): </b></p>
<p style="text-indent:-2em;margin-left:8em;">
<b>Note:</b> In patients who cannot receive a beta-blocker, amiodarone may be used. A variety of regimens have been used in clinical trials, including oral and IV regimens:</p>
<p style="text-indent:-2em;margin-left:8em;">
<b>IV only: </b></p>
<p style="text-indent:-2em;margin-left:10em;">
<i>Preoperative regimen:</i> 150 mg once, followed by 0.4 mg/<b>kg</b>/hour (~0.5 mg/minute for a 70 kg patient) for 3 days prior to surgery and for 5 days postoperatively (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-10921701']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-10921701'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:10em;">
<i>Postoperative regimen:</i> Starting at postoperative recovery: 1 g infused over 24 hours for 2 days (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-10440143']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-10440143'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:8em;">
<b>IV followed by Oral:</b></p>
<p style="text-indent:-2em;margin-left:10em;">
<i>Postoperative regimen:</i>
<b>IV:</b> Starting 6 hours postoperatively: 1,050 mg IV loading dose over 24 hours, followed by 400 mg orally 3 times daily on postop days 1 through 4 (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-12970233']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-12970233'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:8em;">
<b>Oral only:</b> 200 mg 3 times daily for 7 days prior to surgery, followed by 200 mg once daily until hospital discharge (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-9400034']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-9400034'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">
<b>Rate control (alternative agent) (off-label use): </b></p>
<p style="text-indent:-2em;margin-left:8em;">
<b>IV:</b> 300 mg over 1 hour followed by 10 to 50 mg/hour over 24 hours (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-24682347']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-24682347'])">Ref</a></span>) <b>or </b>150 mg over 10 to 30 minutes, then 1 mg/minute for 6 hours, then 0.5 mg/minute for 18 hours; administer repeat boluses of 150 mg over 10 to 30 minutes as needed but no more than 8 additional boluses should be administered in any 24-hour period (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Giardina.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Giardina.1'])">Ref</a></span>). <b>Note:</b> Mean daily doses &gt;2.1 g/day have been associated with hypotension.</p>
<p style="text-indent:-2em;margin-left:8em;">
<b>Oral:</b> 400 mg every 8 to 24 hours for a total loading dose of ~6 to 10 g (total of IV plus oral doses), then change to a maintenance dose (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Giardina.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Giardina.1'])">Ref</a></span>); usual maintenance dose: 100 to 200 mg once daily (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-24682347']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-24682347'])">Ref</a></span>). Also see "Switching to Oral Amiodarone After IV Administration."</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>
<b>Supraventricular tachycardia (eg, atrioventricular nodal reentrant tachycardia, atrioventricular reentrant tachycardia, focal atrial tachycardia) (off-label use): </b></i></p>
<p style="text-indent:-2em;margin-left:6em;">
<b>Note:</b> Amiodarone is usually reserved for use when other therapies have failed or are contraindicated. In general, most patients do not require long-term treatment with antiarrhythmic therapy.</p>
<p style="text-indent:-2em;margin-left:6em;">
<b>Pharmacologic cardioversion:</b></p>
<p style="text-indent:-2em;margin-left:8em;">
<b>IV:</b> 150 mg over 10 minutes, followed by 1 mg/minute for 6 hours, then 0.5 mg/minute for 18 hours or transition to oral dosing (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-26409259']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-26409259'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:8em;">
<b>Oral</b>
<b>:</b> 400 to 600 mg daily in divided doses for 2 to 4 weeks; in an inpatient monitored setting, initial oral doses up to 1.2 g daily in divided doses may be considered; administer a total loading dose of ~6 to 10 g (total of IV plus oral doses) then transition to a maintenance dose (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-26409259','lexi-content-ref-Giardina.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-26409259','lexi-content-ref-Giardina.1'])">Ref</a></span>); usual maintenance dose: 100 to 200 mg once daily (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-26409259']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-26409259'])">Ref</a></span>). Also see "Switching to Oral Amiodarone After IV Administration."</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="2f42c553-e8c4-4b54-98fb-e270b999dc6b">Ventricular arrhythmias</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Ventricular arrhythmias: </b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Electrical storm and incessant ventricular tachycardia, hemodynamically stable (off-label use):</b></p>
<p style="text-indent:-2em;margin-left:6em;">
<b>IV:</b> 150 mg over 10 minutes (may repeat if necessary), followed by 1 mg/minute IV infusion for 6 hours, then 0.5 mg/minute for 18 additional hours or until switched to oral therapy. <b>Note:</b> Coadministration with a beta-blocker (eg, propranolol) is recommended (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-29084731','lexi-content-ref-29699616','lexi-content-ref-26409259.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-29084731','lexi-content-ref-29699616','lexi-content-ref-26409259.1'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">
<b>Oral (following IV therapy): </b>400 mg every 8 to 12 hours for 1 to 2 weeks (loading dose of ~6 to 10 g [total of IV plus oral doses]), followed by 200 to 400 mg once daily (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-29084731','lexi-content-ref-Giardina.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-29084731','lexi-content-ref-Giardina.1'])">Ref</a></span>). Also see "Switching to Oral Amiodarone After IV Administration."</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Nonsustained ventricular tachycardia, symptomatic (off-label use): </b></p>
<p style="text-indent:-2em;margin-left:6em;">
<b>Note: </b>Consider addition of a beta-blocker or nondihydropyridine calcium channel blocker (eg, diltiazem) before starting antiarrhythmic therapy (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-25172618']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-25172618'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">
<b>Oral:</b> 400 mg every 8 to 12 hours for 1 to 2 weeks (total loading dose of ~6 to 10 g), followed by 200 to 400 mg once daily (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-29084731','lexi-content-ref-Giardina.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-29084731','lexi-content-ref-Giardina.1'])">Ref</a></span>). A more gradual oral loading regimen of 200 mg twice daily for the first 4 weeks, followed by 200 mg once daily may also be considered (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Zimetbaum.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Zimetbaum.1'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Prevention of implantable cardioverter defibrillator shocks (off-label use): </b></p>
<p style="text-indent:-2em;margin-left:6em;">
<b>Note:</b> Antiarrhythmic therapy for this indication has not been shown to reduce mortality, but may improve quality of life by reducing frequency of implantable cardioverter defibrillator (ICD) shocks. Amiodarone is the preferred antiarrhythmic for this use (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-16403928','lexi-content-ref-17227788','lexi-content-ref-23108056','lexi-content-ref-26961297','lexi-content-ref-11526368']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-16403928','lexi-content-ref-17227788','lexi-content-ref-23108056','lexi-content-ref-26961297','lexi-content-ref-11526368'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">
<b>Oral:</b> 400 mg twice daily for 2 weeks, followed by 400 mg once daily for 4 weeks, then 200 mg once daily in combination with a beta-blocker (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-16403928']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-16403928'])">Ref</a></span>) <b>or </b>400 mg every 8 to 24 hours for a total loading dose of ~6 to 10 g, then 200 to 400 mg once daily (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Giardina.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Giardina.1'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Primary prevention of sudden cardiac death due to ventricular arrhythmias (off-label use):</b></p>
<p style="text-indent:-2em;margin-left:6em;">
<b>Note:</b> Consider addition of a beta-blocker before starting antiarrhythmic therapy. For patients eligible for an ICD with left ventricular dysfunction, but who cannot or refuse to have ICD implantation, amiodarone can be utilized (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-19336434']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-19336434'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">
<b>Oral:</b> 400 mg every 8 to 24 hours for 1 to 2 weeks for a total loading dose of ~6 to 10 g, then a maintenance dose of 200 to 400 mg once daily (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-26646017','lexi-content-ref-Giardina.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-26646017','lexi-content-ref-Giardina.1'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Secondary prevention of sudden cardiac death due to ventricular arrhythmias (eg, ventricular fibrillation or hemodynamically unstable ventricular tachycardia): </b></p>
<p style="text-indent:-2em;margin-left:6em;">
<b>Note:</b> ICD implantation is preferred over antiarrhythmic therapy. In patients who do not meet ICD implant criteria, have contraindications, or refuse ICD implantation, antiarrhythmics can be utilized. Beta-blockers are recommended prior to or at the time of antiarrhythmic therapy initiation (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-29084731','lexi-content-ref-10440140','lexi-content-ref-Podrid.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-29084731','lexi-content-ref-10440140','lexi-content-ref-Podrid.1'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">
<b>Oral:</b> 400 mg every 8 to 24 hours for 1 to 2 weeks (loading dose of ~6 to 10 g [total of IV plus oral doses]), followed by a maintenance dose of 200 to 400 mg once daily (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-29084731','lexi-content-ref-Giardina.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-29084731','lexi-content-ref-Giardina.1'])">Ref</a></span>). Also see "Switching to Oral Amiodarone After IV Administration."</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Sudden cardiac arrest due to ventricular fibrillation or pulseless ventricular tachycardia (unresponsive to CPR, defibrillation, and epinephrine):</b></p>
<p style="text-indent:-2em;margin-left:6em;">
<b>IV push, Intraosseous (IO):</b> Initial: 300 mg (undiluted) rapid bolus; if ventricular fibrillation or pulseless ventricular tachycardia continues after subsequent defibrillation attempt or reoccurs after initially achieving return of spontaneous circulation, administer supplemental dose of 150 mg (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-20956217','lexi-content-ref-20956224','lexi-content-ref-17125434','lexi-content-ref-Hazinski.1','lexi-content-ref-15101852']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-20956217','lexi-content-ref-20956224','lexi-content-ref-17125434','lexi-content-ref-Hazinski.1','lexi-content-ref-15101852'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:8em;">
<i>Upon return of spontaneous circulation (ROSC): </i>Continuous IV infusion: 1 mg/minute for 6 hours, then 0.5 mg/minute for 18 hours or until switched to oral therapy for <b>secondary prevention of sudden cardiac death due to ventricular arrhythmias</b> (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-20956224']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-20956224'])">Ref</a></span>). <b>Note:</b> If amiodarone was not given during resuscitation but ROSC is achieved, some experts recommend empiric antiarrhythmic therapy with amiodarone (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Podrid.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Podrid.1'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Sustained monomorphic ventricular tachycardia, hemodynamically stable (off-label use):</b></p>
<p style="text-indent:-2em;margin-left:6em;">
<b>IV:</b> 150 mg over 10 minutes, then 1 mg/minute for 6 hours, followed by 0.5 mg/minute for at least 18 hours <b>or</b> until switched to an oral maintenance regimen (see "Switching to Oral Amiodarone After IV Administration").</p>
<p style="text-indent:-2em;margin-left:8em;">
<i>Breakthrough hemodynamically stable ventricular tachycardia:</i>
<b>IV:</b> 150 mg over 10 minutes (mean daily doses &gt;2.1 g/day have been associated with hypotension).</p>
<p style="text-indent:-2em;margin-left:6em;">
<b>Oral (following IV therapy):</b> 400 mg every 8 to 24 hours for 1 to 2 weeks (loading dose of ~6 to 10 g [total of IV plus oral doses]), followed by a maintenance dose of 200 to 400 mg once daily (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-29084731','lexi-content-ref-Giardina.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-29084731','lexi-content-ref-Giardina.1'])">Ref</a></span>); if arrhythmia remains controlled on 200 mg once daily, consider reducing dose further to 100 mg once daily to reduce the risk of adverse effects (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Ganz.1','lexi-content-ref-Giardina.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Ganz.1','lexi-content-ref-Giardina.1'])">Ref</a></span>). Also see "Switching to Oral Amiodarone After IV Administration."</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Ventricular premature beats, symptomatic (off-label use): </b></p>
<p style="text-indent:-2em;margin-left:6em;">
<b>Note:</b> For patients who are refractory to beta-blocker or nondihydropyridine calcium channel blocker therapy (eg, diltiazem) and cannot take class Ic antiarrhythmic agents (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Manolis.2020']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Manolis.2020'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">
<b>Oral:</b> 400 mg every 8 to 12 hours for 1 to 2 weeks (total loading dose of ~6 to 10 g), then when adequate control is achieved, decrease to 200 to 400 mg once daily; use lowest effective dose to minimize adverse effects (eg, may consider 100 mg once daily) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-29084731','lexi-content-ref-Manolis.2020']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-29084731','lexi-content-ref-Manolis.2020'])">Ref</a></span>).</p></div>
</div>
<p style="text-indent:-2em;margin-left:2em;margin-top:2em;">
<b>Switching to oral amiodarone after IV administration:</b> Use the following as a guide:</p>
<p style="text-indent:-2em;margin-left:4em;">&lt;1-week IV infusion: 400 to 1,200 mg daily in divided doses until loading dose of ~6 to 10 g (total of IV plus oral doses) has been administered, then start maintenance dose of 100 to 400 mg once daily (depending on indication).</p>
<p style="text-indent:-2em;margin-left:4em;">1- to 2-week IV infusion: 400 to 800 mg daily in divided doses until loading dose of ~6 to 10 g (total of IV plus oral doses) has been administered, then start maintenance dose of 100 to 400 mg once daily (depending on indication).</p>
<p style="text-indent:-2em;margin-left:4em;">&gt;2-week IV infusion: 100 to 400 mg once daily (depending on indication) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Giardina.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Giardina.1'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Note:</b> Conversion from IV to oral therapy has not been formally evaluated. Some experts recommend a 1- to 2-day overlap when converting from IV to oral therapy, especially when treating ventricular arrhythmias (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Buxton.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Buxton.1'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:2em;margin-top:2em;">
<b>Switching to IV amiodarone after oral administration:</b> Due to the long half-life, replacement therapy may not be necessary when oral maintenance doses are temporarily discontinued for only a few days. If oral maintenance doses must be withheld for ≥5 to 7 days, may consider administering ~50% (range of 30% to 70%) of the oral daily dose IV (based on bioavailability) as a slow bolus infusion once daily (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-10871966']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-10871966'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:2em;margin-top:2em;">
<b>Dosage adjustment for concomitant therapy:</b> Significant drug interactions exist, requiring dose/frequency adjustment or avoidance. Consult drug interactions database for more information.</p></div>
<div class="block dora drugH1Div" id="F50991418"><span class="drugH1">Dosing: Kidney Impairment: Adult</span>
<p style="text-indent:-2em;margin-left:2em;">The renal dosing recommendations are based upon the best available evidence and clinical expertise. Senior Editorial Team: Bruce Mueller, PharmD, FCCP, FASN, FNKF; Jason A. Roberts, PhD, BPharm (Hons), B App Sc, FSHP, FISAC; Michael Heung, MD, MS.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Altered kidney function:</b> Mild to severe impairment: No dosage adjustment necessary (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-8852388']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-8852388'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Hemodialysis, intermittent (thrice weekly):</b> Poorly dialyzed (amiodarone and N-desethylamiodarone): No supplemental dose or dosage adjustment necessary (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-6835293','lexi-content-ref-8852388']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-6835293','lexi-content-ref-8852388'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Peritoneal dialysis:</b> Poorly dialyzed (amiodarone and N-desethylamiodarone): No dosage adjustment necessary (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-6622326']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-6622326'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>CRRT</b>: No dosage adjustment necessary (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Expert.DOR']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Expert.DOR'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>PIRRT (eg, sustained, low-efficiency diafiltration):</b> No dosage adjustment necessary (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Expert.DOR']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Expert.DOR'])">Ref</a></span>).</p></div>
<div class="block doha drugH1Div" id="F50988663"><span class="drugH1">Dosing: Hepatic Impairment: Adult</span>
<p style="text-indent:0em;display:inline">Dosage adjustment is probably necessary in substantial hepatic impairment. No specific guidelines available. If hepatic enzymes exceed 3 times normal or double in a patient with an elevated baseline, consider decreasing the dose or discontinuing amiodarone.</p></div>
<div class="block doe drugH1Div" id="F133635"><span class="drugH1">Dosing: Older Adult</span>
<p style="text-indent:0em;display:inline">Refer to adult dosing. Avoid as first-line therapy for atrial fibrillation unless the patient has heart failure or substantial left ventricular hypertrophy (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-37139824']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-37139824'])">Ref</a></span>). Dose selection should be cautious, at low end of dosage range, and titration should be slower to evaluate response. Although not supported by clinical evidence, a maintenance dose of 100 mg daily is commonly used, especially for elderly patients or patients with low body mass (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-17329700']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-17329700'])">Ref</a></span>).</p></div>
<div class="block dop drugH1Div" id="F133657"><span class="drugH1">Dosing: Pediatric</span><p>(For additional information <a class="drug drug_pediatric" data-topicid="12587" href="/d/html/12587.html" rel="external">see "Amiodarone: Pediatric drug information"</a>)</p>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="df3d707a-b4c5-4834-b31d-5a640cd6258c">Perfusing tachycardias</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Perfusing tachycardias:</b> Infants, Children, and Adolescents: IV, Intraosseous: Loading dose: 5 mg/kg (maximum dose: 300 mg/dose) over 20 to 60 minutes; may repeat twice up to maximum total dose of 15 mg/kg during acute treatment (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-20956230']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-20956230'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="1db5568a-b19e-410b-8e68-312f7999855b">Ventricular fibrillation or pulseless ventricular tachycardia, shock-refractory</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Ventricular fibrillation (VF) or pulseless ventricular tachycardia (VT), shock-refractory:</b> Infants, Children, and Adolescents: IV, Intraosseous: 5 mg/kg (maximum dose: 300 mg/dose) rapid bolus; may repeat twice up to a maximum total dose of 15 mg/kg during acute treatment (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-26473000','lexi-content-ref-30571264','lexi-content-ref-20956230','lexi-content-ref-33081526']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-26473000','lexi-content-ref-30571264','lexi-content-ref-20956230','lexi-content-ref-33081526'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="7684d03f-3d4c-4d6b-800b-28672adb65b8">Tachyarrhythmia, including junctional ectopic tachycardia, paroxysmal supraventricular tachycardia</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Tachyarrhythmia, including junctional ectopic tachycardia (JET), paroxysmal supraventricular tachycardia (PSVT):</b> Limited data available:</p>
<p style="text-indent:-2em;margin-left:4em;">Infants, Children, and Adolescents:</p>
<p style="text-indent:-2em;margin-left:6em;">Oral: Loading dose: 10 to 15 mg/kg/day in 1 to 2 divided doses/day for 4 to 14 days or until adequate control of arrhythmia or prominent adverse effects occur; dosage should then be reduced to 5 mg/kg/day given once daily for several weeks; if arrhythmia does not recur, reduce to lowest effective dosage possible; usual daily minimal dose: 2.5 mg/kg/day; maintenance doses may be given for 5 of 7 days/week.</p>
<p style="text-indent:-2em;margin-left:8em;">
<b>Note:</b> For infants, some have suggested BSA-directed dosing: Loading dose: 600 to 800 mg/<b>1.73 m<sup>2</sup></b>/day in 1 to 2 divided doses (equivalent to 347 to 462 mg/m<sup>2</sup>/day); maintenance dose: 200 to 400 mg/<b>1.73 m<sup>2</sup></b>/day once daily (equivalent to 116 to 231 mg/m<sup>2</sup>/day) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-3756044','lexi-content-ref-7446409','lexi-content-ref-6195613','lexi-content-ref-8047495']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-3756044','lexi-content-ref-7446409','lexi-content-ref-6195613','lexi-content-ref-8047495'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:8em;">
<b>Note:</b> Prolongation of the corrected QT interval was more likely in infants &lt;9 months of age who received higher loading doses (20 mg/kg/day vs 10 mg/kg/day in 2 divided doses) (n=50; mean age: 1 ± 1.5 months) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-11136494']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-11136494'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">IV: Loading dose: 5 mg/kg (maximum dose: 300 mg/dose) given over 60 minutes; <b>Note:</b> Most studies used bolus infusion time of 60 minutes to avoid hypotension; may repeat initial loading dose to a maximum total initial load: 10 mg/kg; do not exceed total daily bolus of 15 mg/kg/<b>day</b> (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-11136494','lexi-content-ref-8074040','lexi-content-ref-19026806','lexi-content-ref-7946778','lexi-content-ref-7753695']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-11136494','lexi-content-ref-8074040','lexi-content-ref-19026806','lexi-content-ref-7946778','lexi-content-ref-7753695'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:8em;">
<b>Note:</b> Dividing the 5 mg/kg loading dose into 1 mg/kg aliquots (each administered over 5 to 10 minutes) has been used; an additional 1 to 5 mg/kg loading dose was given in the same manner, if needed, after 30 minutes (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-8609351']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-8609351'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">Continuous IV infusion (if needed); <b>Note:</b> Reported dosing units for regimens are variable (mcg/kg/minute and mg/kg/day); use caution to ensure appropriate dose and dosing units are used; taper infusion as soon as clinically possible and switch to oral therapy if necessary.</p>
<p style="text-indent:-2em;margin-left:8em;">Dosing based on <b>mcg</b>/kg/<b>minute</b>: Initial: 5 <b>mcg</b>/kg/<b>minute</b>; increase incrementally as clinically needed; usual required dose: 10 <b>mcg</b>/kg/<b>minute</b>; range: 5 to 15 <b>mcg</b>/kg/<b>minute</b>; maximum daily dose: 2,200 mg/<b>day</b> (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-8074040','lexi-content-ref-19632422','lexi-content-ref-20453797']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-8074040','lexi-content-ref-19632422','lexi-content-ref-20453797'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:8em;">Dosing based on <b>mg</b>/kg/<b>day</b>: Initial: 10 <b>mg</b>/kg/<b>day</b>; increase incrementally as clinically needed; range: 10 to 20 <b>mg</b>/kg/<b>day</b>; maximum daily dose: 2,200 mg/<b>day</b> (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-20453797','lexi-content-ref-8609351','lexi-content-ref-7946778','lexi-content-ref-7753695']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-20453797','lexi-content-ref-8609351','lexi-content-ref-7946778','lexi-content-ref-7753695'])">Ref</a></span>).</p></div>
</div>
<p style="text-indent:-2em;margin-left:2em;">
<b>Dosage adjustment for concomitant therapy:</b> Significant drug interactions exist, requiring dose/frequency adjustment or avoidance. Consult drug interactions database for more information.</p></div>
<div class="block dorp drugH1Div" id="F52160935"><span class="drugH1">Dosing: Kidney Impairment: Pediatric</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in the manufacturer's labeling; pharmacokinetic data implies that no dosage adjustment would be necessary. The commercially available premix injectable solution contains the excipient cyclodextrin which may accumulate in patients with renal insufficiency; the clinical significance of this finding is unknown (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-20213839']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-20213839'])">Ref</a></span>); monitor patients closely. Close monitoring is recommended in adults with renal abnormalities who are elderly and/or have left ventricular dysfunction.</p>
<p style="text-indent:-2em;margin-left:2em;">Hemodialysis: Not dialyzable; supplemental dose is not necessary (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Aronoff.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Aronoff.1'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:2em;">Peritoneal dialysis: Not dialyzable; supplemental dose is not necessary (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Aronoff.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Aronoff.1'])">Ref</a></span>)</p></div>
<div class="block dohp drugH1Div" id="F52160936"><span class="drugH1">Dosing: Hepatic Impairment: Pediatric</span>
<p style="text-indent:-2em;margin-left:2em;">Baseline: There are no dosage adjustments provided in the manufacturer's labeling. Although no dosage recommendations exist for adults with hepatic abnormalities, close monitoring is recommended in the elderly and those with left ventricular dysfunction.</p>
<p style="text-indent:-2em;margin-left:2em;">Hepatoxicity during therapy: There are no dosage adjustments provided in the manufacturer's labeling; based on experience in adult patients, dosage adjustment or discontinuation is suggested when hepatic enzymes exceed 3 times normal or double in a patient with an elevated baseline.</p></div>
<div class="block arsc drugH1Div" id="F55173368"><span class="drugH1">Adverse Reactions (Significant): Considerations</span>
<div class="collapsible">
<span class="collapsible-title">Bradycardia/hypotension</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">Amiodarone may cause a range of effects on conduction and/or blood pressure. Acute hemodynamic changes (<b>bradycardia</b> and <b>hypotension</b>) may occur, particularly with IV administration. A variety of longer-term changes in conduction/heart rate are associated with amiodarone use, most commonly bradycardia, even in patients receiving low-dose chronic oral therapy. Significant disruptions in initiation and conduction, including cases of <b>atrioventricular block, </b>as well as <b>sinoatrial arrest</b> have been reported in adult and pediatric patients (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-6799078','lexi-content-ref-3776867']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-6799078','lexi-content-ref-3776867'])">Ref</a></span>). <b>Cardiac conduction disorder</b> (enhanced accessory pathway conduction) has also been reported (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-12535818','lexi-content-ref-3610399']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-12535818','lexi-content-ref-3610399'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Mechanism:</i> Dose-related; related to pharmacologic action (ie, beta-blocking and calcium channel blocking activity are responsible for bradycardia and sinoatrial blockade as well as some of the hypotensive effects) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-30929065']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-30929065'])">Ref</a></span>). Formulation-related; acute hypotension with rapid IV administration has been attributed in part to polysorbate 80 (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-3280316']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-3280316'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Onset:</i> Acute hypotension during IV administration: Rapid; generally has an onset within 90 minutes but may occur up to 12 hours after initiation (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-30929065']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-30929065'])">Ref</a></span>). Other hypotensive adverse reactions: Intermediate; generally reported in the first 12 months of therapy, while bradycardia may develop over months to years (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-31653351']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-31653351'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Risk factors:</i></p>
<p style="text-indent:-2em;margin-left:6em;">Acute hypotension:</p>
<p style="text-indent:-2em;margin-left:8em;">
<i>• </i>Age &gt;65 years with history of myocardial infarction (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-12535818']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-12535818'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:8em;">
<i>• </i>Pediatric patients: Age &lt;3 months; baseline blood pressure below the third percentile for age and height; rapid IV bolus administration (ie, ≤20 minutes) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-30929065']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-30929065'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:8em;">
<i>• </i>Formulations containing polysorbate 80 (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-3280316']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-3280316'])">Ref</a></span>)</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">Hepatotoxicity</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Drug-induced</b>
<b>phospholipidosis</b> is a common finding, reflecting a chemical reaction between amiodarone and phospholipids (amiodarone is a potent inhibitor of phospholipase A), but alone this is not indicative of hepatic impairment. Severe, acute <b>hepatotoxicity</b> has been associated with IV administration (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-25259952']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-25259952'])">Ref</a></span>). Chronic toxicity may take the form of micronodular <b>hepatic cirrhosis</b>, hepatic fibrosis, or (less commonly)<b> cholestasis </b>(<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-16284489','lexi-content-ref-3962737']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-16284489','lexi-content-ref-3962737'])">Ref</a></span>). Hepatotoxicity may be irreversible in some cases (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-30891390','lexi-content-ref-29653592']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-30891390','lexi-content-ref-29653592'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Mechanism:</i></p>
<p style="text-indent:-2em;margin-left:6em;">Acute toxicity: Idiosyncratic, immunologic, and formulation-related (ie, polysorbate 80) mechanisms have been proposed (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-19565059','lexi-content-ref-25259952','lexi-content-ref-9227310','lexi-content-ref-22761971','lexi-content-ref-8491409','lexi-content-ref-26151694']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-19565059','lexi-content-ref-25259952','lexi-content-ref-9227310','lexi-content-ref-22761971','lexi-content-ref-8491409','lexi-content-ref-26151694'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">Chronic toxicity: Idiosyncratic; may be related to mitochondrial dysfunction and free-radical induced injury (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-30873497','lexi-content-ref-3962737']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-30873497','lexi-content-ref-3962737'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Onset:</i></p>
<p style="text-indent:-2em;margin-left:6em;">Acute toxicity following IV administration: Rapid; may occur within 24 hours of initiation (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-25259952','lexi-content-ref-9227310','lexi-content-ref-22761971','lexi-content-ref-8491409']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-25259952','lexi-content-ref-9227310','lexi-content-ref-22761971','lexi-content-ref-8491409'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">Chronic toxicity: Delayed; most cases occur after at least a year of therapy (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-19565059','lexi-content-ref-30891390','lexi-content-ref-20175957','lexi-content-ref-32095172','lexi-content-ref-16284489','lexi-content-ref-3962737']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-19565059','lexi-content-ref-30891390','lexi-content-ref-20175957','lexi-content-ref-32095172','lexi-content-ref-16284489','lexi-content-ref-3962737'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Risk factors:</i></p>
<p style="text-indent:-2em;margin-left:6em;">Acute toxicity:</p>
<p style="text-indent:-2em;margin-left:8em;">
<i>• </i>High doses (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-25259952']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-25259952'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:8em;">• IV administration (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-25259952','lexi-content-ref-22761971','lexi-content-ref-8491409']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-25259952','lexi-content-ref-22761971','lexi-content-ref-8491409'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:8em;">• Hepatic congestion (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-24109195']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-24109195'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">Chronic toxicity:</p>
<p style="text-indent:-2em;margin-left:8em;">• Cumulative dose (potential risk factor) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-19565059','lexi-content-ref-24485640']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-19565059','lexi-content-ref-24485640'])">Ref</a></span>)</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">Proarrhythmic effects</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">Amiodarone may exacerbate arrhythmias; also associated with new-onset <b>ventricular tachycardia</b>, and polymorphic ventricular tachycardia associated with <b>prolonged QT interval on ECG</b> and <b>torsades de pointes</b> (TdP). However, relative to other agents in this class, amiodarone is associated with relatively low rates of proarrhythmia (specifically a low rate of TdP).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Mechanism:</i> Exhibits multiple effects on cardiac conduction, resulting in a net increase in the QTc interval, consistent with type III antiarrhythmic activity (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-9137212']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-9137212'])">Ref</a></span>). Several electrophysiologic properties may contribute to the relative lack of proarrhythmia, including a lack of reverse use dependence, concurrent blockade of the L-type calcium channels, and less QT dispersion (heterogeneity of ventricular repolarization) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-1423949','lexi-content-ref-8067651','lexi-content-ref-3608127']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-1423949','lexi-content-ref-8067651','lexi-content-ref-3608127'])">Ref</a></span>). May increase resistance to cardioversion in some patients (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-12950525','lexi-content-ref-9626850']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-12950525','lexi-content-ref-9626850'])">Ref</a></span>). The major metabolite (desethylamiodarone) increases defibrillation threshold in a dose-dependent fashion; this effect is seen with monophasic and biphasic waveforms (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-11545776','lexi-content-ref-10921789','lexi-content-ref-9626850']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-11545776','lexi-content-ref-10921789','lexi-content-ref-9626850'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Onset: </i>Intermediate; generally proarrhythmic events occur sporadically later in therapy (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-8067651']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-8067651'])">Ref</a></span>). Rare cases have been reported after short-term, low-dose therapy (200 mg/day for 4 to 5 days) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-8842793','lexi-content-ref-17148550']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-8842793','lexi-content-ref-17148550'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Risk factors:</i></p>
<p style="text-indent:-2em;margin-left:6em;">• Concurrent administration of multiple medications (≥2) that prolong the QT interval or medications with drug interactions that increase serum concentrations of QT-prolonging medications (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-8230644','lexi-content-ref-32929996']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-8230644','lexi-content-ref-32929996'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Electrolyte disturbances (hypokalemia, hypomagnesemia) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-8230644']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-8230644'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Females (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-8230644']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-8230644'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• In the treatment of atrial fibrillation, structural heart disease, and concurrent use of medications to control heart rate (beta-blockers and digitalis) were noted to increase the risk of TdP following an IV loading dose (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-16650263']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-16650263'])">Ref</a></span>)</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">Pulmonary toxicity</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Pulmonary toxicity</b> may occur with amiodarone use and include a variety of clinical syndromes which may be categorized by onset. Acute events include pneumonitis, <b>pulmonary alveolar hemorrhage</b>, and <b>acute respiratory distress syndrome</b> (ARDS). Pulmonary adverse reactions associated with longer-term therapy (subacute or chronic) include chronic eosinophilic pneumonia, chronic organizing pneumonia, acute fibrinous organizing pneumonia, and <b>pulmonary fibrosis</b> (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-3282816','lexi-content-ref-20553056','lexi-content-ref-31653638','lexi-content-ref-27916222']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-3282816','lexi-content-ref-20553056','lexi-content-ref-31653638','lexi-content-ref-27916222'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Mechanism:</i></p>
<p style="text-indent:-2em;margin-left:6em;">Acute toxicity:</p>
<p style="text-indent:-2em;margin-left:8em;">Non-dose-related; idiosyncratic. Related to production of superoxide radicals and release of active iodide species (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-20553056','lexi-content-ref-27916222']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-20553056','lexi-content-ref-27916222'])">Ref</a></span>). Diffuse alveolar hemorrhage may occur in patients with preexisting immune dysfunction represented by autoantibodies (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-9149610','lexi-content-ref-16634249']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-9149610','lexi-content-ref-16634249'])">Ref</a></span>). Some cases of acute toxicity may represent an acute vasculitis, possibly related to autoantibodies (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-8038483']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-8038483'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:8em;">Chronic toxicity: More significant pulmonary toxicity, primarily pulmonary fibrosis, is mediated by a combination of direct toxicity to specific pulmonary cells, immune activation, and activation of angiotensin (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-20553056']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-20553056'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Onset:</i></p>
<p style="text-indent:-2em;margin-left:6em;">Acute toxicity: Intermediate; may occur as early as 2 days to 2 weeks (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-11909587','lexi-content-ref-15777308']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-11909587','lexi-content-ref-15777308'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">Chronic toxicity: Delayed; pulmonary fibrosis is usually identified after months to years of therapy (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-3282816','lexi-content-ref-20553056','lexi-content-ref-31653351']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-3282816','lexi-content-ref-20553056','lexi-content-ref-31653351'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Risk factors:</i></p>
<p style="text-indent:-2em;margin-left:6em;">Acute toxicity:</p>
<p style="text-indent:-2em;margin-left:8em;">• Cardiothoracic surgery (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-20553056']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-20553056'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:8em;">• Exposure to a high inspiratory fraction of inhaled oxygen (FiO<sub>2</sub>) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-20553056']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-20553056'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:8em;">• Pulmonary angiography (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-20553056']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-20553056'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">Chronic toxicity:</p>
<p style="text-indent:-2em;margin-left:8em;">• Daily and cumulative doses (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-18460037','lexi-content-ref-3282816','lexi-content-ref-17895560']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-18460037','lexi-content-ref-3282816','lexi-content-ref-17895560'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:8em;">• Chronic kidney disease (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-21704281']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-21704281'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:8em;">• Older adults (particularly &gt;60 years of age) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-18460037','lexi-content-ref-21704281']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-18460037','lexi-content-ref-21704281'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:8em;">• Preexisting lung disease/chronic obstructive pulmonary disease (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-21704281','lexi-content-ref-15670555']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-21704281','lexi-content-ref-15670555'])">Ref</a></span>)</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">Thyroid effects</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">Amiodarone is associated with complex effects on thyroid function, resulting in either <b>hyperthyroidism</b> or <b>hypothyroidism</b>. Most euthyroid patients exhibit transient abnormalities of thyroid tests without overt symptoms and return to a baseline in 3 to 6 months (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-30309693']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-30309693'])">Ref</a></span>). In a subset of patients, often in those with underlying thyroid disease, these effects may result in clinical thyroid disease, including rare cases of <b>thyrotoxicosis</b>, thyroid storm, or <b>myxedema</b> (including myxedema coma) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-29793782','lexi-content-ref-29033440']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-29793782','lexi-content-ref-29033440'])">Ref</a></span>). Hypothyroidism (sometimes severe) may be subsequent to resolution of preceding amiodarone-induced hyperthyroidism.</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Mechanism: </i>Dose-related. Effects may be considered in two categories: Those which are mediated by the high iodine content or those which are related to other effects of amiodarone.</p>
<p style="text-indent:-2em;margin-left:6em;">
<span style="text-decoration: underline">Hyperthyroidism</span>: Two types of amiodarone-induced thyrotoxicosis are generally recognized: Type 1 occurs in patients with underlying thyroid pathology (autonomous nodular goiter or Graves' disease) and is associated with increased synthesis of T<sub>4</sub> and T<sub>3</sub> in the thyroid gland (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-9492158']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-9492158'])">Ref</a></span>). The high iodine content of amiodarone appears to be an important factor in loss of regulation in these susceptible individuals (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-30309693']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-30309693'])">Ref</a></span>). Type 2 results from a subacute thyroiditis, causing release of thyroid hormones into the circulation without an increase in synthesis (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-30309693','lexi-content-ref-19584973']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-30309693','lexi-content-ref-19584973'])">Ref</a></span>). Thyroiditis is considered a direct effect of amiodarone and not related to iodine content (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-30309693']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-30309693'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">
<span style="text-decoration: underline">Hypothyroidism</span>
<i>:</i> Amiodarone inhibits the conversion of T<sub>4</sub> to T<sub>3</sub> (de-iodination), decreases binding of T<sub>3</sub> to its nuclear receptor, and may exert direct toxicity on thyroid follicular cells (thyroiditis) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-30309693']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-30309693'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Onset: </i>Delayed; most cases of hyperthyroidism occur between 3 months and 4 years of therapy (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-17904459']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-17904459'])">Ref</a></span>). In an evaluation of FDA Adverse Reactions Reporting data, median time to diagnosis of hyperthyroidism is 720 days (range: 225 to 1,145 days) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-31400296']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-31400296'])">Ref</a></span>). Most cases of hypothyroidism occur within the first 6 to 7 months of therapy (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-17904459','lexi-content-ref-31400296']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-17904459','lexi-content-ref-31400296'])">Ref</a></span>). In a pediatric series, the majority of thyroid dysfunction was noted within 35 days of amiodarone initiation (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-31361319']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-31361319'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Risk factors:</i></p>
<p style="text-indent:-2em;margin-left:6em;">
<i>• </i>Dietary iodine intake (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-15989900','lexi-content-ref-30309693']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-15989900','lexi-content-ref-30309693'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">
<i>• </i>Thyroid autoantibodies (hypothyroidism) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-3665117']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-3665117'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">
<i>• </i>Thyroid disease (including Graves’ disease or preexisting multinodular goiter) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-30309693']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-30309693'])">Ref</a></span>)</p></div>
</div>
</div>
<div class="block adr drugH1Div" id="F133588"><span class="drugH1">Adverse Reactions</span>
<p style="text-indent:0em;display:inline">The following adverse drug reactions and incidences are derived from product labeling unless otherwise specified. Adverse reactions reported for the oral dosage form unless otherwise specified. Reported adverse reactions are for adults.</p>
<p style="text-indent:-2em;margin-left:2em;">&gt;10%:</p>
<p style="text-indent:-2em;margin-left:4em;">Cardiovascular: Hypotension (refractory in rare cases)</p>
<p style="text-indent:-2em;margin-left:4em;">Gastrointestinal: Nausea, vomiting (oral: &gt;10%; IV: &lt;2%)</p>
<p style="text-indent:-2em;margin-left:4em;">Ophthalmic: Epithelial keratopathy (98% to 99%; vortex; Raizman 2017)</p>
<p style="text-indent:-2em;margin-left:4em;">Respiratory: Pulmonary toxicity (including hypersensitivity pneumonitis and interstitial/alveolar pneumonitis: ≤17%)</p>
<p style="text-indent:-2em;margin-left:2em;">1% to 10%:</p>
<p style="text-indent:-2em;margin-left:4em;">Cardiovascular: Bradycardia (2% to 4%), cardiac arrhythmia, cardiac failure (IV, oral), edema, exacerbation of cardiac arrhythmia (2% to 5%), flushing, prolonged QT interval on ECG (associated with worsening arrhythmia), shock (IV: &lt;2%), sinus node dysfunction, torsades de pointes (IV: &lt;2%), ventricular fibrillation (IV: &lt;2%)</p>
<p style="text-indent:-2em;margin-left:4em;">Dermatologic: Skin photosensitivity, solar dermatitis, Stevens-Johnson syndrome (IV, oral: &lt;2%) (Blumenthal 2015)</p>
<p style="text-indent:-2em;margin-left:4em;">Endocrine &amp; metabolic: Decreased libido, hyperthyroidism (2%), hypothyroidism</p>
<p style="text-indent:-2em;margin-left:4em;">Gastrointestinal: Abdominal pain, altered salivation, anorexia, constipation, diarrhea (IV: &lt;2%), dysgeusia</p>
<p style="text-indent:-2em;margin-left:4em;">Hematologic &amp; oncologic: Disorder of hemostatic components of blood</p>
<p style="text-indent:-2em;margin-left:4em;">Hepatic: Abnormal hepatic function tests (IV, oral), hepatic disease</p>
<p style="text-indent:-2em;margin-left:4em;">Nervous system: Abnormal gait, altered sense of smell, ataxia, dizziness, fatigue, headache, insomnia, involuntary body movements, malaise, paresthesia, sleep disorder</p>
<p style="text-indent:-2em;margin-left:4em;">Neuromuscular &amp; skeletal: Tremor</p>
<p style="text-indent:-2em;margin-left:4em;">Ophthalmic: Blurred vision, visual disturbance, visual halos around lights</p>
<p style="text-indent:-2em;margin-left:4em;">Renal: Renal insufficiency (IV: &lt;2%)</p>
<p style="text-indent:-2em;margin-left:4em;">Respiratory: Acute respiratory distress syndrome (IV, oral: ≤2%; incidence may be higher in patients following anesthesia with high FiO<sub>2</sub> exposure) (Teerakanok 2016), pulmonary fibrosis</p>
<p style="text-indent:-2em;margin-left:2em;">&lt;1%:</p>
<p style="text-indent:-2em;margin-left:4em;">Dermatologic: Alopecia, blue-gray skin pigmentation (incidence may be higher ~8%) (Rappersberger 1989), skin rash</p>
<p style="text-indent:-2em;margin-left:4em;">Hematologic &amp; oncologic: Spontaneous ecchymoses</p>
<p style="text-indent:-2em;margin-left:4em;">Hepatic: Hepatic necrosis (acute: IV)</p>
<p style="text-indent:-2em;margin-left:2em;">Frequency not defined: Cardiovascular: Asystole (IV), atrioventricular block (IV), cardiogenic shock (IV), ventricular tachycardia (IV, oral)</p>
<p style="text-indent:-2em;margin-left:2em;">Postmarketing (oral and/or IV):</p>
<p style="text-indent:-2em;margin-left:4em;">Cardiovascular: Cardiac conduction disorder (including bundle branch block, infra-HIS block, and antegrade conduction via an accessory pathway) (Schützenberger 1987), sinoatrial block, vasculitis</p>
<p style="text-indent:-2em;margin-left:4em;">Dermatologic: Bullous dermatitis, eczema, erythema multiforme (Chen 2013), erythema of skin (palmer) (Serrao 2007), exfoliative dermatitis, toxic epidermal necrolysis (Yung 2002), urticaria (Stafford 2007)</p>
<p style="text-indent:-2em;margin-left:4em;">Endocrine &amp; metabolic: Myxedema (including myxedema coma) (Hawatmeh 2018), SIADH (Marcelino 2019), thyroid nodule, thyrotoxicosis (Inoue 2018)</p>
<p style="text-indent:-2em;margin-left:4em;">Gastrointestinal: Cholestasis (Bratton 2019), pancreatitis (including acute pancreatitis) (Alonso 2015), xerostomia</p>
<p style="text-indent:-2em;margin-left:4em;">Genitourinary: Epididymitis (Dasu 2019), impotence, orchitis (Dasu 2019)</p>
<p style="text-indent:-2em;margin-left:4em;">Hematologic &amp; oncologic: Agranulocytosis (Gershinsky 2019), aplastic anemia (Ba 2019), granulocytosis, granuloma (of bone) (Mukhopadhyay 2004), hemolytic anemia, immune thrombocytopenia (Chhatrala 2021), malignant neoplasm of skin (Maoz 2009), malignant neoplasm of thyroid (Inaba 2012), neutropenia (Groneberg 2001), pancytopenia (Erie 2010), thrombocytopenia</p>
<p style="text-indent:-2em;margin-left:4em;">Hepatic: Cholestatic hepatitis (Rumessen 1986), hepatic cirrhosis (Puli 2005), hepatotoxicity (idiosyncratic) (Chalasani 2014)</p>
<p style="text-indent:-2em;margin-left:4em;">Hypersensitivity: Anaphylactic shock (Kurt 2012), anaphylaxis (Okuyan 2012), angioedema (Burches 2000), nonimmune anaphylaxis</p>
<p style="text-indent:-2em;margin-left:4em;">Immunologic: Drug reaction with eosinophilia and systemic symptoms</p>
<p style="text-indent:-2em;margin-left:4em;">Local: Infusion site reaction (including cellulitis, edema, erythema, granuloma, hypoesthesia, induration, inflammation, pain, phlebitis (IV concentrations of &gt;3 mg/mL have been associated with peripheral vein phlebitis), pigment changes, pruritus, skin sloughing, thrombophlebitis, thrombosis, urticaria (Russell 2006)</p>
<p style="text-indent:-2em;margin-left:4em;">Nervous system: Delirium (Athwal 2003), demyelinating disease (polyneuropathy) (Pulipaka 2002), drug-induced Parkinson's disease (Bondon-Guitton 2011), hallucination, hypoesthesia, increased intracranial pressure, intracranial hypertension (Tan 2020), myasthenia, peripheral neuropathy (chronic treatment, partially to completely reversible with discontinuation) (Roseti 2010)</p>
<p style="text-indent:-2em;margin-left:4em;">Neuromuscular &amp; skeletal: Back pain, lupus-like syndrome (Yachoui 2015), muscle spasm, myopathy, rhabdomyolysis</p>
<p style="text-indent:-2em;margin-left:4em;">Ophthalmic: Corneal deposits, dry eye syndrome (Ikäheimo 2002), optic neuritis, optic neuropathy (Wang 2016)</p>
<p style="text-indent:-2em;margin-left:4em;">Renal: Acute kidney injury (Mohamed 2020)</p>
<p style="text-indent:-2em;margin-left:4em;">Respiratory: Bronchiolitis obliterans organizing pneumonia, bronchospasm (Yavuzgil 2005), hemoptysis (Busch 2019), hypoxia, pleural effusion (Hawatmeh 2017), pleurisy, pulmonary alveolar hemorrhage (Saeed 2019), pulmonary infiltrates</p>
<p style="text-indent:-2em;margin-left:4em;">Miscellaneous: Drug-induced phospholipidosis, fever, mass (pulmonary) (Jarand 2007)</p></div>
<div class="block coi drugH1Div" id="F133607"><span class="drugH1">Contraindications</span>
<p style="text-indent:-2em;margin-left:2em;">Hypersensitivity to amiodarone, iodine, or any component of the formulation; sick sinus syndrome, second- or third-degree atrioventricular block, bradycardia leading to syncope without a functioning pacemaker; cardiogenic shock</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Note:</b> The FDA-approved product labeling states amiodarone is contraindicated in patients with iodine hypersensitivity. This does not include most patients with allergic reactions to shellfish or contrast media, which are usually not due to iodine itself (Beall 2007; Brouse 2005; Lakshmanadoss 2012). However, exercise caution in patients with severe allergies to shellfish or contrast media (Brouse 2005).</p>
<p style="text-indent:-2em;margin-left:2em;">
<i>Canadian labeling (oral formulation):</i> Additional contraindications (not in US labeling): Evidence of hepatitis; pulmonary interstitial abnormalities; thyroid dysfunction</p></div>
<div class="block war drugH1Div" id="F133585"><span class="drugH1">Warnings/Precautions</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Concerns related to adverse effects:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Extravasation: May be a vesicant; ensure proper needle or catheter placement prior to infusion. Avoid extravasation.</p>
<p style="text-indent:-2em;margin-left:4em;">• Ocular effects: Regular ophthalmic examination (including slit lamp and fundoscopy) is recommended. May cause optic neuropathy and/or optic neuritis resulting in visual impairment (peripheral vision loss, changes in acuity) at any time during therapy; permanent blindness has occurred. If symptoms of optic neuropathy and/or optic neuritis occur, prompt ophthalmic evaluation is recommended. If diagnosis of optic neuropathy and/or optic neuritis is confirmed, reevaluate amiodarone therapy. Corneal microdeposits occur in a majority of adults and may cause visual disturbances in up to 10% of patients (blurred vision, halos); asymptomatic microdeposits may be reversible and are not generally considered a reason to discontinue treatment. Corneal refractive laser surgery is generally contraindicated in amiodarone users (from manufacturers of surgical devices).</p>
<p style="text-indent:-2em;margin-left:4em;">• Photosensitivity: Avoid excessive exposure to sunlight; may cause photosensitivity. During long-term treatment, a blue-gray discoloration of exposed skin may occur; risk increased in patients with fair complexion or excessive sun exposure; may be related to cumulative dose and duration of therapy.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Disease-related concerns:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Arrhythmias: Appropriate use: The 2015 ACLS guidelines recommend the consideration of IV amiodarone as the preferred antiarrhythmic for the treatment of pulseless ventricular tachycardia/ventricular fibrillation unresponsive to CPR, defibrillation, and vasopressor therapy (AHA [Link 2015]). In patients with non-life-threatening arrhythmias (eg, atrial fibrillation), amiodarone should be used only if the use of other antiarrhythmics has proven ineffective or are contraindicated.</p>
<p style="text-indent:-2em;margin-left:4em;">• Cardiac devices (eg, implanted defibrillators, pacemakers): Chronic administration of antiarrhythmic drugs may affect defibrillation or pacing thresholds. Assess when initiating amiodarone and during therapy.</p>
<p style="text-indent:-2em;margin-left:4em;">• Electrolyte imbalance: Correct electrolyte disturbances, especially hypokalemia, hypomagnesemia, or hypocalcemia, prior to use and throughout therapy.</p>
<p style="text-indent:-2em;margin-left:4em;">• Myocardial infarction: In the setting of acute myocardial infarction (MI), beta-blocker therapy should be initiated even though concomitant amiodarone therapy provides beta-blockade. In the Cardiac Arrhythmia Suppression Trial (CAST), post-MI patients with asymptomatic, nonlife-threatening ventricular arrhythmias did not benefit and may have been harmed by attempts to suppress arrhythmia with flecainide or encainide. Although use of amiodarone post-MI was not associated with an increase in mortality in 2 trials, antiarrhythmic agents should be reserved for patients with life-threatening ventricular arrhythmias.</p>
<p style="text-indent:-2em;margin-left:4em;">• Wolff-Parkinson-White (WPW) syndrome: Amiodarone should not be used in patients with WPW syndrome and preexcited atrial fibrillation/flutter since ventricular fibrillation may result (AHA/ACC/HRS [January 2014]).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Special populations:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Surgical patients: Use caution and close perioperative monitoring in surgical patients; may enhance myocardial depressant and conduction effects of halogenated inhalational anesthetics; adult respiratory distress syndrome (ARDS) has been reported postoperatively (fatal in rare cases). Hypotension upon discontinuation of cardiopulmonary bypass during open-heart surgery have been reported (rare); relationship to amiodarone is unknown.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Dosage form specific issues:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Benzyl alcohol and derivatives: Some dosage forms may contain benzyl alcohol; large amounts of benzyl alcohol (≥99 mg/kg/day) have been associated with a potentially fatal toxicity ("gasping syndrome") in neonates; the "gasping syndrome" consists of metabolic acidosis, respiratory distress, gasping respirations, CNS dysfunction (including convulsions, intracranial hemorrhage), hypotension, and cardiovascular collapse (AAP ["Inactive" 1997]; CDC 1982); some data suggest that benzoate displaces bilirubin from protein binding sites (Ahlfors 2001); avoid or use dosage forms containing benzyl alcohol with caution in neonates. See manufacturer's labeling.</p>
<p style="text-indent:-2em;margin-left:4em;">• Commercially prepared premixed infusion: Contains the excipient cyclodextrin (sulfobutyl ether beta-cyclodextrin), which may accumulate in patients with renal insufficiency, although the clinical significance of this finding is uncertain (Luke 2010).</p>
<p style="text-indent:-2em;margin-left:4em;">• Long-term use: There has been limited experience in patients receiving IV amiodarone for &gt;3 weeks.</p>
<p style="text-indent:-2em;margin-left:4em;">• Polysorbate 80: Some dosage forms may contain polysorbate 80 (also known as Tweens). Hypersensitivity reactions, usually a delayed reaction, have been reported following exposure to pharmaceutical products containing polysorbate 80 in certain individuals (Isaksson 2002; Lucente 2000; Shelley 1995). Thrombocytopenia, ascites, pulmonary deterioration, and renal and hepatic failure have been reported in premature neonates after receiving parenteral products containing polysorbate 80 (Alade 1986; CDC 1984). See manufacturer's labeling. Commercially prepared premixed amiodarone solutions do not contain polysorbate 80 and may have a lower incidence of hypotension.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Other warnings/precautions: </i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Discontinuation of therapy: Patients may still be at risk for amiodarone-related adverse reactions or drug interactions after the drug has been discontinued. The pharmacokinetics are complex (due to prolonged duration of action and half-life) and difficult to predict.</p></div>
<div class="block dosfc drugH1Div" id="F26978976"><span class="drugH1">Dosage Forms Considerations</span>
<p style="text-indent:0em;display:inline">Vials for injection contain benzyl alcohol which has been associated with “gasping syndrome” in neonates. Commercially-prepared premixed solutions do not contain benzyl alcohol.</p></div>
<div class="block foc drugH1Div" id="F133598"><span class="drugH1">Dosage Forms: US</span>
<p style="text-indent:0em;text-align:justify;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.  [DSC] = Discontinued product</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Solution, Intravenous, as hydrochloride: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Nexterone: 150 mg/100 mL in Dextrose (100 mL); 360 mg/200 mL in Dextrose (200 mL)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 150 mg/3 mL (3 mL); 450 mg/9 mL (9 mL); 900 mg/18 mL (18 mL)</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Tablet, Oral, as hydrochloride: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Pacerone: 100 mg</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Pacerone: 200 mg [scored; contains fd&amp;c red #40 (allura red ac dye), fd&amp;c yellow #6 (sunset yellow)]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Pacerone: 400 mg [scored; contains corn starch]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Pacerone: 400 mg [DSC] [contains quinoline (d&amp;c yellow #10) aluminum lake]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 100 mg, 200 mg, 400 mg</p></div>
<div class="block geq drugH1Div" id="F133581"><span class="drugH1">Generic Equivalent Available: US</span>
<p style="text-indent:0em;display:inline">Yes</p></div>
<div class="block fee drugH1Div" id="F133609"><span class="drugH1">Pricing: US</span>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Solution</b> (Amiodarone HCl Intravenous)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">150 mg/3 mL (per mL): $0.70 - $1.53</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">450 mg/9 mL (per mL): $0.64 - $1.03</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">900 mg/18 mL (per mL): $1.00</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Solution</b> (Nexterone Intravenous)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">150MG/100ML 4.21% (per mL): $0.42</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">360MG/200ML 4.14% (per mL): $0.28</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Tablets</b> (Amiodarone HCl Oral)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">100 mg (per each): $7.43</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">200 mg (per each): $3.30 - $3.48</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">400 mg (per each): $1.60 - $7.48</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Tablets</b> (Pacerone Oral)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">100 mg (per each): $7.43</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">200 mg (per each): $7.27</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">400 mg (per each): $14.96</p>
<p style="text-indent:0em;">
<b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>
<div class="block dinfoc drugH1Div" id="F52865891"><span class="drugH1">Dosage Forms: Canada</span>
<p style="text-indent:0em;text-align:justify;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Solution, Intravenous: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 50 mg/mL (3 mL, 9 mL, 18 mL)</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Solution, Intravenous, as hydrochloride: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 150 mg/3 mL (3 mL)</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Tablet, Oral, as hydrochloride: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 100 mg, 200 mg</p></div>
<div class="block adm drugH1Div" id="F133603"><span class="drugH1">Administration: Adult</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>Oral:</b> Administer consistently with regard to meals. Take in divided doses with meals if GI upset occurs or if taking large daily dose (≥1,000 mg). If GI intolerance occurs with single-dose therapy, use twice daily dosing.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>IV:</b> For infusions &gt;1 hour, use concentrations ≤2 mg/mL unless a central venous catheter is used; commercially prepared premixed solutions in concentrations of 1.5 mg/mL and 1.8 mg/mL are available. Use only volumetric infusion pump; use of drop counting may lead to underdosage. Administer through an IV line located as centrally as possible. For peripheral infusions, an in-line filter has been recommended during administration to reduce the incidence of phlebitis (consult individual institutional policies and procedures). During pulseless VT/VF, administering <b>undiluted</b> is preferred (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-17125434','lexi-content-ref-15101852']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-17125434','lexi-content-ref-15101852'])">Ref</a></span>). <i>The Handbook of Emergency Cardiovascular Care</i> (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Hazinski.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Hazinski.1'])">Ref</a></span>) and the ACLS guidelines do not make any specific recommendations regarding dilution of amiodarone in this setting.</p>
<p style="text-indent:-2em;margin-left:2em;">Adjust administration rate to urgency (give more slowly when perfusing arrhythmia present). Slow the infusion rate if hypotension or bradycardia develops. Infusions &gt;2 hours must be administered in a non-PVC container (eg, glass or polyolefin). PVC tubing is recommended for administration regardless of infusion duration. <b>Incompatible</b> with heparin; flush with saline prior to and following infusion. <b>Note:</b> IV administration at lower flow rates (potentially associated with use in pediatrics) and higher concentrations than recommended may result in leaching of plasticizers (DEHP) from intravenous tubing. DEHP may adversely affect male reproductive tract development. Alternative means of dosing and administration (1 mg/kg aliquots) may need to be considered.</p>
<p style="text-indent:-2em;margin-left:2em;">May be a vesicant; ensure proper needle or catheter placement prior to and during IV infusion. Avoid extravasation.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Extravasation management:</b> If extravasation occurs, stop infusion immediately; leave needle/cannula in place temporarily but do <b>NOT</b> flush the line; gently aspirate extravasated solution, then remove needle/cannula; elevate extremity; apply dry warm compresses; initiate hyaluronidase antidote for refractory cases in addition to supportive management (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-36938775']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-36938775'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Hyaluronidase:</i>
<b>Intradermal or SUBQ:</b> Inject a total of 1 mL (15 units/mL) as 5 separate 0.2 mL injections (using a tuberculin syringe) around the site of extravasation; if IV catheter remains in place, administer IV through the infiltrated catheter; may repeat in 30 to 60 minutes if no resolution (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-28947526','lexi-content-ref-36938775']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-28947526','lexi-content-ref-36938775'])">Ref</a></span>).</p></div>
<div class="block admp drugH1Div" id="F52612221"><span class="drugH1">Administration: Pediatric</span>
<p style="text-indent:-2em;margin-left:2em;">Oral: Administer at same time in relation to meals; do not administer with grapefruit juice. In adults, may administer in divided doses with meals if GI upset occurs or if taking large daily dose.</p>
<p style="text-indent:-2em;margin-left:2em;">IV: Adjust administration rate to patient's clinical condition and urgency; give slowly to patients who have a pulse (ie, perfusing arrhythmia). With perfusing arrhythmias (eg, atrial fibrillation, stable ventricular tachycardia), do not exceed recommended IV concentrations or rates of infusion listed below (severe hepatic toxicity may occur). Slow the infusion rate if hypotension or bradycardia develops. An in-line filter has been recommended during administration to reduce the incidence of phlebitis associated with dilution-induced precipitation (consult individual institutional policies and procedures) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-8410561','lexi-content-ref-manu.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-8410561','lexi-content-ref-manu.1'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">May be a vesicant; ensure proper needle or catheter placement prior to and during IV infusion. Avoid extravasation. If extravasation occurs, stop infusion immediately and disconnect (leave needle/cannula in place); gently aspirate extravasated solution (do <b>NOT</b> flush the line); initiate hyaluronidase antidote for refractory cases (see Management of Drug Extravasations for more details); remove needle/cannula; apply dry warm compresses (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-24420913']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-24420913'])">Ref</a></span>); elevate extremity.</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Pulseless VT or VF:</b> Infants, Children, and Adolescents: Administer via rapid IV bolus; adult data in this setting suggest administration of undiluted drug may be preferred (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-17125434','lexi-content-ref-15101852']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-17125434','lexi-content-ref-15101852'])">Ref</a></span>). Note: PALS guidelines (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-20956230']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-20956230'])">Ref</a></span>) do not specify dilution of bolus dose and <i>The Handbook of Emergency Cardiovascular Care</i> (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Hazinski.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Hazinski.1'])">Ref</a></span>) and the ACLS guidelines do not make any specific recommendations regarding dilution of amiodarone in this setting.</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Perfusing arrhythmias:</b> Information based on adult data: Injection must be diluted before IV use. Administer via central venous catheter, if possible; increased phlebitis may occur with peripheral infusions &gt;3 mg/mL in D<sub>5</sub>W; the use of a central venous catheter with concentrations &gt;2 mg/mL for infusions &gt;1 hour is recommended. Must be infused via volumetric infusion device; drop size of IV solution may be reduced and underdosage may occur if drop counter-infusion sets are used. PVC tubing is recommended for administration regardless of infusion duration. <b>Incompatible</b> with heparin; flush with saline prior to and following infusion. <b>Note:</b> IV administration at lower flow rates (potentially associated with use in pediatrics) and higher concentrations than recommended may result in leaching of plasticizers (DEHP) from intravenous tubing. DEHP may adversely affect male reproductive tract development. Alternative means of dosing and administration (1 mg/kg aliquots) may need to be considered.</p>
<p style="text-indent:-2em;margin-left:6em;">Neonates: Administer loading dose over 60 minutes; may be followed by continuous infusion (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-8074040','lexi-content-ref-19026806','lexi-content-ref-7946778']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-8074040','lexi-content-ref-19026806','lexi-content-ref-7946778'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">Infants, Children, and Adolescents: Administer loading dose over 20 to 60 minutes (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-20956230']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-20956230'])">Ref</a></span>); may be followed by continuous IV infusion</p></div>
<div class="block uica drugH1Div" id="F14471286"><span class="drugH1">Usual Infusion Concentrations: Adult</span>
<p style="text-indent:0em;display:inline">
<b>Note:</b> Premixed solutions available.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>IV bolus or infusion:</b> 1.5 mg/mL (eg, 150 mg in 100 mL of D5W) or 1.8 mg/mL (eg, 360 mg in 200 mL of D5W).</p></div>
<div class="block uicp drugH1Div" id="F14471287"><span class="drugH1">Usual Infusion Concentrations: Pediatric</span>
<p style="text-indent:0em;display:inline">
<b>Note:</b> Premixed solutions available.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>IV infusion:</b> 1.8 mg/mL</p></div>
<div class="block meg drugH1Div" id="F7874279"><span class="drugH1">Medication Guide and/or Vaccine Information Statement (VIS)</span>
<p style="text-indent:0em;display:inline">An FDA-approved patient medication guide, which is available with the product information and as follows, must be dispensed with this medication:</p>
<p style="text-indent:-2em;margin-left:4em;">Cordarone: <a href="/external-redirect?target_url=https%3A%2F%2Fwww.accessdata.fda.gov%2Fdrugsatfda_docs%2Flabel%2F2018%2F018972s054lbl.pdf%23page%3D13&amp;token=Ue5MESOMI%2BUeqyBWWcLP3ehuHD%2Fubw1Sa59LFOtlkrsj0qjcg0NWu9Co84ykrDNFPyYombjhR1c4qBoVDnO2eJBPIjp74F4%2FpWU0UYfVK3%2FNJqr1EMZNlUaBqxVEdkML&amp;TOPIC_ID=8595" target="_blank">https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/018972s054lbl.pdf#page=13</a></p>
<p style="text-indent:-2em;margin-left:4em;">Pacerone: <a href="/external-redirect?target_url=http%3A%2F%2Fwww.fda.gov%2Fdownloads%2FDrugs%2FDrugSafety%2Fucm088668.pdf&amp;token=SHauxSdf9qNc6lLK16E8IL3aNdSXbSTKjKzr5jWxn%2F9%2Bevs591MjKrfB30zg8bRlbDRGHP%2FzX3kXo5tkdFrZrg%3D%3D&amp;TOPIC_ID=8595" target="_blank">http://www.fda.gov/downloads/Drugs/DrugSafety/ucm088668.pdf</a></p></div>
<div class="block use drugH1Div" id="F133602"><span class="drugH1">Use: Labeled Indications</span>
<p style="text-indent:0em;display:inline">
<b>Ventricular arrhythmias: </b>Management of life-threatening recurrent ventricular fibrillation (VF) or recurrent hemodynamically unstable ventricular tachycardia (VT) refractory to other antiarrhythmic agents or in patients intolerant of other agents used for these conditions</p></div>
<div class="block off-label drugH1Div" id="F25724840"><span class="drugH1">Use: Off-Label: Adult</span><p>Atrial fibrillation; Electrical storm and incessant ventricular tachycardia, hemodynamically stable; Nonsustained ventricular tachycardia, symptomatic; Pharmacologic conversion of atrial fibrillation to and maintenance of normal sinus rhythm; Prevention of implantable cardioverter defibrillator shocks; Prevention of postoperative atrial fibrillation and atrial flutter associated with cardiothoracic surgery; Primary prevention of sudden cardiac death due to ventricular arrhythmias; Supraventricular tachycardia (eg, atrioventricular nodal reentrant tachycardia, atrioventricular reentrant tachycardia, focal atrial tachycardia); Sustained monomorphic ventricular tachycardia, hemodynamically stable; Ventricular premature beats, symptomatic</p></div>
<div class="block mst drugH1Div" id="F133691"><span class="drugH1">Medication Safety Issues</span>
<div class="collapsible">
<span class="collapsible-title">Sound-alike/look-alike issues:</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:4em;">Amiodarone may be confused with amantadine, aMILoride, inamrinone.</p>
<p style="text-indent:-2em;margin-left:4em;">Cordarone may be confused with Cardura, Cordran.</p>
<p style="text-indent:-2em;margin-left:4em;">Nexterone may be confused with Cardene IV.</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">High alert medication:</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:4em;">The Institute for Safe Medication Practices (ISMP) includes this medication (IV formulation) among its list of drugs which have a heightened risk of causing significant patient harm when used in error.</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">Older Adult: High-Risk Medication:</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:4em;">Beers Criteria: Amiodarone is identified in the Beers Criteria as a potentially inappropriate medication to be avoided in patients 65 years and older as first-line therapy for atrial fibrillation (unless patient has concomitant heart failure or substantial left ventricular hypertrophy) due to increased toxicities compared to other antiarrhythmics used in atrial fibrillation (Beers Criteria [AGS 2023]).</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">International Issues:</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:4em;">Amyben [brand name for amiodarone (Great Britain)] may be confused with Ambien [US, Argentina, Israel]</p></div>
</div>
</div>
<div class="block cyt drugH1Div" id="F133676"><span class="drugH1">Metabolism/Transport Effects</span>
<p style="text-indent:0em;display:inline">
<b>Substrate</b> of CYP1A2 (minor), CYP2C19 (minor), CYP2C8 (minor), CYP2D6 (minor), CYP3A4 (major), P-glycoprotein/ABCB1 (minor); <b>Note:</b> Assignment of Major/Minor substrate status based on clinically relevant drug interaction potential; <b>Inhibits</b> CYP2C9 (weak), CYP2D6 (weak), CYP3A4 (weak), P-glycoprotein/ABCB1</p></div>
<div class="block dri drugH1Div" id="F133590"><span class="drugH1">Drug Interactions</span><br/><br/><div class="clear"></div><p xmlns=""></p><div class="inner" xmlns=""><p style="text-indent:0em;display:inline"><b>Note</b>: Interacting drugs may <b>not be individually listed below</b> if they are part of a group interaction (eg, individual drugs within “CYP3A4 Inducers [Strong]” are NOT listed).  For a complete list of drug interactions by individual drug name and detailed management recommendations, use the Lexicomp drug interactions program by clicking on the “Launch drug interactions program” link above.</p><p xmlns=""></p></div>
<p style="text-indent:-2em;margin-left:2em;">Afatinib: P-glycoprotein/ABCB1 Inhibitors may increase the serum concentration of Afatinib.  Management: If combined, administer the P-gp inhibitor simultaneously with, or after, the dose of afatinib. Monitor closely for signs and symptoms of afatinib toxicity and if the combination is not tolerated, reduce the afatinib dose by 10 mg.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Agalsidase Alfa: Amiodarone may diminish the therapeutic effect of Agalsidase Alfa. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Agalsidase Beta: Amiodarone may diminish the therapeutic effect of Agalsidase Beta.  Management: Avoid concomitant use of amiodarone with agalsidase beta when possible as amiodarone could antagonize intracellular alpha-galactosidase activity.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Alfuzosin: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Aliskiren: P-glycoprotein/ABCB1 Inhibitors may increase the serum concentration of Aliskiren. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">ALPRAZolam: CYP3A4 Inhibitors (Weak) may increase the serum concentration of ALPRAZolam. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Amifostine: Blood Pressure Lowering Agents may enhance the hypotensive effect of Amifostine.  Management: When used at chemotherapy doses, hold blood pressure lowering medications for 24 hours before amifostine administration. If blood pressure lowering therapy cannot be held, do not administer amifostine. Use caution with radiotherapy doses of amifostine.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Aminolevulinic Acid (Systemic): Photosensitizing Agents may enhance the photosensitizing effect of Aminolevulinic Acid (Systemic). <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Aminolevulinic Acid (Topical): Photosensitizing Agents may enhance the photosensitizing effect of Aminolevulinic Acid (Topical). <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Amisulpride (Oral): QT-prolonging Agents (Highest Risk) may enhance the QTc-prolonging effect of Amisulpride (Oral).  Management: Consider alternatives to this drug combination. If combined, monitor for QTc interval prolongation and ventricular arrhythmias. Patients with additional risk factors for QTc prolongation may be at even greater risk.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Antipsychotic Agents (Second Generation [Atypical]): Blood Pressure Lowering Agents may enhance the hypotensive effect of Antipsychotic Agents (Second Generation [Atypical]). <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Arginine: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Atazanavir: May increase the serum concentration of Amiodarone.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Atorvastatin: Amiodarone may increase the serum concentration of Atorvastatin. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Azithromycin (Systemic): QT-prolonging Agents (Highest Risk) may enhance the QTc-prolonging effect of Azithromycin (Systemic).  Management: Consider alternatives to this combination. Patients with other risk factors (eg, older age, female sex, bradycardia, hypokalemia, hypomagnesemia, heart disease, and higher drug concentrations) are likely at greater risk for these toxicities.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Barbiturates: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Benperidol: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Berotralstat: P-glycoprotein/ABCB1 Inhibitors may increase the serum concentration of Berotralstat.  Management: Decrease the berotralstat dose to 110 mg daily when combined with P-glycoprotein (P-gp) inhibitors.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Beta-Blockers: Amiodarone may enhance the bradycardic effect of Beta-Blockers. Possibly to the point of cardiac arrest. Amiodarone may increase the serum concentration of Beta-Blockers. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Bilastine: P-glycoprotein/ABCB1 Inhibitors may increase the serum concentration of Bilastine. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Bile Acid Sequestrants: May decrease the bioavailability of Amiodarone. Management: Consider alternatives to this combination due to the risk of subtherapeutic amiodarone serum concentrations. If amiodarone is coadministered with colesevelam, administer amiodarone at least 4 hours before colesevelam.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Blood Pressure Lowering Agents: May enhance the hypotensive effect of Hypotension-Associated Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Bradycardia-Causing Agents: May enhance the bradycardic effect of other Bradycardia-Causing Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Brimonidine (Topical): May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Bromperidol: May diminish the hypotensive effect of Blood Pressure Lowering Agents. Blood Pressure Lowering Agents may enhance the hypotensive effect of Bromperidol.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Calcium Channel Blockers (Nondihydropyridine): May enhance the bradycardic effect of Amiodarone. Sinus arrest has been reported.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">CarBAMazepine: CYP3A4 Inhibitors (Weak) may increase the serum concentration of CarBAMazepine. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Carbetocin: May enhance the QTc-prolonging effect of QT-prolonging Agents (Highest Risk). Management: Consider alternatives to this drug combination. If combined, monitor for QTc interval prolongation and ventricular arrhythmias. Patients with additional risk factors for QTc prolongation may be at even higher risk.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Cardiac Glycosides: Amiodarone may increase the serum concentration of Cardiac Glycosides.  Management: Reduce the dose of cardiac glycosides by 30% to 50%  or reduce the frequency of administration when initiating concomitant amiodarone therapy. Monitor for increased serum concentrations and toxic effects of cardiac glycosides.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Celiprolol: P-glycoprotein/ABCB1 Inhibitors may increase the serum concentration of Celiprolol. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ceritinib: Amiodarone may enhance the bradycardic effect of Ceritinib. Amiodarone may enhance the QTc-prolonging effect of Ceritinib.  Management: Consider alternatives to this combination. Patients with other risk factors (eg, older age, female sex, bradycardia, hypokalemia, hypomagnesemia, heart disease, and higher drug concentrations) are likely at greater risk for these toxicities.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Chloroquine: QT-prolonging Agents (Highest Risk) may enhance the QTc-prolonging effect of Chloroquine.  Management: Consider alternatives to this combination. If combined, monitor for QTc interval prolongation and ventricular arrhythmias. Patients with additional risk factors for QTc prolongation may be at even higher risk.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Cimetidine: May increase the serum concentration of Amiodarone.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Citalopram: QT-prolonging Agents (Highest Risk) may enhance the QTc-prolonging effect of Citalopram. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Clarithromycin: QT-prolonging Agents (Highest Risk) may enhance the QTc-prolonging effect of Clarithromycin. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Clofazimine: QT-prolonging Agents (Highest Risk) may enhance the QTc-prolonging effect of Clofazimine.  Management: Consider alternatives to this combination. If combined, monitor for QTc interval prolongation and ventricular arrhythmias. Patients with additional risk factors for QTc prolongation may be at even higher risk.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">ClomiPRAMINE: May enhance the QTc-prolonging effect of QT-prolonging Agents (Highest Risk). Management: Consider alternatives to this drug combination. If combined, monitor for QTc interval prolongation and ventricular arrhythmias. Patients with additional risk factors for QTc prolongation may be at even higher risk.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">CloZAPine: Amiodarone may enhance the QTc-prolonging effect of CloZAPine. Amiodarone may increase the serum concentration of CloZAPine.  Management: Consider alternatives to this combination. Patients with other risk factors (eg, older age, female sex, bradycardia, hypokalemia, hypomagnesemia, heart disease, and higher drug concentrations) are likely at greater risk for these toxicities.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Colchicine: P-glycoprotein/ABCB1 Inhibitors may increase the serum concentration of Colchicine. Colchicine distribution into certain tissues (e.g., brain) may also be increased.  Management: This combination is often contraindicated, but combined use may be permitted with dose adjustment and monitoring. Recommendations vary based on brand, indication, use of CYP3A4 inhibitors, and hepatic/renal function. See interaction monograph for details.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">CycloPHOSphamide: May enhance the adverse/toxic effect of Amiodarone. Specifically, the risk of pulmonary toxicity may be enhanced.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">CycloSPORINE (Systemic): P-glycoprotein/ABCB1 Inhibitors may increase the serum concentration of CycloSPORINE (Systemic). <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">CycloSPORINE (Systemic): CYP3A4 Inhibitors (Weak) may increase the serum concentration of CycloSPORINE (Systemic). <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">CYP2C8 Inhibitors (Strong): May increase the serum concentration of Amiodarone.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">CYP3A4 Inducers (Strong): May decrease serum concentrations of the active metabolite(s) of Amiodarone. CYP3A4 Inducers (Strong) may decrease the serum concentration of Amiodarone.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">CYP3A4 Inhibitors (Moderate): May increase the serum concentration of Amiodarone.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">CYP3A4 Inhibitors (Strong): May increase the serum concentration of Amiodarone. Management: Consider alternatives to use of amiodarone and strong CYP3A4 inhibitors. If combined, monitor for increased amiodarone concentrations and toxicities.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Dabigatran Etexilate: P-glycoprotein/ABCB1 Inhibitors may increase serum concentrations of the active metabolite(s) of Dabigatran Etexilate. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Dabrafenib: May enhance the QTc-prolonging effect of QT-prolonging Agents (Highest Risk). Management: Consider alternatives to this drug combination. If combined, monitor for QTc interval prolongation and ventricular arrhythmias. Patients with additional risk factors for QTc prolongation may be at even higher risk.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Daclatasvir: May enhance the bradycardic effect of Amiodarone.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Dasatinib: QT-prolonging Agents (Highest Risk) may enhance the QTc-prolonging effect of Dasatinib.  Management: Consider alternatives to this combination. Patients with other risk factors (eg, older age, female sex, bradycardia, hypokalemia, hypomagnesemia, heart disease, and higher drug concentrations) are likely at greater risk for these toxicities.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Diazoxide: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Domperidone: QT-prolonging Agents (Highest Risk) may enhance the QTc-prolonging effect of Domperidone. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Doxepin-Containing Products: QT-prolonging Agents (Highest Risk) may enhance the QTc-prolonging effect of Doxepin-Containing Products.  Management: Consider alternatives to this combination. Patients with other risk factors (eg, older age, female sex, bradycardia, hypokalemia, hypomagnesemia, heart disease, and higher drug concentrations) are likely at greater risk for these toxicities.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">DOXOrubicin (Conventional): P-glycoprotein/ABCB1 Inhibitors may increase the serum concentration of DOXOrubicin (Conventional). <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">DOXOrubicin (Liposomal): P-glycoprotein/ABCB1 Inhibitors may increase the serum concentration of DOXOrubicin (Liposomal). <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">DroPERidol: QT-prolonging Agents (Highest Risk) may enhance the QTc-prolonging effect of DroPERidol.  Management: Consider alternatives to this combination. Patients with other risk factors (eg, older age, female sex, bradycardia, hypokalemia, hypomagnesemia, heart disease, and higher drug concentrations) are likely at greater risk for these toxicities.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">DULoxetine: Blood Pressure Lowering Agents may enhance the hypotensive effect of DULoxetine. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Edoxaban: P-glycoprotein/ABCB1 Inhibitors may increase the serum concentration of Edoxaban. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Encorafenib: May enhance the QTc-prolonging effect of Amiodarone. Encorafenib may decrease the serum concentration of Amiodarone. Management: Consider alternatives to this drug combination. If combined, monitor for QTc interval prolongation, ventricular arrhythmias, and decreased amiodarone concentrations. Patients with additional risk factors for QTc prolongation may be at even higher risk.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Entrectinib: May enhance the QTc-prolonging effect of QT-prolonging Agents (Highest Risk).<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Erythromycin (Systemic): Amiodarone may enhance the QTc-prolonging effect of Erythromycin (Systemic). Erythromycin (Systemic) may enhance the QTc-prolonging effect of Amiodarone. Erythromycin (Systemic) may increase the serum concentration of Amiodarone. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Escitalopram: QT-prolonging Agents (Highest Risk) may enhance the QTc-prolonging effect of Escitalopram.  Management: Consider alternatives to this combination. Patients with other risk factors (eg, older age, female sex, bradycardia, hypokalemia, hypomagnesemia, heart disease, and higher drug concentrations) are likely at greater risk for these toxicities.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Etelcalcetide: May enhance the QTc-prolonging effect of QT-prolonging Agents (Highest Risk). Management: Consider alternatives to this drug combination. If combined, monitor for QTc interval prolongation and ventricular arrhythmias. Patients with additional risk factors for QTc prolongation may be at even higher risk.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Etoposide: P-glycoprotein/ABCB1 Inhibitors may increase the serum concentration of Etoposide. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Etoposide Phosphate: P-glycoprotein/ABCB1 Inhibitors may increase the serum concentration of Etoposide Phosphate. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Etrasimod: May enhance the bradycardic effect of Bradycardia-Causing Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Everolimus: P-glycoprotein/ABCB1 Inhibitors may increase the serum concentration of Everolimus. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Fexinidazole: May enhance the QTc-prolonging effect of QT-prolonging Agents (Highest Risk).<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Finerenone: CYP3A4 Inhibitors (Weak) may increase the serum concentration of Finerenone. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Fingolimod: May enhance the QTc-prolonging effect of Amiodarone.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Flecainide: Amiodarone may enhance the QTc-prolonging effect of Flecainide. Amiodarone may increase the serum concentration of Flecainide.  Management: Decrease flecainide dose by 50%.   Monitor for QTc interval prolongation and ventricular arrhythmias, and consider monitoring for elevated flecainide concentrations. Patients with additional risk factors for QTc prolongation may be at even higher risk.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Flibanserin: CYP3A4 Inhibitors (Weak) may increase the serum concentration of Flibanserin. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Fluorouracil Products: QT-prolonging Agents (Highest Risk) may enhance the QTc-prolonging effect of Fluorouracil Products.  Management: Consider alternatives to this drug combination. If combined, monitor for QTc interval prolongation and ventricular arrhythmias. Patients with additional risk factors for QTc prolongation may be at even higher risk.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Flupentixol: QT-prolonging Agents (Highest Risk) may enhance the QTc-prolonging effect of Flupentixol. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Fosphenytoin: May decrease the serum concentration of Amiodarone. Amiodarone may increase the serum concentration of Fosphenytoin.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Fusidic Acid (Systemic): May increase the serum concentration of CYP3A4 Substrates (High risk with Inhibitors).<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Gadobenate Dimeglumine: QT-prolonging Agents (Highest Risk) may enhance the QTc-prolonging effect of Gadobenate Dimeglumine.  Management: Consider alternatives to this combination. If combined, monitor for QTc interval prolongation and ventricular arrhythmias. Patients with additional risk factors for QTc prolongation may be at even higher risk.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Gemifloxacin: May enhance the QTc-prolonging effect of Amiodarone.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Gilteritinib: May enhance the QTc-prolonging effect of QT-prolonging Agents (Highest Risk). Management: Consider alternatives to this combination. If use is necessary, monitor for QTc interval prolongation and arrhythmias.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Glecaprevir and Pibrentasvir: P-glycoprotein/ABCB1 Inhibitors may increase the serum concentration of Glecaprevir and Pibrentasvir. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Grapefruit Juice: May increase the serum concentration of Amiodarone.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Halofantrine: QT-prolonging Agents (Highest Risk) may enhance the QTc-prolonging effect of Halofantrine.  Management: Consider alternatives to this combination. If combined, monitor for QTc interval prolongation and ventricular arrhythmias. Patients with additional risk factors for QTc prolongation may be at even higher risk.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Haloperidol: Amiodarone may enhance the QTc-prolonging effect of Haloperidol.  Management: Consider alternatives to this drug combination. If combined, monitor for QTc interval prolongation and ventricular arrhythmias. Patients with additional risk factors for QTc prolongation may be at even higher risk.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Herbal Products with Blood Pressure Lowering Effects: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">HydrOXYzine: May enhance the QTc-prolonging effect of QT-prolonging Agents (Highest Risk).<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Hypotension-Associated Agents: Blood Pressure Lowering Agents may enhance the hypotensive effect of Hypotension-Associated Agents. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Imipramine: May enhance the QTc-prolonging effect of QT-prolonging Agents (Highest Risk). Management: Consider alternatives to this drug combination. If combined, monitor for QTc interval prolongation and ventricular arrhythmias. Patients with additional risk factors for QTc prolongation may be at even higher risk.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Indinavir: May increase the serum concentration of Amiodarone.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Inotuzumab Ozogamicin: QT-prolonging Agents (Highest Risk) may enhance the QTc-prolonging effect of Inotuzumab Ozogamicin.  Management: Consider alternatives to this combination. If combined, monitor for QTc interval prolongation and ventricular arrhythmias. Patients with additional risk factors for QTc prolongation may be at even higher risk.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ivabradine: Bradycardia-Causing Agents may enhance the bradycardic effect of Ivabradine. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ixabepilone: CYP3A4 Inhibitors (Weak) may increase the serum concentration of Ixabepilone. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Lacosamide: Bradycardia-Causing Agents may enhance the AV-blocking effect of Lacosamide. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Lacosamide: Antiarrhythmic Agents (Class III) may enhance the adverse/toxic effect of Lacosamide. Specifically the risk for bradycardia, ventricular tachyarrhythmias, or a prolonged PR interval may be increased. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Lapatinib: P-glycoprotein/ABCB1 Inhibitors may increase the serum concentration of Lapatinib. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Larotrectinib: P-glycoprotein/ABCB1 Inhibitors may increase the serum concentration of Larotrectinib. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Lefamulin: May enhance the QTc-prolonging effect of QT-prolonging CYP3A4 Substrates. Management: Do not use lefamulin tablets with QT-prolonging CYP3A4 substrates. Lefamulin prescribing information lists this combination as contraindicated.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Lemborexant: CYP3A4 Inhibitors (Weak) may increase the serum concentration of Lemborexant.  Management: The maximum recommended dosage of lemborexant is 5 mg, no more than once per night, when coadministered with weak CYP3A4 inhibitors.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Levodopa-Foslevodopa: Blood Pressure Lowering Agents may enhance the hypotensive effect of Levodopa-Foslevodopa. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Levofloxacin-Containing Products (Systemic): May enhance the QTc-prolonging effect of Amiodarone.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Levoketoconazole: QT-prolonging CYP3A4 Substrates may enhance the QTc-prolonging effect of Levoketoconazole. Levoketoconazole may increase the serum concentration of QT-prolonging CYP3A4 Substrates. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Lidocaine (Systemic): Amiodarone may increase the serum concentration of Lidocaine (Systemic). <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Lofepramine: May enhance the arrhythmogenic effect of Amiodarone.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Lofexidine: May enhance the QTc-prolonging effect of Amiodarone. Management: Consider alternatives to this combination. Patients with other risk factors (eg, older age, female sex, bradycardia, hypokalemia, hypomagnesemia, heart disease, and higher drug concentrations) are likely at greater risk for these toxicities.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Lomitapide: CYP3A4 Inhibitors (Weak) may increase the serum concentration of Lomitapide.  Management: Patients on lomitapide 5 mg/day may continue that dose. Patients taking lomitapide 10 mg/day or more should decrease the lomitapide dose by half. The lomitapide dose may then be titrated up to a max adult dose of 30 mg/day.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Lonafarnib: CYP3A4 Inhibitors (Weak) may increase the serum concentration of Lonafarnib.  Management: Avoid concurrent use of lonafarnib with weak CYP3A4 inhibitors. If concurrent use is unavoidable, reduce the lonafarnib dose to or continue at a dose of 115 mg/square meter. Monitor for evidence of arrhythmia, syncope, palpitations, or similar effects.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Loratadine: Amiodarone may increase the serum concentration of Loratadine.  Management: Due to reported QT interval prolongation and Torsades de Pointes with this combination, consider an alternative to loratadine when possible. If concomitant use cannot be avoided, monitor QT interval and for signs of dyshythmias (eg, syncope).<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Lormetazepam: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Lovastatin: Amiodarone may increase the serum concentration of Lovastatin.  Management: Consider using a non-interacting statin (pravastatin, pitavastatin) in patients on amiodarone. If combined, limit the lovastatin dose to 40 mg daily and monitor for lovastatin toxicities (eg, myalgia, liver function test elevations, rhabdomyolysis).<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Macitentan: Amiodarone may increase the serum concentration of Macitentan. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Meglumine Antimoniate: May enhance the QTc-prolonging effect of QT-prolonging Agents (Highest Risk). Management: Consider alternatives to this drug combination. If combined, monitor for QTc interval prolongation and ventricular arrhythmias. Patients with additional risk factors for QTc prolongation may be at even higher risk.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Methadone: Amiodarone may enhance the QTc-prolonging effect of Methadone.  Management: Consider alternatives to this drug combination. If combined, monitor for QTc interval prolongation and ventricular arrhythmias. Patients with additional risk factors for QTc prolongation may be at even higher risk.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Methoxsalen (Systemic): Photosensitizing Agents may enhance the photosensitizing effect of Methoxsalen (Systemic). <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Midazolam: CYP3A4 Inhibitors (Weak) may increase the serum concentration of Midazolam. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Midodrine: May enhance the bradycardic effect of Bradycardia-Causing Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Midostaurin: QT-prolonging Agents (Highest Risk) may enhance the QTc-prolonging effect of Midostaurin.  Management: Consider alternatives to this combination. If combined, monitor for QTc interval prolongation and ventricular arrhythmias. Patients with additional risk factors for QTc prolongation may be at even higher risk.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Mipomersen: Amiodarone may enhance the hepatotoxic effect of Mipomersen. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Molsidomine: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Morphine (Systemic): P-glycoprotein/ABCB1 Inhibitors may increase the serum concentration of Morphine (Systemic). <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Moxifloxacin (Systemic): QT-prolonging Agents (Highest Risk) may enhance the QTc-prolonging effect of Moxifloxacin (Systemic). <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Nadolol: P-glycoprotein/ABCB1 Inhibitors may increase the serum concentration of Nadolol. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Naftopidil: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Naldemedine: P-glycoprotein/ABCB1 Inhibitors may increase the serum concentration of Naldemedine. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Naloxegol: P-glycoprotein/ABCB1 Inhibitors may increase the serum concentration of Naloxegol. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Nelfinavir: May increase the serum concentration of Amiodarone.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Nicergoline: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Nicorandil: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Nilotinib: QT-prolonging Agents (Highest Risk) may enhance the QTc-prolonging effect of Nilotinib. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">NiMODipine: CYP3A4 Inhibitors (Weak) may increase the serum concentration of NiMODipine. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Nirmatrelvir and Ritonavir: May increase the serum concentration of Amiodarone.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Nitroprusside: Blood Pressure Lowering Agents may enhance the hypotensive effect of Nitroprusside. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Obinutuzumab: May enhance the hypotensive effect of Blood Pressure Lowering Agents. Management: Consider temporarily withholding blood pressure lowering medications beginning 12 hours prior to obinutuzumab infusion and continuing until 1 hour after the end of the infusion.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">OLANZapine: QT-prolonging Agents (Highest Risk) may enhance the QTc-prolonging effect of OLANZapine.  Management: Consider alternatives to this combination. Patients with other risk factors (eg, older age, female sex, bradycardia, hypokalemia, hypomagnesemia, heart disease, and higher drug concentrations) are likely at greater risk for these toxicities.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ondansetron: Amiodarone may enhance the QTc-prolonging effect of Ondansetron.  Management: Consider alternatives to this combination. If combined, monitor for QTc interval prolongation and ventricular arrhythmias. Patients with additional risk factors for QTc prolongation may be at even higher risk.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Orlistat: May decrease the serum concentration of Amiodarone.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Osimertinib: QT-prolonging Agents (Highest Risk) may enhance the QTc-prolonging effect of Osimertinib.  Management: Consider alternatives to this combination. Patients with other risk factors (eg, older age, female sex, bradycardia, hypokalemia, hypomagnesemia, heart disease, and higher drug concentrations) are likely at greater risk for these toxicities.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Oxygen: May enhance the adverse/toxic effect of Amiodarone. Specifically, amiodarone pulmonary toxicity may be enhanced.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Oxytocin: May enhance the QTc-prolonging effect of QT-prolonging Agents (Highest Risk). Management: Consider alternatives to this drug combination. If combined, monitor for QTc interval prolongation and ventricular arrhythmias. Patients with additional risk factors for QTc prolongation may be at even higher risk.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ozanimod: May enhance the bradycardic effect of Bradycardia-Causing Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Pacritinib: QT-prolonging Agents (Highest Risk) may enhance the QTc-prolonging effect of Pacritinib.  Management: Monitor for QTc interval prolongation and ventricular arrhythmias when these agents are combined. Patients with additional risk factors for QTc prolongation may be at even higher risk.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">PAZOPanib: Amiodarone may enhance the QTc-prolonging effect of PAZOPanib. Amiodarone may increase the serum concentration of PAZOPanib. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Pentamidine (Systemic): QT-prolonging Agents (Highest Risk) may enhance the QTc-prolonging effect of Pentamidine (Systemic).  Management: Consider alternatives to this combination. If combined, monitor for QTc interval prolongation and ventricular arrhythmias. Patients with additional risk factors for QTc prolongation may be at even higher risk.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Pentoxifylline: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Phenytoin: May decrease the serum concentration of Amiodarone. Amiodarone may increase the serum concentration of Phenytoin.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Pholcodine: Blood Pressure Lowering Agents may enhance the hypotensive effect of Pholcodine. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Phosphodiesterase 5 Inhibitors: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Pilsicainide: QT-prolonging Agents (Highest Risk) may enhance the QTc-prolonging effect of Pilsicainide.  Management: Consider alternatives to this combination. If combined, monitor for QTc interval prolongation and ventricular arrhythmias. Patients with additional risk factors for QTc prolongation may be at even higher risk.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Pimozide: QT-prolonging Agents (Highest Risk) may enhance the QTc-prolonging effect of Pimozide.  Management: Consider alternatives to this combination. Patients with other risk factors (eg, older age, female sex, bradycardia, hypokalemia, hypomagnesemia, heart disease, and higher drug concentrations) are likely at greater risk for these toxicities.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Piperaquine: QT-prolonging Agents (Highest Risk) may enhance the QTc-prolonging effect of Piperaquine. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ponesimod: Bradycardia-Causing Agents may enhance the bradycardic effect of Ponesimod.  Management: Avoid coadministration of ponesimod with drugs that may cause bradycardia when possible. If combined, monitor heart rate closely and consider obtaining a cardiology consult. Do not initiate ponesimod in patients on beta-blockers if HR is less than 55 bpm.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Porfimer: Photosensitizing Agents may enhance the photosensitizing effect of Porfimer. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Posaconazole: May increase the serum concentration of QT-prolonging CYP3A4 Substrates. Such increases may lead to a greater risk for proarrhythmic effects and other similar toxicities.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Pralsetinib: P-glycoprotein/ABCB1 Inhibitors may increase the serum concentration of Pralsetinib.  Management: If this combo cannot be avoided, decrease pralsetinib dose from 400 mg daily to 300 mg daily; from 300 mg daily to 200 mg daily; and from 200 mg daily to 100 mg daily.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Probucol: QT-prolonging Agents (Highest Risk) may enhance the QTc-prolonging effect of Probucol. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Propafenone: Amiodarone may enhance the QTc-prolonging effect of Propafenone. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Propofol: May enhance the QTc-prolonging effect of QT-prolonging Agents (Highest Risk). Management: Consider alternatives to this drug combination. If combined, monitor for QTc interval prolongation and ventricular arrhythmias. Patients with additional risk factors for QTc prolongation may be at even higher risk.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Prostacyclin Analogues: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">QT-prolonging Agents (Indeterminate Risk - Avoid): May enhance the QTc-prolonging effect of QT-prolonging Agents (Highest Risk). Management: Monitor for QTc interval prolongation and ventricular arrhythmias when these agents are combined. Patients with additional risk factors for QTc prolongation may be at even higher risk.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">QT-prolonging Agents (Indeterminate Risk - Caution): May enhance the QTc-prolonging effect of QT-prolonging Agents (Highest Risk). Management: Monitor for QTc interval prolongation and ventricular arrhythmias when these agents are combined. Patients with additional risk factors for QTc prolongation may be at even higher risk.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">QT-prolonging Class IA Antiarrhythmics (Highest Risk): May enhance the QTc-prolonging effect of Amiodarone. Management: Consider alternatives to this drug combination. If combined, consider dose reductions of the class IA antiarrhythmic (30% to 50%) and monitor for QTc interval prolongation and ventricular arrhythmias.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">QT-prolonging Class III Antiarrhythmics (Highest Risk): May enhance the QTc-prolonging effect of Amiodarone. Management: Consider alternatives to this drug combination. If combined, monitor for QTc interval prolongation and ventricular arrhythmias. Patients with additional risk factors for QTc prolongation may be at even higher risk.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">QT-Prolonging Inhalational Anesthetics (Moderate Risk): May enhance the QTc-prolonging effect of QT-prolonging Agents (Highest Risk). Management: Consider alternatives to this drug combination. If combined, monitor for QTc interval prolongation and ventricular arrhythmias. Patients with additional risk factors for QTc prolongation may be at even higher risk.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">QT-prolonging Kinase Inhibitors (Highest Risk): May enhance the QTc-prolonging effect of Amiodarone. Management: Consider alternatives to this drug combination. If combined, monitor for QTc interval prolongation and ventricular arrhythmias. Patients with additional risk factors for QTc prolongation may be at even higher risk.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">QT-prolonging Miscellaneous Agents (Highest Risk): May enhance the QTc-prolonging effect of Amiodarone. Management: Consider alternatives to this drug combination. If combined, monitor for QTc interval prolongation and ventricular arrhythmias. Patients with additional risk factors for QTc prolongation may be at even higher risk.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">QT-prolonging Moderate CYP3A4 Inhibitors (Moderate Risk): May enhance the QTc-prolonging effect of Amiodarone. QT-prolonging Moderate CYP3A4 Inhibitors (Moderate Risk) may increase the serum concentration of Amiodarone. Management: Consider alternatives to this drug combination. If combined, monitor for QTc interval prolongation and ventricular arrhythmias. Patients with additional risk factors for QTc prolongation may be at even higher risk.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">QT-prolonging Strong CYP3A4 Inhibitors (Highest Risk): May enhance the QTc-prolonging effect of Amiodarone. QT-prolonging Strong CYP3A4 Inhibitors (Highest Risk) may increase the serum concentration of Amiodarone. Management: Consider alternatives to this combination. If combined, monitor for increased amiodarone toxicities, including QTc interval prolongation and ventricular arrhythmias. Patients with additional risk factors for QTc prolongation may be at even higher risk.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">QUEtiapine: QT-prolonging Agents (Highest Risk) may enhance the QTc-prolonging effect of QUEtiapine. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Quinagolide: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Quizartinib: May enhance the QTc-prolonging effect of QT-prolonging Agents (Highest Risk). Management: Consider alternatives to this combination. Patients with other risk factors (eg, older age, female sex, bradycardia, hypokalemia, hypomagnesemia, heart disease, and higher drug concentrations) are likely at greater risk for these toxicities.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ranolazine: P-glycoprotein/ABCB1 Inhibitors may increase the serum concentration of Ranolazine. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Red Yeast Rice: Amiodarone may increase the serum concentration of Red Yeast Rice.  Management: Consider using a non-interacting statin (eg, pravastatin, pitavastatin) in patients on amiodarone. If combined, limit the adult red yeast rice dose to the equivalent of lovastatin 40 mg daily and monitor for toxicities (eg, myalgia, rhabdomyolysis).<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Relugolix: P-glycoprotein/ABCB1 Inhibitors may increase the serum concentration of Relugolix.  Management: Avoid coadministration of relugolix with oral P-gp inhibitors whenever possible. If combined, take relugolix at least 6 hours prior to the P-gp inhibitor and monitor patients more frequently for adverse reactions.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Relugolix, Estradiol, and Norethindrone: P-glycoprotein/ABCB1 Inhibitors may increase the serum concentration of Relugolix, Estradiol, and Norethindrone.  Management: Avoid use of relugolix/estradiol/norethindrone with P-glycoprotein (P-gp) inhibitors. If concomitant use is unavoidable, relugolix/estradiol/norethindrone should be administered at least 6 hours before the P-gp inhibitor.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Repotrectinib: P-glycoprotein/ABCB1 Inhibitors may increase the serum concentration of Repotrectinib. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ribociclib: QT-prolonging Agents (Highest Risk) may enhance the QTc-prolonging effect of Ribociclib. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">RifAXIMin: P-glycoprotein/ABCB1 Inhibitors may increase the serum concentration of RifAXIMin. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Rimegepant: P-glycoprotein/ABCB1 Inhibitors may increase the serum concentration of Rimegepant.  Management: Avoid administration of another dose of rimegepant within 48 hours if given concomitantly with a P-glycoprotein (P-gp) inhibitor.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">RisperiDONE: QT-prolonging Agents (Highest Risk) may enhance the CNS depressant effect of RisperiDONE. QT-prolonging Agents (Highest Risk) may enhance the QTc-prolonging effect of RisperiDONE.  Management: Consider alternatives to this drug combination. If combined, monitor for QTc interval prolongation and ventricular arrhythmias. Patients with additional risk factors for QTc prolongation may be at even higher risk.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ritonavir: May increase the serum concentration of Amiodarone. Management: Ritonavir US prescribing information lists this combination as contraindicated. Amiodarone use should be avoided with lopinavir/ritonavir, but if the combination must be used, monitor closely for increased amiodarone serum concentrations and effects.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Rivaroxaban: Amiodarone may increase the serum concentration of Rivaroxaban. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">RomiDEPsin: P-glycoprotein/ABCB1 Inhibitors may increase the serum concentration of RomiDEPsin. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Saquinavir: May enhance the QTc-prolonging effect of Amiodarone. Saquinavir may increase the serum concentration of Amiodarone.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Sertindole: May enhance the QTc-prolonging effect of QT-prolonging Agents (Highest Risk).<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Silodosin: P-glycoprotein/ABCB1 Inhibitors may increase the serum concentration of Silodosin. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Silodosin: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Simvastatin: Amiodarone may increase serum concentrations of the active metabolite(s) of Simvastatin. Amiodarone may increase the serum concentration of Simvastatin.  Management: Consider using a non-interacting statin (pravastatin) in patients on amiodarone. If combined, limit the adult simvastatin dose to 20 mg daily and monitor for evidence of simvastatin toxicities (eg, myalgia, liver function test elevations, rhabdomyolysis).<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Siponimod: Bradycardia-Causing Agents may enhance the bradycardic effect of Siponimod.  Management: Avoid coadministration of siponimod with drugs that may cause bradycardia. If combined, consider obtaining a cardiology consult regarding patient monitoring.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Sirolimus (Conventional): P-glycoprotein/ABCB1 Inhibitors may increase the serum concentration of Sirolimus (Conventional).  Management: Avoid concurrent use of sirolimus with P-glycoprotein (P-gp) inhibitors when possible and alternative agents with lesser interaction potential with sirolimus should be considered. Monitor for increased sirolimus concentrations/toxicity if combined.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Sirolimus (Protein Bound): P-glycoprotein/ABCB1 Inhibitors may increase the serum concentration of Sirolimus (Protein Bound). <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Sodium Iodide I131: Amiodarone may diminish the therapeutic effect of Sodium Iodide I131.  Management: Discontinue amiodarone at least 6 months before sodium iodide I-131 administration, and avoid concurrent use.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Sofosbuvir: May enhance the bradycardic effect of Amiodarone. Management: Use alternative to a sofosbuvir-containing combo or to amiodarone when possible. If alternatives not possible, monitor in inpatient setting for first 48 hours of coadministration with daily outpatient monitoring for at least 2 weeks.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Sparfloxacin: QT-prolonging Agents (Highest Risk) may enhance the QTc-prolonging effect of Sparfloxacin. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Sulfonylureas: Amiodarone may enhance the hypoglycemic effect of Sulfonylureas. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">SUNItinib: QT-prolonging Agents (Highest Risk) may enhance the QTc-prolonging effect of SUNItinib.  Management: Consider alternatives to this combination. Patients with other risk factors (eg, older age, female sex, bradycardia, hypokalemia, hypomagnesemia, heart disease, and higher drug concentrations) are likely at greater risk for these toxicities.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Tacrolimus (Systemic): May enhance the QTc-prolonging effect of Amiodarone. Amiodarone may increase the serum concentration of Tacrolimus (Systemic).<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Talazoparib: Amiodarone may increase the serum concentration of Talazoparib.  Management: In breast cancer, if concurrent use cannot be avoided, reduce talazoparib dose to 0.75 mg once daily. In prostate cancer, monitor patients for increased adverse events.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Tegaserod (Withdrawn from US Market): P-glycoprotein/ABCB1 Inhibitors may increase the serum concentration of Tegaserod (Withdrawn from US Market). <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Teniposide: P-glycoprotein/ABCB1 Inhibitors may increase the serum concentration of Teniposide. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Tenofovir Disoproxil Fumarate: P-glycoprotein/ABCB1 Inhibitors may increase the serum concentration of Tenofovir Disoproxil Fumarate. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Terbutaline: May enhance the QTc-prolonging effect of QT-prolonging Agents (Highest Risk). Management: Consider alternatives to this combination. Patients with other risk factors (eg, older age, female sex, bradycardia, hypokalemia, hypomagnesemia, heart disease, and higher drug concentrations) are likely at greater risk for these toxicities.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Thioridazine: QT-prolonging Agents (Highest Risk) may enhance the QTc-prolonging effect of Thioridazine. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Thyroid Products: Amiodarone may diminish the therapeutic effect of Thyroid Products. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Tipranavir: May increase the serum concentration of Amiodarone.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">TiZANidine: Amiodarone may increase the serum concentration of TiZANidine. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Tofacitinib: May enhance the bradycardic effect of Bradycardia-Causing Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">TOLBUTamide: CYP2C9 Inhibitors (Weak) may increase the serum concentration of TOLBUTamide. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Topotecan: P-glycoprotein/ABCB1 Inhibitors may increase the serum concentration of Topotecan. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Toremifene: QT-prolonging Agents (Highest Risk) may enhance the QTc-prolonging effect of Toremifene.  Management: Consider alternatives to this combination. Patients with other risk factors (eg, older age, female sex, bradycardia, hypokalemia, hypomagnesemia, heart disease, and higher drug concentrations) are likely at greater risk for these toxicities.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Triazolam: CYP3A4 Inhibitors (Weak) may increase the serum concentration of Triazolam. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ubrogepant: CYP3A4 Inhibitors (Weak) may increase the serum concentration of Ubrogepant.  Management: In patients taking weak CYP3A4 inhibitors, the initial and second dose (given at least 2 hours later if needed) of ubrogepant should be limited to 50 mg.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Vemurafenib: QT-prolonging Agents (Highest Risk) may enhance the QTc-prolonging effect of Vemurafenib.  Management: Consider alternatives to this combination. Patients with other risk factors (eg, older age, female sex, bradycardia, hypokalemia, hypomagnesemia, heart disease, and higher drug concentrations) are likely at greater risk for these toxicities.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Venetoclax: P-glycoprotein/ABCB1 Inhibitors may increase the serum concentration of Venetoclax.  Management: Reduce the venetoclax dose by at least 50% in patients requiring concomitant treatment with P-glycoprotein (P-gp) inhibitors. Resume the previous venetoclax dose 2 to 3 days after discontinuation of a P-gp inhibitor.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Verteporfin: Photosensitizing Agents may enhance the photosensitizing effect of Verteporfin. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">VinCRIStine (Liposomal): P-glycoprotein/ABCB1 Inhibitors may increase the serum concentration of VinCRIStine (Liposomal). <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Vitamin K Antagonists (eg, warfarin): Amiodarone may enhance the anticoagulant effect of Vitamin K Antagonists. Amiodarone may increase the serum concentration of Vitamin K Antagonists.  Management: Monitor patients extra closely for evidence of increased anticoagulant effects if amiodarone is started.  Consider empiric reduction of 30% to 50% in warfarin dose, though no specific guidelines on dose adjustment have been published.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Voriconazole: Amiodarone may enhance the QTc-prolonging effect of Voriconazole. Voriconazole may increase the serum concentration of Amiodarone. <i> Risk X: Avoid combination</i></p></div>
<div class="block foi drugH1Div" id="F133624"><span class="drugH1">Food Interactions</span>
<p style="text-indent:0em;text-align:justify;display:inline">Food increases the rate and extent of absorption of amiodarone. Grapefruit juice increases bioavailability of oral amiodarone by 50% and decreases the conversion of amiodarone to N-DEA (active metabolite); altered effects are possible. Management: Take consistently with regard to meals; grapefruit juice should be avoided during therapy. </p></div>
<div class="block pri drugH1Div" id="F133610"><span class="drugH1">Pregnancy Considerations</span>
<p style="text-indent:0em;">Amiodarone and the active metabolite, N-desethylamiodarone, cross the placenta (Plomp 1992).</p>
<p style="text-indent:0em;margin-top:2em;">In utero exposure may cause fetal harm. Reported risks include neonatal bradycardia, QT prolongation, and periodic ventricular extrasystoles; neonatal hypothyroidism (with or without goiter); neonatal hyperthyroxinemia; neurodevelopmental abnormalities independent of thyroid function; jerk nystagmus with synchronous head titubation; fetal growth retardation; and/or premature birth.</p>
<p style="text-indent:0em;margin-top:2em;">Oral or IV amiodarone should be used in pregnancy only to treat arrhythmias refractory to other treatments or when other treatments are contraindicated (ACC/AHA/HRS [Page 2015]).</p>
<p style="text-indent:0em;margin-top:2em;">Amiodarone (administered either maternally or directly to the fetus) may be considered for the in utero management of fetal atrial flutter and in life-threatening cases of sustained fetal supraventricular tachycardia refractory to first and second line agents, but because of potential toxicity, risks and benefits should be assessed (AHA [Donofrio 2014]; Kang 2015).</p>
<p style="text-indent:0em;margin-top:2em;">If in utero exposure occurs, newborns should be monitored for thyroid disorders and cardiac arrhythmias.</p></div>
<div class="block brc drugH1Div" id="F133611"><span class="drugH1">Breastfeeding Considerations</span>
<p style="text-indent:-2em;margin-left:2em;">Amiodarone and its active metabolite are present in breast milk.</p>
<p style="text-indent:-2em;margin-left:2em;">Actual concentrations of amiodarone and the active metabolite in breast milk vary greatly. The relative infant dose (RID) of amiodarone is reported by the manufacturer to be between 3.5% and 45% of the weight-adjusted maternal dose.</p>
<p style="text-indent:-2em;margin-left:2em;">In general, breastfeeding is considered acceptable when the RID of a medication is &lt;10%; when the RID is &gt;25% breastfeeding should generally be avoided (Anderson 2016; Ito 2000).</p>
<p style="text-indent:-2em;margin-left:2em;">Hypothyroidism and bradycardia have been observed in breastfed infants. The manufacturer does not recommend breastfeeding during therapy. If the mother wishes to breastfeed, thyroid function and plasma concentrations of amiodarone in the infant should be monitored (Ito 2000). Due to the long half-life, amiodarone and the metabolite may be present in breast milk for weeks following discontinuation of maternal therapy (Hall 2003; Javot 2018; Khurana 2014).</p></div>
<div class="block dic drugH1Div" id="F133612"><span class="drugH1">Dietary Considerations</span>
<p style="text-indent:0em;display:inline">Take consistently with regard to meals. Amiodarone is a potential source of large amounts of inorganic iodine; ~3 mg of inorganic iodine per 100 mg of amiodarone is released into the systemic circulation. Recommended daily allowance for iodine in adults is 150 mcg. </p>
<p style="text-indent:0em;margin-top:2em;">Grapefruit juice is not recommended.</p></div>
<div class="block mop drugH1Div" id="F133595"><span class="drugH1">Monitoring Parameters</span>
<p style="text-indent:-2em;margin-left:2em;">BP, heart rate (ECG) and rhythm throughout therapy; history and physical exam every 3 to 6 months; assess patient for signs of lethargy, edema of the hands or feet, weight loss, and pulmonary toxicity (baseline pulmonary function tests and chest X-ray; continue monitoring chest X-ray every 3 to 6 months during therapy); LFTs (baseline and semiannually), signs or symptoms of clinical liver injury; monitor serum electrolytes, especially potassium and magnesium. Assess thyroid function tests before initiation of treatment and then periodically thereafter (some experts suggest every 3 to 6 months; particularly in elderly patients and in patients with underlying thyroid dysfunction). If signs or symptoms of thyroid disease or arrhythmia breakthrough/exacerbation occur then immediate re-evaluation is necessary. Amiodarone partially inhibits the peripheral conversion of T<sub>4</sub> to T<sub>3</sub>; serum T<sub>4</sub> and reverse T<sub>3</sub> concentrations may be increased and serum T<sub>3</sub> may be decreased; most patients remain clinically euthyroid; however, clinical hypothyroidism or hyperthyroidism may occur (Epstein 2016).</p>
<p style="text-indent:-2em;margin-left:2em;">Perform regular ophthalmic exams (Epstein 2016).</p>
<p style="text-indent:-2em;margin-left:2em;">Patients with implantable cardiac devices: Monitor pacing or defibrillation thresholds with initiation of amiodarone and during treatment (Epstein 2016).</p>
<p style="text-indent:-2em;margin-left:2em;">Consult individual institutional policies and procedures.</p></div>
<div class="block rer drugH1Div" id="F133599"><span class="drugH1">Reference Range</span>
<p style="text-indent:0em;display:inline">Adults: Therapeutic: 0.5 to 2.5 mg/L (SI: 1 to 4 micromole/L) (parent); desethyl metabolite is active and is present in equal concentration to parent drug.</p></div>
<div class="block pha drugH1Div" id="F133584"><span class="drugH1">Mechanism of Action</span>
<p style="text-indent:0em;display:inline">Class III antiarrhythmic agent which inhibits adrenergic stimulation (alpha- and beta-blocking properties), affects sodium, potassium, and calcium channels, prolongs the action potential and refractory period in myocardial tissue; decreases AV conduction and sinus node function</p></div>
<div class="block phk drugH1Div" id="F133606"><span class="drugH1">Pharmacokinetics (Adult Data Unless Noted)</span>
<p style="text-indent:-2em;margin-left:2em;">Onset of action: Oral: 2 days to 3 weeks; IV: (electrophysiologic effects) within hours; Antiarrhythmic effects: 2 to 3 days to 1 to 3 weeks; mean onset of effect may be shorter in children vs adults and in patients receiving IV loading doses</p>
<p style="text-indent:-2em;margin-left:4em;">Peak effect: 1 week to 5 months</p>
<p style="text-indent:-2em;margin-left:2em;">Duration after discontinuing therapy: Variable, 2 weeks to months: Children: less than a few weeks; Adults: Several months</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Note:</b> Duration after discontinuation may be shorter in children than adults</p>
<p style="text-indent:-2em;margin-left:2em;">Absorption: Oral: Slow and variable</p>
<p style="text-indent:-2em;margin-left:2em;">Distribution:</p>
<p style="text-indent:-2em;margin-left:4em;">IV: Rapid redistribution with a decrease to 10% of peak values within 30 to 45 minutes after completion of infusion</p>
<p style="text-indent:-2em;margin-left:4em;">IV single dose: V<sub>dss</sub>: Mean range: 40 to 84 L/kg</p>
<p style="text-indent:-2em;margin-left:4em;">Oral: V<sub>d</sub>: 66 L/kg (range: 18 to 148 L/kg)</p>
<p style="text-indent:-2em;margin-left:2em;">Protein binding: &gt;96%</p>
<p style="text-indent:-2em;margin-left:2em;">Metabolism: Hepatic via CYP2C8 and 3A4 to active N-desethylamiodarone metabolite; possible enterohepatic recirculation</p>
<p style="text-indent:-2em;margin-left:2em;">Bioavailability: Oral: ~50% (range: 35% to 65%)</p>
<p style="text-indent:-2em;margin-left:2em;">Half-life elimination: <b>Note:</b> Half-life is shortened in children vs adults</p>
<p style="text-indent:-2em;margin-left:4em;">Amiodarone:</p>
<p style="text-indent:-2em;margin-left:6em;">Single dose: 58 days (range: 15 to 142 days)</p>
<p style="text-indent:-2em;margin-left:6em;">Oral chronic therapy: Mean range: 40 to 55 days (range: 26 to 107 days)</p>
<p style="text-indent:-2em;margin-left:6em;">IV single dose: Mean range: 9 to 36 days</p>
<p style="text-indent:-2em;margin-left:4em;">N-desethylamiodarone (active metabolite):</p>
<p style="text-indent:-2em;margin-left:6em;">Single dose: 36 days (range: 14 to 75 days)</p>
<p style="text-indent:-2em;margin-left:6em;">Oral chronic therapy: 61 days</p>
<p style="text-indent:-2em;margin-left:6em;">IV single dose: Mean range: 9 to 30 days</p>
<p style="text-indent:-2em;margin-left:2em;">Time to peak, serum: Oral: 3 to 7 hours</p>
<p style="text-indent:-2em;margin-left:2em;">Excretion: Feces; urine (&lt;1% as unchanged drug)</p></div>
<div class="block phksp drugH1Div" id="F51220363"><span class="drugH1">Pharmacokinetics: Additional Considerations (Adult Data Unless Noted)</span>
<p style="text-indent:-2em;margin-left:2em;">Hepatic function impairment: After a single dose of amiodarone injection in cirrhotic patients, C<sub>max</sub> was significantly lower and average concentration values were seen for desethylamiodarone, but mean amiodarone levels were unchanged.</p>
<p style="text-indent:-2em;margin-left:2em;">Older adult: Clearance is lower and half-life is increased.</p></div>
<div class="list fbnlist drugH1Div drugBrandNames" id="F2869363"><span class="drugH1">Brand Names: International</span><div class="ibn-search drugBrandNames"></div>
<div class="collapsible-indication brand-names-accordion drugBrandNames"><span class="collapsible-indication-title">International Brand Names by Country</span><div class="collapsible-indication-wrap-frame drugBrandNames"><div class="collapsible-indication-wrap drugBrandNames">For country code abbreviations (<a class="graphic graphic_table" href="/d/html/116421.html" rel="external">show table</a>)<br xmlns=""/><br/><ul>
<li>
<span class="countryCode">(AE)</span> <span class="country">United Arab Emirates</span><span class="countrySeparator">: </span><span class="drugName">Amirone | Cordarone</span>;</li>
<li>
<span class="countryCode">(AR)</span> <span class="country">Argentina</span><span class="countrySeparator">: </span><span class="drugName">Amiocar | Amiodarona | Amiodarona duncan | Amiodarona fabra | Amiodarona gen med | Amiodarona lacefa | Amiodarona Northia | Amiodarona puntanos | Amiodarona vannier | Angoten | Atlansil | Batmotropin | Cistimela | Coronovo | Miodarona | Miotenk | Ritmocardyl | Ritmonil</span>;</li>
<li>
<span class="countryCode">(AT)</span> <span class="country">Austria</span><span class="countrySeparator">: </span><span class="drugName">Amiodaron | Amiodaron hameln | Amiodaron Hcl Hikma | Sedacoron</span>;</li>
<li>
<span class="countryCode">(AU)</span> <span class="country">Australia</span><span class="countrySeparator">: </span><span class="drugName">Amdarone | Amiodarone | Amiodarone actavis | Amiodarone sandoz | Apo Amiodarone | Aratac | Cardinorm | Cm amiodarone | Cordarone x | Rithmik | Tw amiodarone</span>;</li>
<li>
<span class="countryCode">(BD)</span> <span class="country">Bangladesh</span><span class="countrySeparator">: </span><span class="drugName">Cardiron | Pacet</span>;</li>
<li>
<span class="countryCode">(BE)</span> <span class="country">Belgium</span><span class="countrySeparator">: </span><span class="drugName">Amiodarone ab | Amiodarone bexal | Amiodarone Eurogenerics | Amiodarone merck-generics | Amiodarone sandoz | Cordarone</span>;</li>
<li>
<span class="countryCode">(BF)</span> <span class="country">Burkina Faso</span><span class="countrySeparator">: </span><span class="drugName">Cordarone | Eurythmic</span>;</li>
<li>
<span class="countryCode">(BG)</span> <span class="country">Bulgaria</span><span class="countrySeparator">: </span><span class="drugName">Amiocordin | Amiodaron | Amiodarone | Amiodarone Nihfi | Amiohexal | Cordarone</span>;</li>
<li>
<span class="countryCode">(BR)</span> <span class="country">Brazil</span><span class="countrySeparator">: </span><span class="drugName">Amiobal | Amiodarona | Amiodex | Amioron | Ancoron | Angiodarona | Angyton | Atlansil | Cardicoron | Cardioron | Cloridrato de amiodarona | Cor mio | Diodarone | Hiperterona | Miocor | Miocoron | Miodarid | Miodaron | Miodon | Taquicord</span>;</li>
<li>
<span class="countryCode">(CH)</span> <span class="country">Switzerland</span><span class="countrySeparator">: </span><span class="drugName">Amiodar | Amiodaron Labatec | Amiodaron-mepha | Amiodarone Zentiva | Cordarone | Escodaron</span>;</li>
<li>
<span class="countryCode">(CI)</span> <span class="country">Côte d'Ivoire</span><span class="countrySeparator">: </span><span class="drugName">Amiodarone aguettant | Eurythmic</span>;</li>
<li>
<span class="countryCode">(CL)</span> <span class="country">Chile</span><span class="countrySeparator">: </span><span class="drugName">Amiodarona | Atlansil | Cordarone | Ritmocardyl</span>;</li>
<li>
<span class="countryCode">(CN)</span> <span class="country">China</span><span class="countrySeparator">: </span><span class="drugName">Amiodarone | Cordarone | Ke da long | Sedacoron | Yi jie an</span>;</li>
<li>
<span class="countryCode">(CO)</span> <span class="country">Colombia</span><span class="countrySeparator">: </span><span class="drugName">Amiodarona | Amiorit | Arycor | Asulblan | Cordarone | Daronal</span>;</li>
<li>
<span class="countryCode">(CZ)</span> <span class="country">Czech Republic</span><span class="countrySeparator">: </span><span class="drugName">Amiodaron hameln | Amiodaron Mylan | Amiohexal | Amiokordin | Cordarone | Rivodaron | Sedacoron</span>;</li>
<li>
<span class="countryCode">(DE)</span> <span class="country">Germany</span><span class="countrySeparator">: </span><span class="drugName">Amiobeta | Amiod | Amiodarex | Amiodaron | Amiodaron - 1 a pharma | Amiodaron aurobindo | Amiodaron beta | Amiodaron Carino | Amiodaron hameln | Amiodaron hcl stragen | Amiodaron Heumann | Amiodaron holsten | Amiodaron puren | Amiodaron sandoz | Amiodaron stada | Amiodaron winthrop | Amiodaron-ratiopharm | Amiodaronhydrochlorid HEXAL | Amiodura | Amiogamma | Amiohexal | Cordarex | Cordarone | Cornaron | Eucard | Sedacoron | Tachydaron</span>;</li>
<li>
<span class="countryCode">(DK)</span> <span class="country">Denmark</span><span class="countrySeparator">: </span><span class="drugName">Cordan</span>;</li>
<li>
<span class="countryCode">(DO)</span> <span class="country">Dominican Republic</span><span class="countrySeparator">: </span><span class="drugName">Amiocar | Amiodarona | Amiodarona MK | Amioran | Amiorit | Atlansil | Cardiogesic | Cordarone | Coronal | Isorrit | Miodafran | Miodar | Mionor</span>;</li>
<li>
<span class="countryCode">(EC)</span> <span class="country">Ecuador</span><span class="countrySeparator">: </span><span class="drugName">Acrodarona | Amiodarona | Amiodarona clorhidrato | Amiodarona MK | Atlansil | Cordarone | Ritmocardyl</span>;</li>
<li>
<span class="countryCode">(EE)</span> <span class="country">Estonia</span><span class="countrySeparator">: </span><span class="drugName">Amiodarone-alpharma | Amiokordin | Cordaron | Cordarone | Sedacoron</span>;</li>
<li>
<span class="countryCode">(EG)</span> <span class="country">Egypt</span><span class="countrySeparator">: </span><span class="drugName">Amiron | Cardio mep | Cordarone | Farcodarone | Ronecard | Sedacoron | Ventromed</span>;</li>
<li>
<span class="countryCode">(ES)</span> <span class="country">Spain</span><span class="countrySeparator">: </span><span class="drugName">Amiodarona aurovitas | Trangorex</span>;</li>
<li>
<span class="countryCode">(ET)</span> <span class="country">Ethiopia</span><span class="countrySeparator">: </span><span class="drugName">Amiodarone sandoz</span>;</li>
<li>
<span class="countryCode">(FI)</span> <span class="country">Finland</span><span class="countrySeparator">: </span><span class="drugName">Amiodaron hameln | Cordarone</span>;</li>
<li>
<span class="countryCode">(FR)</span> <span class="country">France</span><span class="countrySeparator">: </span><span class="drugName">Amiodarone | Amiodarone actavis | Amiodarone aguettant | Amiodarone Almus | Amiodarone Alter | Amiodarone arrow | Amiodarone biogaran | Amiodarone cristers | Amiodarone g gam | Amiodarone gnr | Amiodarone irex | Amiodarone ivax | Amiodarone merck | Amiodarone Qualimed | Amiodarone ratiopharm | Amiodarone rpg | Amiodarone sandoz | Amiodarone teva | Amiodarone Zydus | Corbionax | Cordarone</span>;</li>
<li>
<span class="countryCode">(GB)</span> <span class="country">United Kingdom</span><span class="countrySeparator">: </span><span class="drugName">Amidox | Amiodarone | Amiodarone Almus | Amiodarone arrow | Amiodarone cox | Amiodarone focus | Amiodarone kent | Amiodarone Medreich | Amiodarone sandoz | Amyben | Cordarone x | Rotaritmil</span>;</li>
<li>
<span class="countryCode">(GR)</span> <span class="country">Greece</span><span class="countrySeparator">: </span><span class="drugName">Angoron</span>;</li>
<li>
<span class="countryCode">(HK)</span> <span class="country">Hong Kong</span><span class="countrySeparator">: </span><span class="drugName">Amiodarone HCL | Amiodarone sandoz | Apo Amiodarone | Cordarone | Sedacoron</span>;</li>
<li>
<span class="countryCode">(HR)</span> <span class="country">Croatia</span><span class="countrySeparator">: </span><span class="drugName">Amiodaron | Amiokordin | Amlox | Cordarone</span>;</li>
<li>
<span class="countryCode">(HU)</span> <span class="country">Hungary</span><span class="countrySeparator">: </span><span class="drugName">Amiodarona lph | Amiohexal | Amiokordin | Cordarone | Sedacoron</span>;</li>
<li>
<span class="countryCode">(ID)</span> <span class="country">Indonesia</span><span class="countrySeparator">: </span><span class="drugName">Cordarone | Kendaron | Rexidron | Tiaryt</span>;</li>
<li>
<span class="countryCode">(IE)</span> <span class="country">Ireland</span><span class="countrySeparator">: </span><span class="drugName">Cordarone x</span>;</li>
<li>
<span class="countryCode">(IL)</span> <span class="country">Israel</span><span class="countrySeparator">: </span><span class="drugName">Amiodacore | Procor</span>;</li>
<li>
<span class="countryCode">(IN)</span> <span class="country">India</span><span class="countrySeparator">: </span><span class="drugName">Amidon | Amiodar | Amiodon | Amione | Amipace | Cardarone | Cardasol | Cordarone | Duron | Eurythmic | Pacenorm | Panaron | Ritebeat | Tachyra</span>;</li>
<li>
<span class="countryCode">(IT)</span> <span class="country">Italy</span><span class="countrySeparator">: </span><span class="drugName">Amiodar | Amiodarone | Amiodarone aurobindo | Amiodarone cloridrato bioindustria | Amiodarone eg | Amiodarone ratiopharm | Cordarone</span>;</li>
<li>
<span class="countryCode">(JO)</span> <span class="country">Jordan</span><span class="countrySeparator">: </span><span class="drugName">Cordarone | Sedacoron</span>;</li>
<li>
<span class="countryCode">(JP)</span> <span class="country">Japan</span><span class="countrySeparator">: </span><span class="drugName">Amiodarone hydrochloride te | Amiodarone hydrochloride towa | Ancaron</span>;</li>
<li>
<span class="countryCode">(KE)</span> <span class="country">Kenya</span><span class="countrySeparator">: </span><span class="drugName">Cordarone | Eurythmic</span>;</li>
<li>
<span class="countryCode">(KR)</span> <span class="country">Korea, Republic of</span><span class="countrySeparator">: </span><span class="drugName">Cordarone</span>;</li>
<li>
<span class="countryCode">(KW)</span> <span class="country">Kuwait</span><span class="countrySeparator">: </span><span class="drugName">Cordarone</span>;</li>
<li>
<span class="countryCode">(LB)</span> <span class="country">Lebanon</span><span class="countrySeparator">: </span><span class="drugName">Cordarone | Rivodarone | Sedacoron</span>;</li>
<li>
<span class="countryCode">(LT)</span> <span class="country">Lithuania</span><span class="countrySeparator">: </span><span class="drugName">Amiodaron | Amiodarona aurobindo | Amiodarone | Amiodarone actiopharma | Amiokordin | Cordarone | Sedacoron</span>;</li>
<li>
<span class="countryCode">(LU)</span> <span class="country">Luxembourg</span><span class="countrySeparator">: </span><span class="drugName">Amiodarone Eurogenerics | Cordarone</span>;</li>
<li>
<span class="countryCode">(LV)</span> <span class="country">Latvia</span><span class="countrySeparator">: </span><span class="drugName">Amiocordin | Amiodarone | Cordarone</span>;</li>
<li>
<span class="countryCode">(MA)</span> <span class="country">Morocco</span><span class="countrySeparator">: </span><span class="drugName">Cordarone</span>;</li>
<li>
<span class="countryCode">(MX)</span> <span class="country">Mexico</span><span class="countrySeparator">: </span><span class="drugName">Amiodarona | Braxan | Cirtrent | Cordarone | Darfin | Defaven | Keritmon | Ranfodar | Tecnovid</span>;</li>
<li>
<span class="countryCode">(MY)</span> <span class="country">Malaysia</span><span class="countrySeparator">: </span><span class="drugName">Amiodarone hcl bioindustria | Amiohexal | Aratac | Cardilor | Cordarone | Eurythmic</span>;</li>
<li>
<span class="countryCode">(NL)</span> <span class="country">Netherlands</span><span class="countrySeparator">: </span><span class="drugName">Amiodaron | Amiodaron gf | Amiodaron Hcl | Amiodaron hcl Aurobindo | Amiodaron Hcl Hikma | Amiodaron hcl sandoz | Amiodaron HCl Teva | Amiodaron kwk | Cordarone</span>;</li>
<li>
<span class="countryCode">(NO)</span> <span class="country">Norway</span><span class="countrySeparator">: </span><span class="drugName">Amiodaron | Amiodaron Hcl Hikma | Amiodarone | Amiodarone gevita | Cordarone</span>;</li>
<li>
<span class="countryCode">(NZ)</span> <span class="country">New Zealand</span><span class="countrySeparator">: </span><span class="drugName">Amiodarone HCL | Amiodarone hydrochloride hameln | Aratac | Cordarone x</span>;</li>
<li>
<span class="countryCode">(PE)</span> <span class="country">Peru</span><span class="countrySeparator">: </span><span class="drugName">Amiodarona | Atlansil | Cordarone | Ritmax | Ritmocardyl</span>;</li>
<li>
<span class="countryCode">(PH)</span> <span class="country">Philippines</span><span class="countrySeparator">: </span><span class="drugName">Amiodarone sandoz | Amiron | Anoion | Cordarone | Daryth | Medodarone | Myodial | Rythma | Triodone</span>;</li>
<li>
<span class="countryCode">(PK)</span> <span class="country">Pakistan</span><span class="countrySeparator">: </span><span class="drugName">Aldaron | Cordarone x | Sedacoron</span>;</li>
<li>
<span class="countryCode">(PL)</span> <span class="country">Poland</span><span class="countrySeparator">: </span><span class="drugName">Amiodaron hameln | Amiokordin | Cordarone | Opacorden | Sedacoron</span>;</li>
<li>
<span class="countryCode">(PR)</span> <span class="country">Puerto Rico</span><span class="countrySeparator">: </span><span class="drugName">Amiodarone | Amiodarone HCL | Cordarone | Nexterone | Pacerone</span>;</li>
<li>
<span class="countryCode">(PT)</span> <span class="country">Portugal</span><span class="countrySeparator">: </span><span class="drugName">Amiodarona | Amiodarona aurobindo | Cordarone | Miodrone</span>;</li>
<li>
<span class="countryCode">(PY)</span> <span class="country">Paraguay</span><span class="countrySeparator">: </span><span class="drugName">Acetal | Amiodar | Amiodarona clorhidrato | Amiodarona la sante | Atlansil | Cordarone | Miodaron | Prinox</span>;</li>
<li>
<span class="countryCode">(QA)</span> <span class="country">Qatar</span><span class="countrySeparator">: </span><span class="drugName">Amiodaron | Amirone | Cordalin | Cordarone | Sedacoron</span>;</li>
<li>
<span class="countryCode">(RO)</span> <span class="country">Romania</span><span class="countrySeparator">: </span><span class="drugName">Amiodarona | Amiodarona arena | Amiodarona lph | Amiokordin | Cordarone | Daritmin</span>;</li>
<li>
<span class="countryCode">(RU)</span> <span class="country">Russian Federation</span><span class="countrySeparator">: </span><span class="drugName">Amiocordin | Amiodaron | Amiodaron FPO | Amiodaron hexal | Amiodarone | Amiodarone sandoz | Amiokordin | Cardiodaron | Cordarone | Rhythmiodarone | Sedacoron | Vero amiodarone</span>;</li>
<li>
<span class="countryCode">(SA)</span> <span class="country">Saudi Arabia</span><span class="countrySeparator">: </span><span class="drugName">Amirone | Cordarone | Pms-amiodarone | Sedacoron</span>;</li>
<li>
<span class="countryCode">(SE)</span> <span class="country">Sweden</span><span class="countrySeparator">: </span><span class="drugName">Amiodaron Evolan | Amiodaron hameln | Amiodaron stragen | Cordarone</span>;</li>
<li>
<span class="countryCode">(SG)</span> <span class="country">Singapore</span><span class="countrySeparator">: </span><span class="drugName">Amiodarone ph&amp;t | Aratac | Cordarone</span>;</li>
<li>
<span class="countryCode">(SI)</span> <span class="country">Slovenia</span><span class="countrySeparator">: </span><span class="drugName">Amiokordin | Amjodaron Hameln | Cordarone</span>;</li>
<li>
<span class="countryCode">(SK)</span> <span class="country">Slovakia</span><span class="countrySeparator">: </span><span class="drugName">Amiodaron | Amiohexal | Amiokordin | Cordarone | Rivodaron | Sedacoron</span>;</li>
<li>
<span class="countryCode">(TH)</span> <span class="country">Thailand</span><span class="countrySeparator">: </span><span class="drugName">Aldarone | Amdarone | Amidarone | Amiodarone aguettant | Aratac | Cardilor | Cordarone | Eurythmic | Zydarone</span>;</li>
<li>
<span class="countryCode">(TN)</span> <span class="country">Tunisia</span><span class="countrySeparator">: </span><span class="drugName">Amiocard | Amiodarone | Amiodarone aguettant | Cordarone | Ricardyl | Rythmarone | Sedacoron</span>;</li>
<li>
<span class="countryCode">(TR)</span> <span class="country">Turkey</span><span class="countrySeparator">: </span><span class="drugName">Cordarone</span>;</li>
<li>
<span class="countryCode">(TW)</span> <span class="country">Taiwan</span><span class="countrySeparator">: </span><span class="drugName">Adarone | Amiorone | Cordarone | Harten | Rythmarone | Sedacoron</span>;</li>
<li>
<span class="countryCode">(UA)</span> <span class="country">Ukraine</span><span class="countrySeparator">: </span><span class="drugName">Amiocordin | Amiodaron | Amiodaron darnitsa | Aritmil | Cardiodaron | Cordarone | Miorytmil | Rotaritmil | Sedacoron</span>;</li>
<li>
<span class="countryCode">(UG)</span> <span class="country">Uganda</span><span class="countrySeparator">: </span><span class="drugName">Cordarone</span>;</li>
<li>
<span class="countryCode">(UY)</span> <span class="country">Uruguay</span><span class="countrySeparator">: </span><span class="drugName">Amiodarona | Amiodarona lazar | Atlansil | Miodorit | Taquirona | Trangorex</span>;</li>
<li>
<span class="countryCode">(VE)</span> <span class="country">Venezuela, Bolivarian Republic of</span><span class="countrySeparator">: </span><span class="drugName">Amiodarona | Amiodarona clorhidrato | Amioran | Arycor | Cardiogesic | Coradona | Diarona | Novarona | Trangorex</span>;</li>
<li>
<span class="countryCode">(ZA)</span> <span class="country">South Africa</span><span class="countrySeparator">: </span><span class="drugName">Activo amiodarone | Adcorone | Amiotach | Arycor | Bio Amiodarone | Cordarone x | Hexarone</span></li></ul></div>
</div>
</div>
</div>
</div><div class="headingAnchor" id="references"><ol id="reference">
<li>
<div class="reference" id="lexi-content-ref-37139824">
<a name="37139824"></a>2023 American Geriatrics Society Beers Criteria Update Expert Panel. American Geriatrics Society 2023 updated AGS Beers Criteria for potentially inappropriate medication use in older adults. <i>J Am Geriatr Soc</i>. 2023;71(7):2052-2081. doi:10.1111/jgs.18372<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/amiodarone-drug-information/abstract-text/37139824/pubmed" id="37139824" target="_blank">37139824</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-11487763">
<a name="11487763"></a>Ahlfors CE. Benzyl alcohol, kernicterus, and unbound bilirubin. <i>J Pediatr</i>. 2001;139(2):317-319.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/amiodarone-drug-information/abstract-text/11487763 /pubmed" id="11487763 " target="_blank">11487763 </a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-3960626">
<a name="3960626"></a>Alade SL, Brown RE, Paquet A. Polysorbate 80 and E-Ferol toxicity. <i>Pediatrics.</i> 1986;77(4):593-597.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/amiodarone-drug-information/abstract-text/3960626/pubmed" id="3960626" target="_blank">3960626</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29084731">
<a name="29084731"></a>Al-Khatib SM, Stevenson WG, Ackerman MJ, et al. 2017 AHA/ACC/HRS guideline for management of patients with ventricular arrhythmias and the prevention of sudden cardiac death [published correction appears in <i>Circulation</i>. 2018;138(13):e419-e420]. <i>Circulation</i>. 2018;138(13):e272-e391. doi: 10.1161/CIR.0000000000000549.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/amiodarone-drug-information/abstract-text/29084731/pubmed" id="29084731" target="_blank">29084731</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-25599328">
<a name="25599328"></a>Alonso A, MacLehose RF, Lutsey PL, Konety S, Chen LY. Association of amiodarone use with acute pancreatitis in patients with atrial fibrillation: a nested case-control study. <i>JAMA Intern Med</i>. 2015;175(3):449-450. doi:10.1001/jamainternmed.2014.6927<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/amiodarone-drug-information/abstract-text/25599328/pubmed" id="25599328" target="_blank">25599328</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-9024461">
<a name="9024461"></a>American Academy of Pediatrics Committee on Drugs. "Inactive" ingredients in pharmaceutical products: update (subject review). <i>Pediatrics</i>. 1997;99(2):268-278.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/amiodarone-drug-information/abstract-text/9024461/pubmed" id="9024461" target="_blank">9024461</a>]</span>
</div>
</li>
<li>
<div class="reference">
                  Amiodarone Hydrochloride (amiodarone) for injection [product monograph]. Boucherville, Quebec, Canada: Jamp Pharma Corp; October 2020.</div>
</li>
<li>
<div class="reference">
                  Amiodarone injection [prescribing information]. Lake Zurich, IL: Fresenius Kabi; May 2020.</div>
</li>
<li>
<div class="reference">
                  Amiodarone tablets [prescribing information]. Louisville, KY: Cameron Pharmaceuticals, LLC; April 2018.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27060684">
<a name="27060684"></a>Anderson PO, Sauberan JB. Modeling drug passage into human milk. <i>Clin Pharmacol Ther</i>. 2016;100(1):42-52.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/amiodarone-drug-information/abstract-text/27060684/pubmed" id="27060684" target="_blank">27060684</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Aronoff.1">
<a name="Aronoff.1"></a>Aronoff GR, Bennett WM, Berns JS, et al. <i>Drug Prescribing in Renal Failure: Dosing Guidelines for Adults and Children</i>, 5th ed. Philadelphia, PA: American College of Physicians; 2007.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-ASHP.1">
<a name="ASHP.1"></a>ASHP. Standardize 4 Safety Initiative Compounded Oral Liquid Version 1.01. July 2017. https://www.ashp.org/-/media/assets/pharmacy-practice/s4s/docs/s4s-ashp-oral-compound-liquids.ashx?la=en&amp;hash=4C2E4F370B665C028981B61F6210335AD5D0D1D6.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-14609814">
<a name="14609814"></a>Athwal H, Murphy G Jr, Chun S. Amiodarone-induced delirium. <i>Am J Geriatr Psychiatry</i>. 2003;11(6):696-697. doi:10.1176/appi.ajgp.11.6.696<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/amiodarone-drug-information/abstract-text/14609814/pubmed" id="14609814" target="_blank">14609814</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19565059">
<a name="19565059"></a>Atiq M, Davis JC, Lamps LW, Beland SS, Rose JE. Amiodarone induced liver cirrhosis. Report of two cases. <i>J Gastrointestin Liver Dis</i>. 2009;18(2):233-235<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/amiodarone-drug-information/abstract-text/19565059/pubmed" id="19565059" target="_blank">19565059</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31552206">
<a name="31552206"></a>Ba H, Xu L, Peng H, et al. Amiodarone-related pure red cell aplastic anemia and hypothyroidism in a child with total anomalous pulmonary venous connection. <i>Front Pediatr</i>. 2019;7:361. doi:10.3389/fped.2019.00361<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/amiodarone-drug-information/abstract-text/31552206/pubmed" id="31552206" target="_blank">31552206</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31361319">
<a name="31361319"></a>Barrett B, Hawkes CP, Isaza A, Bauer AJ. The effects of amiodarone on thyroid function in pediatric and young adult patients. <i>J Clin Endocrinol Metab</i>. 2019;104(11):5540-5546. doi:10.1210/jc.2019-00990<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/amiodarone-drug-information/abstract-text/31361319/pubmed" id="31361319" target="_blank">31361319</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-15989900">
<a name="15989900"></a>Basaria S, Cooper DS. Amiodarone and the thyroid. <i>Am J Med</i>. 2005;118(7):706-714. doi:10.1016/j.amjmed.2004.11.028<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/amiodarone-drug-information/abstract-text/15989900/pubmed" id="15989900" target="_blank">15989900</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-17904459">
<a name="17904459"></a>Batcher EL, Tang XC, Singh BN, Singh SN, Reda DJ, Hershman JM; SAFE-T Investigators. Thyroid function abnormalities during amiodarone therapy for persistent atrial fibrillation. <i>Am J Med</i>. 2007;120(10):880-885. doi:10.1016/j.amjmed.2007.04.022<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/amiodarone-drug-information/abstract-text/17904459/pubmed" id="17904459" target="_blank">17904459</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-17458403">
<a name="17458403"></a>Beall JW, Mahan EF 3rd, Blau AB. Use of amiodarone in a patient with a shellfish allergy. <i>South Med J</i>. 2007;100(4):405-406.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/amiodarone-drug-information/abstract-text/17458403/pubmed" id="17458403" target="_blank">17458403</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-14557344">
<a name="14557344"></a>Blomström-Lundqvist C, Scheinman MM, Aliot EM, et al, “ACC/AHA/ESC Guidelines for the Management of Patients With Supraventricular Arrhythmias--Executive Summary. A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the European Society of Cardiology Committee for Practice Guidelines (Writing Committee to Develop Guidelines for the Management of Patients With Supraventricular Arrhythmias),” <i>Circulation</i>, 2003, 108(15):1871-909.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/amiodarone-drug-information/abstract-text/14557344/pubmed" id="14557344" target="_blank">14557344</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-25609329">
<a name="25609329"></a>Blumenthal KG, Wickner PG, Lau JJ, Zhou L. Stevens-Johnson syndrome and toxic epidermal necrolysis: a cross-sectional analysis of patients in an integrated allergy repository of a large health care system. <i>J Allergy Clin Immunol Pract</i>. 2015;3(2):277-280.e1. doi:10.1016/j.jaip.2014.10.002<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/amiodarone-drug-information/abstract-text/25609329/pubmed" id="25609329" target="_blank">25609329</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-6835293">
<a name="6835293"></a>Bonati M, Galletti F, Volpi A, et al. Amiodarone in patients on long-term dialysis. <i>N Engl J Med</i>. 1983;308(15):906. doi:10.1056/NEJM198304143081518<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/amiodarone-drug-information/abstract-text/6835293/pubmed" id="6835293" target="_blank">6835293</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-21674626">
<a name="21674626"></a>Bondon-Guitton E, Perez-Lloret S, Bagheri H, Brefel C, Rascol O, Montastruc JL. Drug-induced parkinsonism: a review of 17 years' experience in a regional pharmacovigilance center in France. <i>Mov Disord</i>. 2011;26(12):2226-2231. doi:10.1002/mds.23828<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/amiodarone-drug-information/abstract-text/21674626/pubmed" id="21674626" target="_blank">21674626</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-16167664">
<a name="16167664"></a>Bradley D, Creswell LL, Hogue CW Jr, Epstein AE, Prystowsky EN, Daoud EG; American College of Chest Physicians. Pharmacologic prophylaxis: American College of Chest Physicians guidelines for the prevention and management of postoperative atrial fibrillation after cardiac surgery. <i>Chest</i>. 2005;128(2)(suppl):39S-47S.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/amiodarone-drug-information/abstract-text/16167664/pubmed" id="16167664" target="_blank">16167664</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30891390">
<a name="30891390"></a>Bratton H, Alomari M, Al Momani LA, Aasen T, Young M. Prolonged jaundice secondary to amiodarone use: a case report and literature review. <i>Cureus</i>. 2019;11(1):e3850. doi:10.7759/cureus.3850<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/amiodarone-drug-information/abstract-text/30891390/pubmed" id="30891390" target="_blank">30891390</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-15843290">
<a name="15843290"></a>Brouse SD, Phillips SM. Amiodarone use in patients with documented allergy to iodine-containing compounds. <i>Pharmacotherapy</i>. 2005;25(3):429-434.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/amiodarone-drug-information/abstract-text/15843290/pubmed" id="15843290" target="_blank">15843290</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-3756044">
<a name="3756044"></a>Bucknall CA, Keeton BR, Curry PV, et al, "Intravenous and Oral Amiodarone for Arrhythmias in Children," <i>Br Heart J</i>, 1986, 56(3):278-84.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/amiodarone-drug-information/abstract-text/3756044/pubmed" id="3756044" target="_blank">3756044</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31433922">
<a name="31433922"></a>Burch HB. Drug effects on the thyroid. <i>N Engl J Med</i>. 2019;381(8):749-761. doi: 10.1056/NEJMra1901214.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/amiodarone-drug-information/abstract-text/31433922/pubmed" id="31433922" target="_blank">31433922</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-11117281">
<a name="11117281"></a>Burches E, Garcia-Verdegay F, Ferrer M, Pelaez A. Amiodarone-induced angioedema. <i>Allergy</i>. 2000;55(12):1199-1200. doi:10.1034/j.1398-9995.2000.00824.x<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/amiodarone-drug-information/abstract-text/11117281/pubmed" id="11117281" target="_blank">11117281</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31576278">
<a name="31576278"></a>Busch CD, Heiberger CJ, Mehta TI, Yim D. Amiodarone-induced hemoptysis: a rare presentation of amiodarone-induced pulmonary toxicity occurs at a low dose. <i>Cureus</i>. 2019;11(7):e5289. doi:10.7759/cureus.5289<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/amiodarone-drug-information/abstract-text/31576278/pubmed" id="31576278" target="_blank">31576278</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Buxton.1">
<a name="Buxton.1"></a>Buxton A. Sustained monomorphic ventricular tachycardia in patients with structural heart disease: Treatment and prognosis. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed March 7, 2022.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-6810084">
<a name="6810084"></a>Centers for Disease Control (CDC). Neonatal deaths associated with use of benzyl alcohol - United States. <i>MMWR Morb Mortal Wkly Rep</i>. 1982;31(22):290-291. Available at <a href="https://www.cdc.gov/mmwr/preview/mmwrhtml/00001109.htm" target="_blank">http://www.cdc.gov/mmwr/preview/mmwrhtml/00001109.htm</a>
<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/amiodarone-drug-information/abstract-text/6810084 /pubmed" id="6810084 " target="_blank">6810084 </a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-6423951">
<a name="6423951"></a>Centers for Disease Control (CDC). Unusual syndrome with fatalities among premature infants: association with a new intravenous vitamin E product.<i> MMWR Morb Mortal Wkly Rep</i>. 1984;33(14):198-199. <a href="https://www.cdc.gov/mmwr/preview/mmwrhtml/00000319.htm" target="_blank">http://www.cdc.gov/mmwr/preview/mmwrhtml/00000319.htm</a>
<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/amiodarone-drug-information/abstract-text/6423951/pubmed" id="6423951" target="_blank">6423951</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24935270">
<a name="24935270"></a>Chalasani NP, Hayashi PH, Bonkovsky HL, Navarro VJ, Lee WM, Fontana RJ; Practice Parameters Committee of the American College of Gastroenterology. ACG Clinical Guideline: the diagnosis and management of idiosyncratic drug-induced liver injury. <i>Am J Gastroenterol</i>. 2014;109(7):950-966, quiz 967. doi:10.1038/ajg.2014.131<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/amiodarone-drug-information/abstract-text/24935270/pubmed" id="24935270" target="_blank">24935270</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-11286148">
<a name="11286148"></a>Chalmers JR, Bobek MB, and Militello MA, "Visual Compatibility of Amiodarone Hydrochloride Injection With Various Intravenous Drugs," <i>Am J Health Syst Pharm</i>, 2001, 58(6):504-6.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/amiodarone-drug-information/abstract-text/11286148/pubmed" id="11286148" target="_blank">11286148</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-25901429">
<a name="25901429"></a>Chan TC, Jhanji V, “Amiodarone-Induced Vortex Keratopathy,” <i>N Engl J Med</i>, 2015, 372(17):1656.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/amiodarone-drug-information/abstract-text/25901429/pubmed" id="25901429" target="_blank">25901429</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29699616">
<a name="29699616"></a>Chatzidou S, Kontogiannis C, Tsilimigras DI, et al. Propranolol versus metoprolol for treatment of electrical storm in patients with implantable cardioverter-defibrillator. <i>J Am Coll Cardiol</i>. 2018;71(17):1897-1906. doi: 10.1016/j.jacc.2018.02.056.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/amiodarone-drug-information/abstract-text/29699616/pubmed" id="29699616" target="_blank">29699616</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23507205">
<a name="23507205"></a>Chen A, Sauer W, Nguyen DT. A dire reaction: rash after amiodarone administration. <i>Am J Med</i>. 2013;126(4):301-303. doi:10.1016/j.amjmed.2012.12.002<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/amiodarone-drug-information/abstract-text/23507205/pubmed" id="23507205" target="_blank">23507205</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-25259952">
<a name="25259952"></a>Chen CC, Wu CC. Acute hepatotoxicity of intravenous amiodarone: case report and review of the literature. <i>Am J Ther</i>. 2016;23(1):e260-263. doi:10.1097/MJT.0000000000000149<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/amiodarone-drug-information/abstract-text/25259952/pubmed" id="25259952" target="_blank">25259952</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-33824822">
<a name="33824822"></a>Chhatrala H, Ghetiya S, Chahin M, Zuberi L, Quan W. Amiodarone-induced immune thrombocytopenia: a rare hematologic side effect of a common cardiac drug. <i>Cureus</i>. 2021;13(3):e13671. doi:10.7759/cureus.13671<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/amiodarone-drug-information/abstract-text/33824822/pubmed" id="33824822" target="_blank">33824822</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26646017">
<a name="26646017"></a>Claro JC, Candia R, Rada G, Baraona F, Larrondo F, Letelier LM. Amiodarone versus other pharmacological interventions for prevention of sudden cardiac death. <i>Cochrane Database Syst Rev</i>. 2015;(12):CD008093. doi: 10.1002/14651858.CD008093.pub2.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/amiodarone-drug-information/abstract-text/26646017/pubmed" id="26646017" target="_blank">26646017</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-16403928">
<a name="16403928"></a>Connolly SJ, Dorian P, Roberts RS, et al; Optimal Pharmacological Therapy in Cardioverter Defibrillator Patients (OPTIC) Investigators. Comparison of beta-blockers, amiodarone plus beta-blockers, or sotalol for prevention of shocks from implantable cardioverter defibrillators: the OPTIC study: a randomized trial. <i>JAMA</i>. 2006;295(2):165-171.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/amiodarone-drug-information/abstract-text/16403928/pubmed" id="16403928" target="_blank">16403928</a>]</span>
</div>
</li>
<li>
<div class="reference">
                  Cordarone (amiodarone) [prescribing information]. Philadelphia, PA: Wyeth Pharmaceuticals Inc; October 2018.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-7446409">
<a name="7446409"></a>Coumel P and Fidelle J, "Amiodarone in the Treatment of Cardiac Arrhythmias in Children: One Hundred Thirty-Five Cases," <i>Am Heart J</i>, 1980, 100(6 Pt 2):1063-9.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/amiodarone-drug-information/abstract-text/7446409/pubmed" id="7446409" target="_blank">7446409</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-6195613">
<a name="6195613"></a>Coumel P, Lucet V, Do Ngoc D. The use of amiodarone in children. <i>Pacing Clin Electrophysiol</i>. 1983;6(5 Pt 1):930-939.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/amiodarone-drug-information/abstract-text/6195613/pubmed" id="6195613" target="_blank">6195613</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-17125434">
<a name="17125434"></a>Dager WE, Sanoski CA, Wiggins BS, Tisdale TE. Pharmacotherapy considerations in advanced cardiac life support. <i>Pharmacotherapy. </i>2006;26(12):1703-1729.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/amiodarone-drug-information/abstract-text/17125434/pubmed" id="17125434" target="_blank">17125434</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-9400034">
<a name="9400034"></a>Daoud EG, Strickberger SA, Man KC, et al. Preoperative amiodarone as prophylaxis against atrial fibrillation after heart surgery. <i>N Engl J Med.</i> 1997;337(25):1785-1791.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/amiodarone-drug-information/abstract-text/9400034/pubmed" id="9400034" target="_blank">9400034</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31198686">
<a name="31198686"></a>Dasu N, Khalid Y, Panuganti S, Daly S. Amiodarone induced epididymo-orchitis. <i>Urol Case Rep</i>. 2019;26:100929. doi:10.1016/j.eucr.2019.100929<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/amiodarone-drug-information/abstract-text/31198686/pubmed" id="31198686" target="_blank">31198686</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26473000">
<a name="26473000"></a>de Caen AR, Berg MD, Chameides L, et al. Part 12: pediatric advanced life support: 2015 American Heart Association guidelines update for cardiopulmonary resuscitation and emergency cardiovascular care. <i>Circulation</i>. 2015;132(18 Suppl 2):S526-542.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/amiodarone-drug-information/abstract-text/26473000 /pubmed" id="26473000 " target="_blank">26473000 </a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24763516">
<a name="24763516"></a>Donofrio MT, Moon-Grady AJ, Hornberger LK, et al. Diagnosis and treatment of fetal cardiac disease: a scientific statement from the American Heart Association. <i>Circulation</i>. 2014;129(21):2183-2242.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/amiodarone-drug-information/abstract-text/24763516/pubmed" id="24763516" target="_blank">24763516</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-12950525">
<a name="12950525"></a>Dorian P, Mangat I. Role of amiodarone in the era of the implantable cardioverter defibrillator. <i>J Cardiovasc Electrophysiol</i>. 2003;14(9 suppl):S78-81. doi:10.1046/j.1540-8167.14.s9.22.x<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/amiodarone-drug-information/abstract-text/12950525/pubmed" id="12950525" target="_blank">12950525</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30571264">
<a name="30571264"></a>Duff JP, Topjian A, Berg MD, et al. 2018 American Heart Association focused update on pediatric advanced life support: an update to the American Heart Association guidelines for cardiopulmonary resuscitation and emergency cardiovascular care. <i>Circulation</i>. 2018;138(23):e731-e739.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/amiodarone-drug-information/abstract-text/30571264/pubmed" id="30571264" target="_blank">30571264</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26497904">
<a name="26497904"></a>Epstein AE, Olshansky B, Naccarelli GV, Kennedy JI Jr, Murphy EJ, Goldschlager N. Practical management guide for clinicians who treat patients with amiodarone. <i>Am J Med</i>. 2016;129(5):468-475. doi: 10.1016/j.amjmed.2015.08.039.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/amiodarone-drug-information/abstract-text/26497904/pubmed" id="26497904" target="_blank">26497904</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22184519">
<a name="22184519"></a>Erie AJ, McClure RF, Wolanskyj AP. Amiodarone-induced bone marrow granulomas: an unusual cause of reversible pancytopenia. <i>Hematol Rep</i>. 2010;2(1):e6. doi:10.4081/hr.2010.e6<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/amiodarone-drug-information/abstract-text/22184519/pubmed" id="22184519" target="_blank">22184519</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-18460037">
<a name="18460037"></a>Ernawati DK, Stafford L, Hughes JD. Amiodarone-induced pulmonary toxicity. <i>Br J Clin Pharmacol</i>. 2008;66(1):82-87. doi:10.1111/j.1365-2125.2008.03177.x<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/amiodarone-drug-information/abstract-text/18460037/pubmed" id="18460037" target="_blank">18460037</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-12535818">
<a name="12535818"></a>Essebag V, Hadjis T, Platt RW, Pilote L. Amiodarone and the risk of bradyarrhythmia requiring permanent pacemaker in elderly patients with atrial fibrillation and prior myocardial infarction. <i>J Am Coll Cardiol</i>. 2003;41(2):249-254. doi:10.1016/s0735-1097(02)02709-2<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/amiodarone-drug-information/abstract-text/12535818/pubmed" id="12535818" target="_blank">12535818</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-11136494">
<a name="11136494"></a>Etheridge SP, Craig JE, and Compton SJ, “Amiodarone is Safe and Highly Effective Therapy for Supraventricular Tachycardia in Infants,” <i>Am Heart J</i>, 2001, 141(1):105-10.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/amiodarone-drug-information/abstract-text/11136494/pubmed" id="11136494" target="_blank">11136494</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-21873418">
<a name="21873418"></a>European Society of Gynecology (ESG); Association for European Paediatric Cardiology (AEPC); German Society for Gender Medicine (DGesGM), et al, "ESC Guidelines on the Management of Cardiovascular Diseases During Pregnancy: The Task Force on the Management of Cardiovascular Diseases During Pregnancy of the European Society of Cardiology (ESC)," <i>Eur Heart J</i>, 2011, 32(24):3147-97.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/amiodarone-drug-information/abstract-text/21873418/pubmed" id="21873418" target="_blank">21873418</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-10440140">
<a name="10440140"></a>Exner DV, Reiffel JA, Epstein AE, et al. Beta-blocker use and survival in patients with ventricular fibrillation or symptomatic ventricular tachycardia: the Antiarrhythmics Versus Implantable Defibrillators (AVID) trial. <i>J Am Coll Cardiol</i>. 1999;34(2):325-333.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/amiodarone-drug-information/abstract-text/10440140/pubmed" id="10440140" target="_blank">10440140</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Expert.DOR">
<a name="Expert.DOR"></a>Expert opinion. Senior Renal Editorial Team: Bruce Mueller, PharmD, FCCP, FASN, FNKF; Jason A. Roberts, PhD, BPharm (Hons), B App Sc, FSHP, FISAC; Michael Heung, MD, MS.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-8842793">
<a name="8842793"></a>Faggiano P, Gardini A, D'Aloia A, Benedini G, Giordano A. Torsade de pointes occurring early during oral amiodarone treatment. <i>Int J Cardiol</i>. 1996;55(2):205-208. doi:10.1016/0167-5273(96)02675-7<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/amiodarone-drug-information/abstract-text/8842793/pubmed" id="8842793" target="_blank">8842793</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-17227788">
<a name="17227788"></a>Ferreira-González I, Dos-Subirá L, Guyatt GH. Adjunctive antiarrhythmic drug therapy in patients with implantable cardioverter defibrillators: a systematic review. <i>Eur Heart J</i>. 2007;28(4):469-477.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/amiodarone-drug-information/abstract-text/17227788/pubmed" id="17227788" target="_blank">17227788</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-20956217">
<a name="20956217"></a>Field JM, Hazinski MF, Sayre MR, et al. Part 1: executive summary: 2010 American Heart Association guidelines for cardiopulmonary resuscitation and emergency cardiovascular care. <i>Circulation</i>. 2010;122(18)(suppl 3):S640-S656. doi: 10.1161/CIRCULATIONAHA.110.970889.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/amiodarone-drug-information/abstract-text/20956217/pubmed" id="20956217" target="_blank">20956217</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-8074040">
<a name="8074040"></a>Figa FH, Gow RM, Hamilton RM, et al, “Clinical Efficacy and Safety of Intravenous Amiodarone in Infants and Children,” <i>Am J Cardiol</i>, 1994, 74(6):573-7.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/amiodarone-drug-information/abstract-text/8074040/pubmed" id="8074040" target="_blank">8074040</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19495851">
<a name="19495851"></a>Fishberger SB, Hannan RL, Welch EM, et al, "Amiodarone for Pediatric Resuscitation: A Word of Caution," <i>Pediatr Cardiol</i>, 2009, 30(7):1006-8.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/amiodarone-drug-information/abstract-text/19495851/pubmed" id="19495851" target="_blank">19495851</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28947526">
<a name="28947526"></a>Fox AN, Villanueva R, Miller JL. Management of amiodarone extravasation with intradermal hyaluronidase. <i>Am J Health Syst Pharm</i>. 2017;74(19):1545-1548. doi: 10.2146/ajhp160737.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/amiodarone-drug-information/abstract-text/28947526/pubmed" id="28947526" target="_blank">28947526</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-16904574">
<a name="16904574"></a>Fuster V, Rydén LE, Cannom DS, et al, "ACC/AHA/ESC 2006 Guidelines for the Management of Patients With Atrial Fibrillation-Executive Summary: A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the European Society of Cardiology Committee for Practice Guidelines (Writing Committee to Revise the 2001 Guidelines for the Management of Patients With Atrial Fibrillation)," <i>J Am Coll Cardiol</i>, 2006, 48(4):854-906.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/amiodarone-drug-information/abstract-text/16904574/pubmed" id="16904574" target="_blank">16904574</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Ganz.1">
<a name="Ganz.1"></a>Ganz L, Buxton A. Sustained monomorphic ventricular tachycardia in patients with structural heart disease: treatment and prognosis. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed November 11, 2020.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30648930">
<a name="30648930"></a>Gershinsky M, Saliba W, Lavi I, Shapira C, Gronich N. Increased risk of antithyroid drug agranulocytosis associated with amiodarone-induced thyrotoxicosis: a population-based cohort study. <i>Thyroid</i>. 2019;29(2):193-201. doi:10.1089/thy.2018.0274<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/amiodarone-drug-information/abstract-text/30648930/pubmed" id="30648930" target="_blank">30648930</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Giardina.1">
<a name="Giardina.1"></a>Giardina EG, Passman R. Amiodarone: Clinical uses. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed May 24, 2022.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-10871966">
<a name="10871966"></a>Goldschlager N, Epstein AE, Naccarelli G, Olshansky B, Singh B. Practical guidelines for clinicians who treat patients with amiodarone. Practice Guidelines Subcommittee, North American Society of Pacing and Electrophysiology. <i>Arch Intern Med</i>. 2000;160(12):1741-1748. doi:10.1001/archinte.160.12.1741<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/amiodarone-drug-information/abstract-text/10871966/pubmed" id="10871966" target="_blank">10871966</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-9149610">
<a name="9149610"></a>Goldstein I, Topilsky M, Segev D, Isakov A, Heller I. Very early onset of acute amiodarone pulmonary toxicity presenting with hemoptysis. <i>Chest</i>. 1997;111(5):1446-1447. doi:10.1378/chest.111.5.1446<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/amiodarone-drug-information/abstract-text/9149610/pubmed" id="9149610" target="_blank">9149610</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-11388342">
<a name="11388342"></a>Groneberg DA, Barkhuizen A. Neutropenia during treatment with amiodarone. <i>Am J Med</i>. 2001;110(8):671. doi:10.1016/s0002-9343(01)00707-0<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/amiodarone-drug-information/abstract-text/11388342/pubmed" id="11388342" target="_blank">11388342</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-10440143">
<a name="10440143"></a>Guarnieri T, Nolan S, Gottlieb SO, Dudek A, Lowry DR. Intravenous amiodarone for the prevention of atrial fibrillation after open heart surgery: The Amiodarone Reduction in Coronary Heart (ARCH) trial. <i>J Am Coll Cardiol.</i> 1999;34(2):343-347.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/amiodarone-drug-information/abstract-text/10440143/pubmed" id="10440143" target="_blank">10440143</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-8038483">
<a name="8038483"></a>Gutierrez R, Del Pozo J, Carrión C, et al. Vasculitis associated with amiodarone treatment. <i>Ann Pharmacother</i>. 1994;28(4):537. doi:10.1177/106002809402800421<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/amiodarone-drug-information/abstract-text/8038483/pubmed" id="8038483" target="_blank">8038483</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23108056">
<a name="23108056"></a>Ha AH, Ham I, Nair GM, et al. Implantable cardioverter-defibrillator shock prevention does not reduce mortality: a systemic review. <i>Heart Rhythm</i>. 2012;9(12):2068-2074. doi: 10.1016/j.hrthm.2012.08.032.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/amiodarone-drug-information/abstract-text/23108056/pubmed" id="23108056" target="_blank">23108056</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19026806">
<a name="19026806"></a>Haas NA and Camphausen CK, "Impact of Early and Standardized Treatment With Amiodarone on Therapeutic Success and Outcome in Pediatric Patients With Postoperative Tachyarrhythmia," <i>J Thorac Cardiovasc Surg</i>, 2008, 136(5):1215-22.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/amiodarone-drug-information/abstract-text/19026806/pubmed" id="19026806" target="_blank">19026806</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-12719404">
<a name="12719404"></a>Hall CM and McCormick KP, "Amiodarone and Breast Feeding," <i>Arch Dis Child Fetal Neonatal Ed</i>, 2003, 88(3):F255-4.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/amiodarone-drug-information/abstract-text/12719404/pubmed" id="12719404" target="_blank">12719404</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-6622326">
<a name="6622326"></a>Harris L, Hind CR, McKenna WJ, et al. Renal elimination of amiodarone and its desethyl metabolite. <i>Postgrad Med J</i>. 1983;59(693):440-442. doi:10.1136/pgmj.59.693.440<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/amiodarone-drug-information/abstract-text/6622326/pubmed" id="6622326" target="_blank">6622326</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29793782">
<a name="29793782"></a>Hawatmeh A, Thawabi M, Abuarqoub A, Shamoon F. Amiodarone induced myxedema coma: two case reports and literature review. <i>Heart Lung</i>. 2018;47(4):429-431. doi:10.1016/j.hrtlng.2018.03.012<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/amiodarone-drug-information/abstract-text/29793782/pubmed" id="29793782" target="_blank">29793782</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28250689">
<a name="28250689"></a>Hawatmeh A, Thawabi M, Jmeian A, Shaaban H, Shamoon F. Amiodarone-induced loculated pleural effusion without pulmonary parenchymal involvement: a case report and literature review. <i>J Nat Sci Biol Med</i>. 2017;8(1):130-133. doi:10.4103/0976-9668.198345<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/amiodarone-drug-information/abstract-text/28250689/pubmed" id="28250689" target="_blank">28250689</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Hazinski.1">
<a name="Hazinski.1"></a>Hazinski MF, Shuster M, Donnino MW, et al.<i> 2015 Handbook of Emergency Cardiovascular Care for Healthcare Providers</i>. South Deerfield, MA: American Heart Association; 2015.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-1423949">
<a name="1423949"></a>Hii JT, Wyse DG, Gillis AM, Duff HJ, Solylo MA, Mitchell LB. Precordial QT interval dispersion as a marker of torsade de pointes. Disparate effects of class Ia antiarrhythmic drugs and amiodarone. <i>Circulation</i>. 1992;86(5):1376-1382. doi:10.1161/01.cir.86.5.1376<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/amiodarone-drug-information/abstract-text/1423949/pubmed" id="1423949" target="_blank">1423949</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22064599">
<a name="22064599"></a>Hillis LD, Smith PK, Anderson JL, et al. 2011 ACCF/AHA guideline for coronary artery bypass graft surgery: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. [published correction appears in <i>Circulation</i> 2011;124(25):e957]. <i>Circulation</i>. 2011;124(23):e652-e735. doi: 10.1161/CIR.0b013e31823c074e.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/amiodarone-drug-information/abstract-text/22064599/pubmed" id="22064599" target="_blank">22064599</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-8067651">
<a name="8067651"></a>Hohnloser SH, Klingenheben T, Singh BN. Amiodarone-associated proarrhythmic effects. A review with special reference to torsade de pointes tachycardia. <i>Ann Intern Med</i>. 1994;121(7):529-535. doi:10.7326/0003-4819-121-7-199410010-00009<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/amiodarone-drug-information/abstract-text/8067651/pubmed" id="8067651" target="_blank">8067651</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23577267">
<a name="23577267"></a>Hussain N, Bhattacharyya A, Prueksaritanond S. Amiodarone-induced cirrhosis of liver: what predicts mortality? <i>ISRN Cardiol</i>. 2013;2013:617943. doi:10.1155/2013/617943<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/amiodarone-drug-information/abstract-text/23577267/pubmed" id="23577267" target="_blank">23577267</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-11906306">
<a name="11906306"></a>Ikäheimo K, Kettunen R, Mäntyjärvi M. Visual functions and adverse ocular effects in patients with amiodarone medication. <i>Acta Ophthalmol Scand</i>. 2002;80(1):59-63. doi:10.1034/j.1600-0420.2002.800112.x<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/amiodarone-drug-information/abstract-text/11906306/pubmed" id="11906306" target="_blank">11906306</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22095156">
<a name="22095156"></a>Inaba H, Suzuki S, Takeda T, Kobayashi S, Akamizu T, Komatsu M. Amiodarone-induced thyrotoxicosis with thyroid papillary cancer in multinodular goiter: case report. <i>Med Princ Pract</i>. 2012;21(2):190-192. doi:10.1159/000333697<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/amiodarone-drug-information/abstract-text/22095156/pubmed" id="22095156" target="_blank">22095156</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29033440">
<a name="29033440"></a>Inoue K, Saito J, Kondo T, et al. Amiodarone-induced thyrotoxicosis with cardiopulmonary arrest. <i>Intern Med</i>. 2018;57(1):59-63. doi:10.2169/internalmedicine.9177-17<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/amiodarone-drug-information/abstract-text/29033440/pubmed" id="29033440" target="_blank">29033440</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-12534540">
<a name="12534540"></a>Isaksson M, Jansson L. Contact allergy to Tween 80 in an inhalation suspension. <i>Contact Dermatitis</i>. 2002;47(5):312-313.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/amiodarone-drug-information/abstract-text/12534540/pubmed" id="12534540" target="_blank">12534540</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-20175957">
<a name="20175957"></a>Ishida S, Sugino M, Hosokawa T, et al. Amiodarone-induced liver cirrhosis and parkinsonism: a case report. <i>Clin Neuropathol</i>. 2010;29(2):84-88. doi:10.5414/npp29084<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/amiodarone-drug-information/abstract-text/20175957/pubmed" id="20175957" target="_blank">20175957</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-16634249">
<a name="16634249"></a>Iskandar SB, Abi-Saleh B, Keith RL, Byrd RP Jr, Roy TM. Amiodarone-induced alveolar hemorrhage. <i>South Med J</i>. 2006;99(4):383-387. doi:10.1097/01.smj.0000208971.43461.bb<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/amiodarone-drug-information/abstract-text/16634249/pubmed" id="16634249" target="_blank">16634249</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-10891521">
<a name="10891521"></a>Ito S. Drug therapy for breast-feeding women. <i>N Engl J Med</i>. 2000;343(2):118-126.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/amiodarone-drug-information/abstract-text/10891521/pubmed" id="10891521" target="_blank">10891521</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-21704281">
<a name="21704281"></a>Jackevicius CA, Tom A, Essebag V, et al. Population-level incidence and risk factors for pulmonary toxicity associated with amiodarone. <i>Am J Cardiol</i>. 2011;108(5):705-710. doi:10.1016/j.amjcard.2011.04.024<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/amiodarone-drug-information/abstract-text/21704281/pubmed" id="21704281" target="_blank">21704281</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-9227310">
<a name="9227310"></a>James PR, Hardman SM. Acute hepatitis complicating parenteral amiodarone does not preclude subsequent oral therapy. <i>Heart</i>. 1997;77(6):583-584. doi:10.1136/hrt.77.6.583<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/amiodarone-drug-information/abstract-text/9227310/pubmed" id="9227310" target="_blank">9227310</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24682347">
<a name="24682347"></a>January CT, Wann LS, Alpert JS, et al. 2014 AHA/ACC/HRS guideline for the management of patients with atrial fibrillation: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the Heart Rhythm Society [published online March 28, 2014]. <i>Circulation</i>.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/amiodarone-drug-information/abstract-text/24682347/pubmed" id="24682347" target="_blank">24682347</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30686041">
<a name="30686041"></a>January CT, Wann LS, Calkins H, Chen, et al. 2019 AHA/ACC/HRS focused update of the 2014 AHA/ACC/HRS guideline for the management of patients with atrial fibrillation: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Rhythm Society in collaboration with the Society of Thoracic Surgeons. <i>Circulation</i>. 2019;140(2):e125-e151. doi: 10.1161/CIR.0000000000000665.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/amiodarone-drug-information/abstract-text/30686041/pubmed" id="30686041" target="_blank">30686041</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-17485692">
<a name="17485692"></a>Jarand J, Lee A, Leigh R. Amiodaronoma: an unusual form of amiodarone-induced pulmonary toxicity. <i>CMAJ</i>. 2007;176(10):1411-1413. doi:10.1503/cmaj.061102<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/amiodarone-drug-information/abstract-text/17485692/pubmed" id="17485692" target="_blank">17485692</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30471135">
<a name="30471135"></a>Javot L, Pape E, Yéléhé-Okouma M, et al. Intravenous single administration of amiodarone and breastfeeding. <i>Fundam Clin Pharmacol</i>. 2018 [published online November 24, 2018].<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/amiodarone-drug-information/abstract-text/30471135/pubmed" id="30471135" target="_blank">30471135</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24811422">
<a name="24811422"></a>Kang SL, Howe D, Coleman M, Roman K, Gnanapragasam J. Foetal supraventricular tachycardia with hydrops fetalis: a role for direct intraperitoneal amiodarone. <i>Cardiol Young</i>. 2015;25(3):447-453.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/amiodarone-drug-information/abstract-text/24811422/pubmed" id="24811422" target="_blank">24811422</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-11909587">
<a name="11909587"></a>Kharabsheh S, Abendroth CS, Kozak M. Fatal pulmonary toxicity occurring within two weeks of initiation of amiodarone. <i>Am J Cardiol</i>. 2002;89(7):896-898. doi:10.1016/s0002-9149(02)02213-0<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/amiodarone-drug-information/abstract-text/11909587/pubmed" id="11909587" target="_blank">11909587</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24482268">
<a name="24482268"></a>Khurana R, Bin Jardan YA, Wilkie J, Brocks DR. Breast milk concentrations of amiodarone, desethylamiodarone, and bisoprolol following short-term drug exposure: two case reports. <i>J Clin Pharmacol. </i>2014;54(7):828-831.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/amiodarone-drug-information/abstract-text/24482268/pubmed" id="24482268" target="_blank">24482268</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24485640">
<a name="24485640"></a>Kim BB, Kim DM, Choi DH, et al. Amiodarone toxicity showing high liver density on CT scan with normal liver function and plasma amiodarone levels in a long-term amiodarone user. <i>Int J Cardiol</i>. 2014;172(2):494-495. doi:10.1016/j.ijcard.2014.01.020<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/amiodarone-drug-information/abstract-text/24485640/pubmed" id="24485640" target="_blank">24485640</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31400296">
<a name="31400296"></a>Kinoshita S, Hosomi K, Yokoyama S, Takada M. Time-to-onset analysis of amiodarone-associated thyroid dysfunction. <i>J Clin Pharm Ther</i>. 2020;45(1):65-71. doi:10.1111/jcpt.13024<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/amiodarone-drug-information/abstract-text/31400296/pubmed" id="31400296" target="_blank">31400296</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-20956230">
<a name="20956230"></a>Kleinman ME, Chameides L, Schexnayder SM, et al. Part 14: pediatric advanced life support: 2010 American Heart Association guidelines for cardiopulmonary resuscitation and emergency cardiovascular care. <i>Circulation</i>. 2010;122(18)(suppl 3):S876-S908. doi: 10.1161/CIRCULATIONAHA.110.971101.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/amiodarone-drug-information/abstract-text/20956230/pubmed" id="20956230" target="_blank">20956230</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19632422">
<a name="19632422"></a>Kovacikova L, Hakacova N, Dobos D, et al, "Amiodarone as a First-Line Therapy for Postoperative Junctional Ectopic Tachycardia," <i>Ann Thorac Surg</i>, 2009, 88(2):616-22.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/amiodarone-drug-information/abstract-text/19632422/pubmed" id="19632422" target="_blank">19632422</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-9137212">
<a name="9137212"></a>Kowey PR, Marinchak RA, Rials SJ, Filart RA. Intravenous amiodarone. <i>J Am Coll Cardiol</i>. 1997;29(6):1190-1198. doi:10.1016/s0735-1097(97)00069-7<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/amiodarone-drug-information/abstract-text/9137212/pubmed" id="9137212" target="_blank">9137212</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-21266300">
<a name="21266300"></a>Kurt İH, Yalcin F. Anaphylactic shock due to intravenous amiodarone. <i>Am J Emerg Med</i>. 2012;30(1):265.e1-2. doi: 10.1016/j.ajem.2010.12.001<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/amiodarone-drug-information/abstract-text/21266300/pubmed" id="21266300" target="_blank">21266300</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22761971">
<a name="22761971"></a>Lahbabi M, Aqodad N, Ibrahimi A, Lahlou M, Aqodad H. Acute hepatitis secondary to parenteral amiodarone does not preclude subsequent oral therapy. <i>World J Hepatol</i>. 2012;4(6):196-198. doi:10.4254/wjh.v4.i6.196<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/amiodarone-drug-information/abstract-text/22761971/pubmed" id="22761971" target="_blank">22761971</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22605538">
<a name="22605538"></a>Lakshmanadoss U, Lindsley J, Glick D, Twilley CH, Lewin JJ 3rd, Marine JE. Incidence of amiodarone hypersensitivity in patients with previous allergy to iodine or iodinated contrast agents. <i>Pharmacotherapy</i>. 2012;32(7):618-622. doi:10.1002/j.1875-9114.2012.01094.x.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/amiodarone-drug-information/abstract-text/22605538/pubmed" id="22605538" target="_blank">22605538</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-20453797">
<a name="20453797"></a>Lane RD, Nguyen KT, Niemann JT, et al, "Amiodarone for the Emergency Care of Children," <i>Pediatr Emerg Care</i>, 2010, 26(5):382-9.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/amiodarone-drug-information/abstract-text/20453797/pubmed" id="20453797" target="_blank">20453797</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-10921701">
<a name="10921701"></a>Lee SH, Chang CM, Lu MJ, et al, Intravenous amiodarone for prevention of atrial fibrillation after coronary artery bypass grafting. <i>Ann Thorac Surg</i>. 2000;70(1):157-161.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/amiodarone-drug-information/abstract-text/10921701/pubmed" id="10921701" target="_blank">10921701</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-17148550">
<a name="17148550"></a>Lim HE, Pak HN, Ahn JC, Song WH, Kim YH. Torsade de pointes induced by short-term oral amiodarone therapy. <i>Europace</i>. 2006;8(12):1051-1053. doi:10.1093/europace/eul118<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/amiodarone-drug-information/abstract-text/17148550/pubmed" id="17148550" target="_blank">17148550</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26472995">
<a name="26472995"></a>Link MS, Berkow LC, Kudenchuk PJ, et al. Part 7: Adult Advanced Cardiovascular Life Support: 2015 American Heart Association Guidelines Update for Cardiopulmonary Resuscitation and Emergency Cardiovascular Care. <i>Circulation</i>. 2015;132(suppl 2):S444-S464.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/amiodarone-drug-information/abstract-text/26472995/pubmed" id="26472995" target="_blank">26472995</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-10985636">
<a name="10985636"></a>Lucente P, Iorizzo M, Pazzaglia M. Contact sensitivity to Tween 80 in a child. <i>Contact Dermatitis</i>. 2000;43(3):172.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/amiodarone-drug-information/abstract-text/10985636/pubmed" id="10985636" target="_blank">10985636</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-20213839">
<a name="20213839"></a>Luke DR, Tomaszewski K, Damle B, Schlamm HT. Review of the basic and clinical pharmacology of sulfobutylether-beta-cyclodextrin (SBECD). <i>J Pharm Sci</i>. 2010;99(8):3291-3301.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/amiodarone-drug-information/abstract-text/20213839/pubmed" id="20213839" target="_blank">20213839</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30929065">
<a name="30929065"></a>Maghrabi K, Uzun O, Kirsh JA, Balaji S, Von Bergen NH, Sanatani S. Cardiovascular collapse with intravenous amiodarone in children: a multi-center retrospective cohort study. <i>Pediatr Cardiol</i>. 2019;40(5):925-933. doi:10.1007/s00246-019-02090-7<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/amiodarone-drug-information/abstract-text/30929065/pubmed" id="30929065" target="_blank">30929065</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-8230644">
<a name="8230644"></a>Makkar RR, Fromm BS, Steinman RT, Meissner MD, Lehmann MH. Female gender as a risk factor for torsades de pointes associated with cardiovascular drugs. <i>JAMA</i>. 1993;270(21):2590-2597. doi:10.1001/jama.270.21.2590<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/amiodarone-drug-information/abstract-text/8230644/pubmed" id="8230644" target="_blank">8230644</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Manolis.2020">
<a name="Manolis.2020"></a>Manolis AS. Premature ventricular complexes: Treatment and prognosis. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed Accessed February 13, 2020.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-20415682">
<a name="20415682"></a>Maoz KB, Dvash S, Brenner S, Brenner S. Amiodarone-induced skin pigmentation and multiple basal-cell carcinomas. <i>Int J Dermatol</i>. 2009;48(12):1398-1400. doi:10.1111/j.1365-4632.2008.03819.x<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/amiodarone-drug-information/abstract-text/20415682/pubmed" id="20415682" target="_blank">20415682</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31258313">
<a name="31258313"></a>Marcelino GP, Collantes CMC, Oommen JK, et al. Amiodarone-induced syndrome of inappropriate antidiuretic hormone: a case report and review of the literature. <i>P T</i>. 2019;44(7):416-423.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/amiodarone-drug-information/abstract-text/31258313/pubmed" id="31258313" target="_blank">31258313</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-3282816">
<a name="3282816"></a>Martin WJ 2nd, Rosenow EC 3rd. Amiodarone pulmonary toxicity. Recognition and pathogenesis (Part I). <i>Chest</i>. 1988;93(5):1067-1075. doi:10.1378/chest.93.5.1067<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/amiodarone-drug-information/abstract-text/3282816/pubmed" id="3282816" target="_blank">3282816</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-3665117">
<a name="3665117"></a>Martino E, Aghini-Lombardi F, Mariotti S, et al. Amiodarone iodine-induced hypothyroidism: risk factors and follow-up in 28 cases. <i>Clin Endocrinol (Oxf)</i>. 1987;26(2):227-237. doi:10.1111/j.1365-2265.1987.tb00781.x<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/amiodarone-drug-information/abstract-text/3665117/pubmed" id="3665117" target="_blank">3665117</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-6799078">
<a name="6799078"></a>McGovern B, Garan H, Ruskin JN. Sinus arrest during treatment with amiodarone. <i>Br Med J (Clin Res Ed)</i>. 1982;284(6310):160-161. doi:10.1136/bmj.284.6310.160<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/amiodarone-drug-information/abstract-text/6799078/pubmed" id="6799078" target="_blank">6799078</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32095172">
<a name="32095172"></a>Mohamed M, Al-Hillan A, Flores M, et al. Concomitant acute hepatic failure and renal failure induced by intravenous amiodarone: a case report and literature review. <i>Gastroenterology Res</i>. 2020;13(1):40-43. doi:10.14740/gr1254<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/amiodarone-drug-information/abstract-text/32095172/pubmed" id="32095172" target="_blank">32095172</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-14755379">
<a name="14755379"></a>Mukhopadhyay S, Mukhopadhyay S, Abraham NZ Jr, Jones LA, Howard L, Gajra A. Unexplained bone marrow granulomas: is amiodarone the culprit? A report of 2 cases. <i>Am J Hematol</i>. 2004;75(2):110-112. doi:10.1002/ajh.10465<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/amiodarone-drug-information/abstract-text/14755379/pubmed" id="14755379" target="_blank">14755379</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-3280316">
<a name="3280316"></a>Munoz A, Karila P, Gallay P, et al. A randomized hemodynamic comparison of intravenous amiodarone with and without Tween 80. <i>Eur Heart J</i>. 1988;9(2):142-148. doi:10.1093/oxfordjournals.eurheartj.a062467<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/amiodarone-drug-information/abstract-text/3280316/pubmed" id="3280316" target="_blank">3280316</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24109195">
<a name="24109195"></a>Nasser M, Larsen TR, Waanbah B, Sidiqi I, McCullough PA. Hyperacute drug-induced hepatitis with intravenous amiodarone: case report and review of the literature. <i>Drug Healthc Patient Saf</i>. 2013;5:191-198. doi:10.2147/DHPS.S48640<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/amiodarone-drug-information/abstract-text/24109195/pubmed" id="24109195" target="_blank">24109195</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-3608127">
<a name="3608127"></a>Nattel S, Talajic M, Quantz M, DeRoode M. Frequency-dependent effects of amiodarone on atrioventricular nodal function and slow-channel action potentials: evidence for calcium channel-blocking activity. <i>Circulation</i>. 1987;76(2):442-449. doi:10.1161/01.cir.76.2.442<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/amiodarone-drug-information/abstract-text/3608127/pubmed" id="3608127" target="_blank">3608127</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-20956224">
<a name="20956224"></a>Neumar RW, Otto CW, Link MS, et al. Part 8: adult advanced cardiovascular life support: 2010 American Heart Association guidelines for cardiopulmonary resuscitation and emergency cardiovascular care [published corrections appear in <i>Circulation</i>. 2011;123(6):e236; <i>Circulation</i>. 2013;128(25):e480]. <i>Circulation</i>. 2010;122(18)(suppl 3):S729-S767. doi: 10.1161/CIRCULATIONAHA.110.970988.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/amiodarone-drug-information/abstract-text/20956224/pubmed" id="20956224" target="_blank">20956224</a>]</span>
</div>
</li>
<li>
<div class="reference">
                  Nexterone (amiodarone hydrochloride) [prescribing information]. Deerfield, IL: Baxter Healthcare Corporation; September 2021.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-11545776">
<a name="11545776"></a>Nielsen TD, Hamdan MH, Kowal RC, Barbera SJ, Page RL, Joglar JA. Effect of acute amiodarone loading on energy requirements for biphasic ventricular defibrillation. <i>Am J Cardiol</i>. 2001 Aug;88(4):446-448. doi:10.1016/s0002-9149(01)01701-5<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/amiodarone-drug-information/abstract-text/11545776/pubmed" id="11545776" target="_blank">11545776</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23816686">
<a name="23816686"></a>Okuyan H, Altin C, Arihan O. Anaphylaxis during intravenous administration of amiodarone. <i>Ann Card Anaesth</i>. 2013;16(3):229-230. doi:10.4103/0971-9784.114251<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/amiodarone-drug-information/abstract-text/23816686/pubmed" id="23816686" target="_blank">23816686</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-15670555">
<a name="15670555"></a>Olshansky B, Sami M, Rubin A, et al; NHLBI AFFIRM Investigators. Use of amiodarone for atrial fibrillation in patients with preexisting pulmonary disease in the AFFIRM study. <i>Am J Cardiol</i>. 2005;95(3):404-405. doi:10.1016/j.amjcard.2004.09.044<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/amiodarone-drug-information/abstract-text/15670555/pubmed" id="15670555" target="_blank">15670555</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Pacerone.1">
<a name="Pacerone.1"></a>Pacerone 100 mg, 200 mg, and 400 mg tablets (amiodarone) [prescribing information]. Maple Grove, MN: Upsher-Smith Laboratories LLC; May 2023.</div>
</li>
<li>
<div class="reference">
                  Pacerone 400 mg tablets (amiodarone) [prescribing information]. Maple Grove, MN: Upsher-Smith Laboratories, LLC; November 2018.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26409259">
<a name="26409259"></a>Page RL, Joglar JA, Caldwell MA, et al. 2015 ACC/AHA/HRS guideline for the management of adult patients with supraventricular tachycardia: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Rhythm Society. <i>J Am Coll Cardiol</i>. 2016;67(13):e27-e115.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/amiodarone-drug-information/abstract-text/26409259/pubmed" id="26409259" target="_blank">26409259</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-20553056">
<a name="20553056"></a>Papiris SA, Triantafillidou C, Kolilekas L, Markoulaki D, Manali ED. Amiodarone: review of pulmonary effects and toxicity. <i>Drug Saf</i>. 2010;33(7):539-558. doi:10.2165/11532320-000000000-00000<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/amiodarone-drug-information/abstract-text/20553056/pubmed" id="20553056" target="_blank">20553056</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26409259.1">
<a name="26409259.1"></a>Passman R. Electrical storm and incessant ventricular tachycardia. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed August 26, 2020.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-8047495">
<a name="8047495"></a>Paul T and Guccione P, "New Antiarrhythmic Drugs in Pediatric Use: Amiodarone," <i>Pediatr Cardiol</i>, 1994, 15(3):132-8.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/amiodarone-drug-information/abstract-text/8047495/pubmed" id="8047495" target="_blank">8047495</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-25172618">
<a name="25172618"></a>Pedersen CT, Kay GN, Kalman J, et al. EHRA/HRS/APHRS expert consensus on ventricular arrhythmias. <i>Europace</i>. 2014;16(9):1257-1283. doi: 10.1093/europace/euu194.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/amiodarone-drug-information/abstract-text/25172618/pubmed" id="25172618" target="_blank">25172618</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-10921789">
<a name="10921789"></a>Pelosi F Jr, Oral H, Kim MH, et al. Effect of chronic amiodarone therapy on defibrillation energy requirements in humans. <i>J Cardiovasc Electrophysiol</i>. 2000;11(7):736-740. doi:10.1111/j.1540-8167.2000.tb00043.x<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/amiodarone-drug-information/abstract-text/10921789/pubmed" id="10921789" target="_blank">10921789</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-8609351">
<a name="8609351"></a>Perry JC, Fenrich AL, Hulse JE, et al, “Pediatric Use of Intravenous Amiodarone: Efficacy and Safety in Critically Ill Patients From a Multicenter Protocol,” <i>J Am Coll Cardiol</i>, 1996, 27(5):1246-50.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/amiodarone-drug-information/abstract-text/8609351/pubmed" id="8609351" target="_blank">8609351</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22058104">
<a name="22058104"></a>Phillips MS, "Standardizing I.V. Infusion Concentrations: National Survey Results," <i>Am J Health Syst Pharm</i>, 2011, 68(22):2176-82.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/amiodarone-drug-information/abstract-text/22058104/pubmed" id="22058104" target="_blank">22058104</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19336434">
<a name="19336434"></a>Piccini JP, Berger JS, O'Connor CM. Amiodarone for the prevention of sudden cardiac death: a meta-analysis of randomized controlled trials. <i>Eur Heart J</i>. 2009;30(10):1245-1253. doi: 10.1093/eurheartj/ehp100.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/amiodarone-drug-information/abstract-text/19336434/pubmed" id="19336434" target="_blank">19336434</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-1563571">
<a name="1563571"></a>Plomp TA, Vulsma T, de Vijlder JJ. Use of amiodarone during pregnancy. <i>Eur J Obstet Gynecol Reprod Biol</i>. 1992;43(3):201-207.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/amiodarone-drug-information/abstract-text/1563571/pubmed" id="1563571" target="_blank">1563571</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Podrid.1">
<a name="Podrid.1"></a>Podrid PJ. Pharmacologic therapy in survivors of sudden cardiac arrest. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed January 5, 2022.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-16284489">
<a name="16284489"></a>Puli SR, Fraley MA, Puli V, Kuperman AB, Alpert MA. Hepatic cirrhosis caused by low-dose oral amiodarone therapy. <i>Am J Med Sci</i>. 2005;330(5):257-261. doi:10.1097/00000441-200511000-00012<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/amiodarone-drug-information/abstract-text/16284489/pubmed" id="16284489" target="_blank">16284489</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19078662">
<a name="19078662"></a>Pulipaka U, Lacomis D, Omalu B. Amiodarone-induced neuromyopathy: three cases and a review of the literature. <i>J Clin Neuromuscul Dis</i>. 2002;3(3):97-105. doi:10.1097/00131402-200203000-00001<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/amiodarone-drug-information/abstract-text/19078662/pubmed" id="19078662" target="_blank">19078662</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-7946778">
<a name="7946778"></a>Raja P, Hawker RE, Chaikitpinyo A, et al. Amiodarone Management of Junctional Ectopic Tachycardia After Cardiac Surgery in Children. <i>Br Heart J.</i> 1994; 72(3):261-265.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/amiodarone-drug-information/abstract-text/7946778/pubmed" id="7946778" target="_blank">7946778</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27890620">
<a name="27890620"></a>Raizman MB, Hamrah P, Holland EJ, et al. Drug-induced corneal epithelial changes. <i>Surv Ophthalmol</i>. 2017;62(3):286-301.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/amiodarone-drug-information/abstract-text/27890620/pubmed" id="27890620" target="_blank">27890620</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30873497">
<a name="30873497"></a>Ramachandran A, Visschers RGJ, Duan L, Akakpo JY, Jaeschke H. Mitochondrial dysfunction as a mechanism of drug-induced hepatotoxicity: current understanding and future perspectives. <i>J Clin Transl Res</i>. 2018;4(1):75-100. doi:10.18053/jctres.04.201801.005<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/amiodarone-drug-information/abstract-text/30873497/pubmed" id="30873497" target="_blank">30873497</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-2754275">
<a name="2754275"></a>Rappersberger K, Hönigsmann H, Ortel B, Tanew A, Konrad K, Wolff K. Photosensitivity and hyperpigmentation in amiodarone-treated patients: incidence, time course, and recovery. <i>J Invest Dermatol</i>. 1989;93(2):201-209. doi:10.1111/1523-1747.ep12277571<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/amiodarone-drug-information/abstract-text/2754275/pubmed" id="2754275" target="_blank">2754275</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-21873418">
<a name="21873418"></a>Regitz-Zagrosek V, Blomstrom Lundqvist C, Borghi C, et al. ESC guidelines on the management of cardiovascular diseases during pregnancy: the Task Force on the Management of Cardiovascular Diseases during Pregnancy of the European Society of Cardiology (ESC). <i>Eur Heart J</i>. 2011;32(24):3147-3197.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/amiodarone-drug-information/abstract-text/21873418/pubmed" id="21873418" target="_blank">21873418</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-manu.1">
<a name="manu.1"></a>Refer to manufacturer's labeling.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24420913">
<a name="24420913"></a>Reynolds PM, Maclaren R, Mueller SW, Fish DN, Kiser TH. Management of extravasation injuries: a focused evaluation of noncytotoxic medications. <i>Pharmacotherapy</i>. 2014;34(6):617-632. doi: 10.1002/phar.1396.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/amiodarone-drug-information/abstract-text/24420913/pubmed" id="24420913" target="_blank">24420913</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-8491409">
<a name="8491409"></a>Rhodes A, Eastwood JB, Smith SA. Early acute hepatitis with parenteral amiodarone: a toxic effect of the vehicle? <i>Gut</i>. 1993;34(4):565-566. doi:10.1136/gut.34.4.565<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/amiodarone-drug-information/abstract-text/8491409/pubmed" id="8491409" target="_blank">8491409</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-21422798">
<a name="21422798"></a>Rosseti N, Calza L, Piergentili B, et al. Amiodarone-related pneumonitis and peripheral neuropathy in an elderly patient. <i>Aging Clin Exp Res</i>. 2010;22(5-6):466-469. doi:10.1007/BF03324945<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/amiodarone-drug-information/abstract-text/21422798/pubmed" id="21422798" target="_blank">21422798</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-10738049">
<a name="10738049"></a>Roy D, Talajic M, Dorian P, et al, "Amiodarone to Prevent Recurrence of Atrial Fibrillation. Canadian Trial of Atrial Fibrillation Investigators," <i>N Engl J Med</i>, 2000, 342(13):913-20.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/amiodarone-drug-information/abstract-text/10738049/pubmed" id="10738049" target="_blank">10738049</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-3962737">
<a name="3962737"></a>Rumessen JJ. Hepatotoxicity of amiodarone. <i>Acta Med Scand</i>. 1986;219(2):235-239. doi:10.1111/j.0954-6820.1986.tb03304.x<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/amiodarone-drug-information/abstract-text/3962737/pubmed" id="3962737" target="_blank">3962737</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-16973793">
<a name="16973793"></a>Russell SJ, Saltissi S. Amiodarone induced skin necrosis. <i>Heart</i>. 2006;92(10):1395. doi:10.1136/hrt.2005.086157<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/amiodarone-drug-information/abstract-text/16973793/pubmed" id="16973793" target="_blank">16973793</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31653351">
<a name="31653351"></a>Ruzieh M, Moroi MK, Aboujamous NM, et al. Meta-analysis comparing the relative risk of adverse events for amiodarone versus placebo. Am J Cardiol. 2019;124(12):1889-1893. doi:10.1016/j.amjcard.2019.09.008<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/amiodarone-drug-information/abstract-text/31653351/pubmed" id="31653351" target="_blank">31653351</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31653638">
<a name="31653638"></a>Saeed J, Waqas QA, Khan UI, Abdullah HMA. Amiodarone-induced diffuse alveolar haemorrhage: a rare but potentially life-threatening complication of a commonly prescribed medication. <i>BMJ Case Rep</i>. 2019;12(10):e232149. doi:10.1136/bcr-2019-232149<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/amiodarone-drug-information/abstract-text/31653638/pubmed" id="31653638" target="_blank">31653638</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26961297">
<a name="26961297"></a>Santangeli P, Muser D, Maeda S, et al. Comparative effectiveness of antiarrhythmic drugs and catheter ablation for the prevention of recurrent ventricular tachycardia in patients with implantable cardioverter-defibrillators: a systematic review and meta-analysis of randomized controlled trials. <i>Heart Rhythm</i>. 2016;13(7):1552-1559. doi: 10.1016/j.hrthm.2016.03.004.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/amiodarone-drug-information/abstract-text/26961297/pubmed" id="26961297" target="_blank">26961297</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-16650263">
<a name="16650263"></a>Schrickel JW, Schwab JO, Yang A, Bitzen A, Lüderitz B, Lewalter T. "Torsade de pointes" in patients with structural heart disease and atrial fibrillation treated with amiodarone, beta-blockers, and digitalis. <i>Pacing Clin Electrophysiol</i>. 2006;29(4):363-366. doi:10.1111/j.1540-8159.2006.00354.x<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/amiodarone-drug-information/abstract-text/16650263/pubmed" id="16650263" target="_blank">16650263</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-3610399">
<a name="3610399"></a>Schützenberger W, Leisch F, Gmeiner R. Enhanced accessory pathway conduction following intravenous amiodarone in atrial fibrillation. A case report. <i>Int J Cardiol</i>. 1987;16(1):93-95. doi:10.1016/0167-5273(87)90273-7<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/amiodarone-drug-information/abstract-text/3610399/pubmed" id="3610399" target="_blank">3610399</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-18039017">
<a name="18039017"></a>Serrao R, Zirwas M, English JC. Palmar erythema. <i>Am J Clin Dermatol</i>. 2007;8(6):347-356. doi:10.2165/00128071-200708060-00004<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/amiodarone-drug-information/abstract-text/18039017/pubmed" id="18039017" target="_blank">18039017</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-7746084">
<a name="7746084"></a>Shelley WB, Talanin N, Shelley ED. Polysorbate 80 hypersensitivity. <i>Lancet</i>. 1995;345(8980):1312-1313.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/amiodarone-drug-information/abstract-text/7746084/pubmed" id="7746084" target="_blank">7746084</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Simpson.1">
<a name="Simpson.1"></a>Simpson MC, Schaefer EG. <i>Extended Stability for Parenteral Drugs</i>. 7th ed. American Society of Health-System Pharmacists; 2023.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-15872201">
<a name="15872201"></a>Singh BN, Singh SN, Reda DJ, et al. Amiodarone versus sotalol for atrial fibrillation. <i>N Engl J Med</i>. 2005;352(18):1861-1872.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/amiodarone-drug-information/abstract-text/15872201/pubmed" id="15872201" target="_blank">15872201</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-15101852">
<a name="15101852"></a>Skrifvars MB, Kuisma M, Boyd J, et al. The use of undiluted amiodarone in the management of out-of-hospital cardiac arrest. <i>Acta Anaesthesiol Scand. </i>2004;48(5):582-587.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/amiodarone-drug-information/abstract-text/15101852/pubmed" id="15101852" target="_blank">15101852</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-15777308">
<a name="15777308"></a>Skroubis G, Galiatsou E, Metafratzi Z, Karahaliou A, Kitsakos A, Nakos G. Amiodarone-induced acute lung toxicity in an ICU setting. <i>Acta Anaesthesiol Scand</i>. 2005;49(4):569-571. doi:10.1111/j.1399-6576.2005.00606.x<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/amiodarone-drug-information/abstract-text/15777308/pubmed" id="15777308" target="_blank">15777308</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-7753695">
<a name="7753695"></a>Soult JA, Munoz M, Lopez JD, et al, “Efficacy and Safety of Intravenous Amiodarone for Short-Term Treatment of Paroxysmal Supraventricular Tachycardia in Children,” <i>Pediatr Cardiol</i>, 1995, 16(1):16-9.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/amiodarone-drug-information/abstract-text/7753695 /pubmed" id="7753695 " target="_blank">7753695 </a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-17609235">
<a name="17609235"></a>Stafford L. Hypersensitivity reaction to amiodarone in a patient with a previous reaction to an iodinated radiocontrast agent. <i>Ann Pharmacother</i>. 2007;41(7):1310-1314. doi:10.1345/aph.1K027<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/amiodarone-drug-information/abstract-text/17609235/pubmed" id="17609235" target="_blank">17609235</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-9492158">
<a name="9492158"></a>Stanbury JB, Ermans AE, Bourdoux P, et al. Iodine-induced hyperthyroidism: occurrence and epidemiology. <i>Thyroid</i>. 1998;8(1):83-100. doi:10.1089/thy.1998.8.83<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/amiodarone-drug-information/abstract-text/9492158/pubmed" id="9492158" target="_blank">9492158</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-36938775">
<a name="36938775"></a>Stefanos SS, Kiser TH, MacLaren R, Mueller SW, Reynolds PM. Management of noncytotoxic extravasation injuries: a focused update on medications, treatment strategies, and peripheral administration of vasopressors and hypertonic saline. <i>Pharmacotherapy</i>. 2023;43(4):321-337. doi:10.1002/phar.2794<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/amiodarone-drug-information/abstract-text/36938775/pubmed" id="36938775" target="_blank">36938775</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-11526368">
<a name="11526368"></a>Steinberg JS, Martins J, Sadanandan S, et al; AVID Investigators. Antiarrhythmic drug use in the implantable defibrillator arm of the Antiarrhythmics Versus Implantable Defibrillators (AVID) study. <i>Am Heart J</i>. 2001;142(3):520-529.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/amiodarone-drug-information/abstract-text/11526368/pubmed" id="11526368" target="_blank">11526368</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26151694">
<a name="26151694"></a>Stratton A, Fenderson J, Kenny P, Helman DL. Severe acute hepatitis following intravenous amiodarone : a case report and review of the literature. <i>Acta Gastroenterol Belg</i>. 2015;78(2):233-239.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/amiodarone-drug-information/abstract-text/26151694/pubmed" id="26151694" target="_blank">26151694</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31741184">
<a name="31741184"></a>Tan MG, Worley B, Kim WB, Ten Hove M, Beecker J. Drug-induced intracranial hypertension: a systematic review and critical assessment of drug-induced causes. <i>Am J Clin Dermatol</i>. 2020;21(2):163-172. doi:10.1007/s40257-019-00485-z<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/amiodarone-drug-information/abstract-text/31741184/pubmed" id="31741184" target="_blank">31741184</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27916222">
<a name="27916222"></a>Teerakanok J, Tantrachoti P, Chariyawong P, Nugent K. Acute amiodarone pulmonary toxicity after surgical procedures. <i>Am J Med Sci</i>. 2016;352(6):646-651. doi:10.1016/j.amjms.2016.08.013<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/amiodarone-drug-information/abstract-text/27916222/pubmed" id="27916222" target="_blank">27916222</a>]</span>
</div>
</li>
<li>
<div class="reference">
                  Teva-Amiodarone tablets [product monograph]. Toronto, Ontario, Canada: Teva Canada Limited; December 2021.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32929996">
<a name="32929996"></a>Tisdale JE, Chung MK, Campbell KB, et al. Drug-induced arrhythmias: a scientific statement from the American Heart Association. <i>Circulation</i>. 2020;142(15):e214-e233. doi:10.1161/CIR.0000000000000905<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/amiodarone-drug-information/abstract-text/32929996/pubmed" id="32929996" target="_blank">32929996</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-33081526">
<a name="33081526"></a>Topjian AA, Raymond TT, Atkins D, et al. Part 4: Pediatric basic and advanced life support: 2020 American Heart Association guidelines for cardiopulmonary resuscitation and emergency cardiovascular care. <i>Circulation</i>. 2020;142(16 Suppl 2):S469-S523. doi:10.1161/CIR.0000000000000901<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/amiodarone-drug-information/abstract-text/33081526/pubmed" id="33081526" target="_blank">33081526</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30309693">
<a name="30309693"></a>Trohman RG, Sharma PS, McAninch EA, Bianco AC. Amiodarone and thyroid physiology, pathophysiology, diagnosis and management. <i>Trends Cardiovasc Med</i>. 2019;29(5):285-295. doi:10.1016/j.tcm.2018.09.005<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/amiodarone-drug-information/abstract-text/30309693/pubmed" id="30309693" target="_blank">30309693</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19584973">
<a name="19584973"></a>Tsang W, Houlden RL. Amiodarone-induced thyrotoxicosis: a review. <i>Can J Cardiol</i>. 2009;25(7):421-424. doi:10.1016/s0828-282x(09)70512-4<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/amiodarone-drug-information/abstract-text/19584973/pubmed" id="19584973" target="_blank">19584973</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29653592">
<a name="29653592"></a>Tsuda T, Tada H, Tanaka Y, et al. Amiodarone-induced reversible and irreversible hepatotoxicity: two case reports. <i>J Med Case Rep</i>. 2018;12(1):95. doi:10.1186/s13256-018-1629-8<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/amiodarone-drug-information/abstract-text/29653592/pubmed" id="29653592" target="_blank">29653592</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-8852388">
<a name="8852388"></a>Ujhelyi MR, Klamerus KJ, Vadiei K, et al. Disposition of intravenous amiodarone in subjects with normal and impaired renal function. <i>J Clin Pharmacol</i>. 1996;36(2):122-130. doi:10.1002/j.1552-4604.1996.tb04177.x<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/amiodarone-drug-information/abstract-text/8852388/pubmed" id="8852388" target="_blank">8852388</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-3776867">
<a name="3776867"></a>Veltri EP, Reid PR. Sinus arrest with intravenous amiodarone. <i>Am J Cardiol</i>. 1986;58(11):1110-1111. doi:10.1016/0002-9149(86)90126-8<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/amiodarone-drug-information/abstract-text/3776867/pubmed" id="3776867" target="_blank">3776867</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-9283542">
<a name="9283542"></a>Vorperian VR, Havighurst TC, Miller S, et al, "Adverse Effects of Low Dose Amiodarone: A Meta-analysis," <i>J Am Coll Cardiol</i>, 1997, 30(3):791-8.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/amiodarone-drug-information/abstract-text/9283542/pubmed" id="9283542" target="_blank">9283542</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28348626">
<a name="28348626"></a>Wang AG, Cheng HC. Amiodarone-associated optic neuropathy: clinical review. <i>Neuroophthalmology</i>. 2016;41(2):55-58. doi:10.1080/01658107.2016.1247461<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/amiodarone-drug-information/abstract-text/28348626/pubmed" id="28348626" target="_blank">28348626</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-8410561">
<a name="8410561"></a>Ward GH, Yalkowsky SH. Studies in phlebitis. VI: Dilution-induced precipitation of amiodarone HCL. <i>J Parenter Sci Technol</i>. 1993;47(4):161-165.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/amiodarone-drug-information/abstract-text/8410561/pubmed" id="8410561" target="_blank">8410561</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-12970233">
<a name="12970233"></a>White CM, Caron MF, Kalus JS, et al. Intravenous plus oral amiodarone, atrial septal pacing, or both strategies to prevent post-cardiothoracic surgery atrial fibrillation: the Atrial Fibrillation Suppression Trial II (AFIST II). <i>Circulation</i>. 2003;108(suppl 1):II200-II206.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/amiodarone-drug-information/abstract-text/12970233/pubmed" id="12970233" target="_blank">12970233</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23846521">
<a name="23846521"></a>Yachoui R, Saad W. Amiodarone-induced lupus-like syndrome.<i> Am J Ther</i>. 2015;22(1):e20-1. doi:10.1097/MJT.0b013e318296ee78<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/amiodarone-drug-information/abstract-text/23846521/pubmed" id="23846521" target="_blank">23846521</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-17895560">
<a name="17895560"></a>Yamada Y, Shiga T, Matsuda N, Hagiwara N, Kasanuki H. Incidence and predictors of pulmonary toxicity in Japanese patients receiving low-dose amiodarone. <i>Circ J</i>. 2007;71(10):1610-1616. doi:10.1253/circj.71.1610<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/amiodarone-drug-information/abstract-text/17895560/pubmed" id="17895560" target="_blank">17895560</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-15644477">
<a name="15644477"></a>Yavuzgil O, Goksel T, Gurgun C, Hasdemir C. New-onset bronchial asthma induced by low-dose amiodarone. <i>Ann Pharmacother</i>. 2005;39(2):385-386. doi:10.1345/aph.1E388<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/amiodarone-drug-information/abstract-text/15644477/pubmed" id="15644477" target="_blank">15644477</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-11869206">
<a name="11869206"></a>Yung A, Agnew K, Snow J, Oliver F. Two unusual cases of toxic epidermal necrolysis. <i>Australas J Dermatol</i>. 2002;43(1):35-38. doi:10.1046/j.1440-0960.2002.00549.x<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/amiodarone-drug-information/abstract-text/11869206/pubmed" id="11869206" target="_blank">11869206</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-9626850">
<a name="9626850"></a>Zhou L, Chen BP, Kluger J, Fan C, Chow MS. Effects of amiodarone and its active metabolite desethylamiodarone on the ventricular defibrillation threshold. <i>J Am Coll Cardiol</i>. 1998;31(7):1672-1678. doi:10.1016/s0735-1097(98)00160-0<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/amiodarone-drug-information/abstract-text/9626850/pubmed" id="9626850" target="_blank">9626850</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-17329700">
<a name="17329700"></a>Zimetbaum P. Amiodarone for atrial fibrillation. <i>N Engl J Med.</i> 2007;356(9):935-941.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/amiodarone-drug-information/abstract-text/17329700/pubmed" id="17329700" target="_blank">17329700</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Zimetbaum.1">
<a name="Zimetbaum.1"></a>Zimetbaum PJ, Wylie JV. Nonsustained ventricular tachycardia: Clinical manifestations, evaluation, and management. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed October 7, 2019.</div>
</li></ol></div><div id="topicVersionRevision">Topic 8595 Version 633.0</div></div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
